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 Kisspeptin and gpr-54 regulate the HPG axis via GnRH. 
 Kisspeptin and gpr-54 are critical to puberty onset. 
 Kisspeptin signals via differential mechanisms in GnRH neuronal and 
trophoblast cell lines. 
 Kisspeptin modulates migratory signalling pathways in model and placental cell 
lines. 





 To develop and characterise kisspeptin analogues to screen for agonists and 
antagonists. 
 To test antagonists in vitro and in vivo to delineate the role of kisspeptin in the 
HPG axis and puberty. 
 To investigate the signalling pathways activated by kisspeptin-10 in a model cell 
line (CHO/gpr-54), GnRH neuronal cell line, placental cell lines and cancer cell 
lines. 
 To determine the signalling pathways important for kisspeptin-mediated 
inhibition of migration. 





GnRH neurons represent the final common pathway for the regulation of the 
reproductive axis and they are modulated by multiple signals. It has recently been 
shown that a potent effector of GnRH neuron function is an afferent network of 
kisspeptin-producing neurons.  Kisspeptin released from these neurons acts upon a 
specific receptor (gpr-54) expressed on GnRH neurons, and increases the secretion 
of GnRH from the hypothalamus.  The kisspeptin system has since been implicated 
as a downstream mediator for regulation of the Hypothalamic-Pituitary-Gonadal 
(HPG) axis by steroid hormones, metabolic signals and photoperiod, potentially 
placing it at the centre of reproductive physiology.  However, the supporting 
evidence to date has been indirect, relying on interpretation of changes in mRNA 
levels and immuno-histochemical staining to infer the actions of kisspeptin upon 
the central control of reproduction. The detailed mechanisms of kisspeptin action 
are yet to be fully elucidated.   
 
The research within this thesis elucidates the effect of kisspeptin on the HPG axis 
via the development of kisspeptin-10 (kp-10) analogues with antagonistic 
properties. Functionally important residues within the peptide were delineated.  
Structure-activity studies of kp-10 analogues indicated that residues Asn2, Trp3, 
Phe6, Arg9 and Phe10 interact with gpr-54 to facilitate receptor binding.  Two other 
residues, Tyr1 and Leu8 were shown to be critical for receptor activation by 
kisspeptin.  Four synthetic peptide antagonists were selected according to a  
consensus sequence for good antagonism: X1-N-W-N-X5-F-G-X8-R-F-NH2 where X
1 
= D-Ala or D-Tyr, X5 = Gly or D-Ser and X8 = D-Trp or D-Leu.  One of the 
antagonists, peptide 234, was used in in vivo studies, where it inhibited the 
amplitude of GnRH and LH pulses without affecting basal secretion of GnRH or 
LH.  These results indicate for the first time that basal and pulsatile secretion of 
these factors is regulated by separate pathways.  Use of the antagonist also 
  Abstract 
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demonstrated the direct involvement of endogenous kisspeptin in steroid hormone 
negative feedback, positive regulation of the pre-ovulatory LH surge and in 
regulating the onset of puberty in rodents, as had been suggested via indirect 
methods. 
 
Although a major role of the kisspeptin system is in the regulation of the HPG axis, 
the system may also be important in the inhibition of cancer cell metastasis and in 
placental development (trophoblast cell invasion) but little is known about the 
mechanisms involving kisspeptin in these processes.  This thesis describes novel 
signalling mechanisms for the regulation cell migration by kisspeptin, involving the 
MAPK and GSK3β signalling pathways. Using a stably transfected CHO cell line, 
kisspeptin-gpr-54 signalling can activate all members of the MAPK pathway, the β-
catenin/GSK3β pathway, NFκB and FAK.  These factors are involved in inhibiting 
the migration of these cells via an ERK1/2-p90rsk-GSK3β-β catenin pathway to 
potentially up- regulate formation of adherens junctions at the plasma membrane. 
This pathway was also shown to be involved in the inhibition of migration within 
an immortalised human first trimester placental trophoblast cell line and in human 
umbilical vein endothelial cells.  Some of these pathways were also active within a 
mouse GnRH neuronal cell line, where ERK1/2, NFκB and GSK3β were activated 
by kisspeptin with no effect on migration.  However, the role of these pathways in 
the GnRH neuronal cells requires further investigation. 
 
In summary, the research presented within this thesis defines receptor-binding and 
activating residues within kisspeptin-10, which should enable more details of 
ligand-receptor binding interactions to be fully elucidated. Novel gpr-54 
antagonists have been identified and used in in vivo studies. The thesis 
demonstrates the direct involvement of endogenous kisspeptin in the regulation of 
GnRH/LH secretion at the onset of puberty and throughout the reproductive cycle 
in mature animals.  The antagonists developed within this thesis represent useful 
tools to further delineate mechanisms of kisspeptin action within the HPG axis and 
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peripheral tissues.  Other findings describe kisspeptin signalling mechanisms for 
the inhibition of cell migration, potentially important in a variety of normal and 
pathological processes, including for the first time a description of the regulation of 





 Literature Review 





This literature review will cover advances in our understanding of the role of kisspeptin 
and gpr-54 in reproduction. It will focus on kisspeptin and gpr-54 as major regulators of 
the hypothalamic-pituitary-gonadal axis, their role in puberty, steroid hormone feedback 
and metabolic regulation of reproduction.   It will also review putative functions of the 
kisspeptin/gpr-54 system in peripheral reproductive systems, such as in the placenta 
where a role in inhibiting trophoblast invasion has been proposed and in the ovary where 
kisspeptin may directly regulate ovulation.  This literature review will also cover the 
signalling pathways which have been implicated in kisspeptin/gpr-54 actions and the 
specific signalling pathways examined within this thesis.  
 
1.1. Discovery of kisspeptin and gpr-54 
 
1.1.1. Discovery of kisspeptins and RFamide peptide hormones 
 
Kisspeptins are peptide products of the KiSS-1 gene, which was first discovered by Lee 
et al. in 1996 as a metastasis suppressing gene in malignant melanoma cells (Lee et al., 
1996).  As it was discovered in Hershey, USA, the gene was named after Hershey’s 
famous chocolate kisses; however, the nomenclature also has a scientific grounding as 
the inclusion of SS in the name also indicates that the gene is a cancer suppressor 
sequence. The KiSS-1 gene is located on human chromosome 1q32 and consists of 2 
non-translated and 2 partially translated regions within 4 exons to give rise to an 145 
amino acid precursor peptide (West et al., 1998).  This precursor is then cleaved to 54 
amino acids in length, which can be further truncated to 14, 13 or 10 amino acid 
carboxyl terminal fragments (Fig. 1).  Collectively these N-terminally truncated peptides 
are known as the kisspeptins, and belong to a larger family of peptides known as 
RFamides which all share a common Arg-Phe-NH2 motif at their C-terminus.  





Figure 1. Kisspeptin carboxyl terminal fragments. Schematic diagram showing the relative 
size and cleavage points for processing of human kisspeptin-145 (Kp-145) to the carboxyl 
terminal fragments, Kp-54, Kp-14, Kp-13 and Kp-10.  Also shown is the signal peptide (SP) 
within the Kp-145 precursor peptide.  The amino acid sequence for human kp-145 is given with 
kp-54 (red) and SP (blue) highlighted. 
 
 
RFamide hormones were first discovered in 1977 when FMRFamide was isolated from 
the clam, Macrocallista nimbosa, as a cardioexcitatory peptide. Since then RFamides 
have been found in many vertebrates and invertebrates, with the first mammalian 
RFamides discovered in 1985.  The two peptides, Neuropeptide FF (NPFF) and 
neuropeptide AF (NPAF), were found in bovine brain extracts using an anti-sera to the 
original RFamide (FMRFamide), and have subsequently been shown to be derived from 
a single gene. Since then, due to a breakthrough in pharmacological methods for 
identifying ligands for orphan g-protein coupled receptors (GPCRs), many more 
mammalian RFamides have been discovered (Table 1).  In fact it is by this method that 
the kisspeptin peptides were found to act on an orphan GPCR.  As more RFamides such 
as kisspeptins are discovered, it can be seen that many of these peptides have important 
functions in reproductive systems.  NPSF and NPFF have been reported to inhibit 
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release of gonadotropins in mammals and birds and kisspeptin has been shown to 
stimulate gonadotropins (Fukusumi et al., 2006). Kisspeptins are highly conserved 
within mammalian (Clements et al., 2001; Kotani et al., 2001) and non-mammalian 
vertebrates (Biran et al., 2008; Kanda et al., 2008; van Aerle et al., 2008), suggesting 
they have an important role to play in a wide range of animals. 
 
 
Table 1. Summary of mammalian RFamides and their receptors.  The designations of the 
peptide-encoding genes (farp-1 to -5) and their receptor genes (rfr-1 to -5) are proposed by 
Dockray (Dockray, 2004). Alternative names for peptides and receptors are indicated by ‘/’.  
Table taken from Fukusumi et al., Recent advances in mammalian RFamide peptides: The 
discovery and functional analyses of PrPR, RFRPs and QRFP. Peptides 2006. 27 (5): p1073-
1086. 
 
1.1.2. Discovery of gpr-54 
 
Kisspeptins are the natural ligands for the orphan GPCR known as gpr-54 in rat (Lee et 
al., 1999) and AXOR12 in humans (Muir et al., 2001).  However, for ease, throughout 
the rest of the thesis only the gpr-54 designation will be used. Gpr-54 is a 396 amino 
acid receptor and is a member of the rhodopsin family/class A g-protein coupled 
receptors (Fig. 2).  Gpr-54 was first discovered in 1999 by a PCR search of rat brain, as 
an orphan receptor related to galanin receptors (GalR).  Gpr-54 had a 45% homology to 
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GalR1-3 (Fig. 3); however it possessed a relatively low affinity for the ligand, galanin 
(Lee et al., 1999). Then in 2001, two papers reported that peptides derived from the 
KiSS-1 gene (kisspeptins) were the natural ligands for gpr-54 (Kotani et al., 2001; Muir 
et al., 2001). Muir et al. used a reverse pharmacology system, screening a large library 
of possible ligands for calcium mobilization (Muir et al., 2001).  Whereas, Kotani et al. 
purified fractions from tissue extracts where gpr-54 was known to be expressed.  These 
were then tested on an aequorin-based luminescence assay and two hplc peaks from a 
placental extract where purified and sequenced.  The sequence and mass was then 
compared to protein and nucleotide sequence libraries to identify kisspeptin-13 and 
kisspeptin-10 (Kotani et al., 2001).  Studies also discovered, that gpr-54 is highly 
conserved among mammals with the human receptor having 85% homology to the rat 
receptor, 80% homology to the mouse (Clements et al., 2001) and about 40% homology 




Figure 2. Schematic diagram of human gpr-54.  Diagram showing amino acid sequence of 
human gpr-54. The diagram shows the seven transmembrane structure of the receptor, with an 
extracellular N-terminus and cytoplasmic C-terminus.  Inactivating mutations (red) and 
activating mutations (blue) are highlighted. 
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The 10 amino acid carboxyl-terminal sequence of mature kisspeptin (kp-10) is the 
minimal length required for activation of gpr-54. The receptor couples to the Gq/11 class 
of g-proteins to activate phospholipase C (PLC) which hydrolyses phosphatidyl inositol 
bisphosphate (PIP2) in the cell membrane to diacyl glycerol (DAG) to activate protein 
kinase C (PKC) and inositol trisphosphate (IP3) which modulates release of intracellular 
calcium.  The activation of PKC then leads to phosphorylation of ERK1/2 and 
p38MAPK, reorganisation of intracellular stress fibres and induction of focal adhesion 
kinase to inhibit cell movement (Fig. 4), a process that is thought to be important for 
kisspeptin-mediated suppression of cancer metastasis. (Hori et al., 2001; Kotani et al., 
2001).  Kisspeptin can also inhibit the migration and invasive capacity of a model CHO 
cell line stably expressing the gpr-54 receptor, further suggesting a role for the system in 
the regulation of cell migration (Hori et al., 2001). 
 
1.1.3. Reproductive functions for kisspeptin and gpr-54 
 
Although kisspeptins and gpr-54 were first described in relation to cancer metastasis, 
kisspeptin action was subsequently shown to play a pivotal role in the control of the 
hypothalamic-pituitary-gonadal (HPG) axis via regulation of gonadotropin-releasing 
hormone (GnRH) secretion (Funes et al., 2003; Gottsch et al., 2004; Irwig et al., 2004; 
Messager et al., 2005). Immunohistochemical localisation and mRNA analysis of the 
receptor and ligand within the brain and peripheral tissues, demonstrated gpr-54 and 
KiSS-1 expression within the hypothalamus, brainstem, spinal cord, pituitary, ovary, 
prostate and placenta.  This localisation suggests they may regulate the reproductive axis 
at a number of levels (Castellano et al., 2006a; Clements et al., 2001; Kotani et al., 2001; 
Mead et al., 2006; Muir et al., 2001). The high expression in the placenta, led 
researchers to hypothesise that there may be a role for kisspeptin/gpr-54 in placentation.  
Then in 2004, kisspeptin was shown to inhibit the migration of primary trophoblast 
explants, supporting this hypothesis (Bilban et al., 2004).  
 
 






Figure 3.  Gpr-54 and the Galanin receptors.  Schematic alignment of Gpr-54 and GalR1-3 
with conserved residues indicated by the shaded boxes.  The schematic also highlights the seven 
transmembrane domains. Diagram taken from Lee et al. Discovery of a receptor related to the 
galanin receptors FEBS letters 1999. 446 (1): p103-107. 






Figure 4. Primary signalling pathways activate by Gpr-54 via Gαq/11.  Signalling diagram 
showing gpr-54 activating the classical Gαq/11 signalling pathway in an epithelial cell. This 
activates inositol phosphate to stimulate intracellular calcium release and diacyl glycerol (DAG) 
to activate PKC.  Activation of the MAPK and focal adhesion pathways has also been shown. 
 
 
1.2.  Structure of KiSS-1, kisspeptins and gpr-54 
 
1.2.1. Structural elements of the KiSS-1 gene 
 
The human KiSS-1 gene was first discovered in 1996 and has since been mapped to the 
long arm of chromosome 1 at 1q32 by radiation hybrid mapping and fluorescent in-situ 
hybridisation (FISH). This has been confirmed by genome sequencing (see Ensemble 
database). The gene consists of four exons of which two are non-translated and two 
translated exons (Fig. 5), which give rise to an open reading frame (ORF) of 438 base 
pairs (bp) or 145 amino acids.  The first exon consists of 109 non-coding base pairs and 
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exon 2 contains 91 non-coding bases.  Translation commences in the third exon where 
35 non-coding base pairs are followed by a putative methionine start codon and 103 
translated base pairs.  The fourth exon is the largest and contains 335 base pair long 
coding region and a stop codon followed by 121 non-coding bases, which contains a 
polyadenylation sequence (West et al., 1998). Two introns have also been partially 
identified; one is thought to be 37 bases upstream of the methionine start codon and the 
second around base 103 of the coding region. Analysis of the sequence also found the 
following homology domains:  a tyrosine kinase phosphorylation site was located within 
amino acid positions 105-112 with a sequence of REKDLPNY.  An N-myristoylation 
site was also found at amino acids 118-123; this had the sequence GLRFGK. Two PKC 
consensus sites were also found within KiSS-1 at amino acid positions 54-56 and 61-63.  
These sequences followed the motif [S/T]-X-[R/K] and finally a PKA phosphorylation 
site was located at amino acids 66-69 with the motif [R/K]2-X-[S/T].  This suggests that 
the KiSS-1 gene is modified at a number of sites to effect translation and post-





Figure 5. Schematic diagram of KiSS-1 gene.  Diagram showing intron and exon lengths, with 




1.2.2. Structural elements of kisspeptins 
 
The KiSS-1 gene encodes a polypeptide consisting of 145 amino acids, known as the 
precursor peptide to kisspeptins.  This precursor peptide contains a 19 amino acid leader 
sequence that directs the protein into the endoplasmic reticulum (ER) and which gives 
rise to a secretory precursor protein of 126 amino acids which is proteolytically cleaved 
and modified to form a C-terminal amide moiety in the Golgi membrane network 
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(Takino et al., 2003).  The kisspeptin-54 (metastin) produced is then cleaved further to 
smaller fragments of 14, 13 and 10 amino acids in length.  These fragments have 
subsequently been shown to bind to and activate gpr-54 with equal potency (Kotani et 
al., 2001).  Therefore, the final 10 amino acid fragment of the C-terminus has been used 
to analyse the structure of kisspeptins by nuclear magnetic resonance spectroscopy 
(NMR).  Two studies have used NMR to determine the structure; the first used sodium 
dodecyl sulphate (SDS) micelles NMR, which involves use of a negatively charged 
membrane.  In this study kisspeptin-13 was utilised and residues Asn7 to Phe13 were 
found to form a stable helical structure (Orsini et al., 2007). The second study utilised 
dodecylphosphocholine (DPC) micelles NMR which represent a membrane with a 
neutral charge, similar to the mammalian lipid membrane.  Using kisspeptin-10, they 
showed that Trp3 to Phe10 contained several tight turn structures but no helices.  The 
tight turns contained one β-turn from Tyr3 to Phe6; two miscellaneous type IV β-turns at 
Asn4 to Gly7 and Gly7 to Phe10; and finally one γ-turn from Ser5 to Gly7 (Lee et al., 
2009). This suggests that hydrophobic environments may cause kisspeptins to form a 




Figure 6. NMR structures for Kisspeptins. (A) NMR model from Orsini et al. (Orsini et al., 
2007) showing helical structure of kisspeptin-13. (B) NMR model from Lee et al. (Lee et al., 
2009) showing alternative tight turn structure for kisspeptin-10.  
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The use of NMR to determine the structure of kisspeptin fragments has also shown that 
hydrogen bonds are important within these peptides, with eight hydrogen bonds being 
formed within Kisspeptin-13, allowing 16 hydrogen constraints.  These are formed 
between residues Phe9, Leu11, Arg12 and Phe13.  These four residues have also been 
shown to form a pharmacophore which is important for receptor binding.  The 
pharmacophore consists of the phenyl ring of Phe9 with the Phe13 phenyl ring on top.  
These are then flanked by the positively charged Arg12, which is all in close proximity to 
the amide moiety (Fig. 7).  Even though the pharmacophore residues can form hydrogen 
bonds, it appears that the positive charge is more important for receptor binding (Orsini 
et al., 2007). 
 
 
Figure 7. Binding pharmacophore within Kisspeptin-10. (A) Diagram of binding 
pharmacophore alone showing the two phenyl rings on top of each other, next to the positively 
charged arginine. (B) Model showing position of pharmacophore within the helical NMR 
structure of kisspeptin-13. Diagrams taken from Orsini et al. Metastin (KISS-1) mimetics 
identified from peptide structure-activity relationship-derived pharmacophores and direct small 
molecule database screening J Med Chem 2007. 50(3): p462-471. 
 
 
All kisspeptins fragments have also been shown to contain a matrix metalloproteinase 
(MMP) mediated cleavage site, which is thought to be a mechanism to inactivate the 
protein.  This site is at the C-terminus consisting of Phe-Gly-Leu-Arg, where MMP-2 
and MMP-9 can cleave kisspeptin-54 between Gly51 and Leu52. MMPs have also been 
shown to form a complex with the kisspeptin precursor peptide involving the N-terminal 
48 amino acids with Cys53 being critical to this process and the propeptide domain of 
MMPs (Takino et al., 2003).   





1.2.3. Structural elements of gpr-54 
 
Gpr-54 is a member of the rhodopsin-like or class A family of g-protein coupled 
receptors located on human chromosome 19p13.3.  GPCRs are membrane bound 
receptors that contain seven hydrophobic transmembrane domains each containing 
between 25-40 amino acids.  The transmembrane (TM) domains form α-helices of 
unequal length that can extend beyond the lipid bi-layer, and these form a counter 
clockwise barrel shape perpendicular to the membrane (Fig. 8). Of these domains TM II, 
IV and VII are the most hydrophobic as they contain only one hydrophilic residue, 
whereas the other domains contain a mixture of hydrophilic and neutral residues.  
GPCRs also have an extracellular N-terminus and a cytoplasmic C-terminus as well as 3 
extracellular loops (EL) and 3 intracellular loops (IL).  Each of these loops is between 
10-40 amino acids in length except IL3 which can vary in length dramatically and 
contain up to 150 amino acids. GPCRs also have many conserved residues to ensure 
receptor activation and signalling.  For example, Aspartate in TM II and Asparagine in 
TM III are conserved to keep TM II and VII in close proximity via hydrogen bonds 




Figure 8. Structure of a Class A GPCR. Crystal structure of rhodopsin showing the counter 
clockwise orientation of the seven transmembrane domains. Diagram taken from Palczewski et 
al. Crystal Structure of Rhodopsin: a G-protein coupled receptor Science 2000. 289: 
p739-745. 
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Gpr-54 is a typical class A GPCR in primary structure with an ORF of 1191 base pairs 
or 396 amino acids.  The receptor gene contains 5 exons with 4 introns within TM II 
(800bp) and III (800bp) and ICL3 (180bp).  Gpr-54 also contains many of the conserved 
residues found in this type of GPCR.  Gpr-54 contains the conserved asparagine in TM I, 
the conserved aspartate in TM II mentioned above and conserved prolines in TM IV-
VII.  Gpr-54 also contains three consensus sequences for N-linked glycosylation at its 
N-terminus and a consensus sequence for PKC phosphorylation in IL3.  Cysteines 
involved in the classical N-terminal disulphide bond are located in EL1 and EL2. There 
are also three possible palmitoylation cysteine sites in the C-terminus (Lee et al., 1999).  
The C-terminus of gpr-54 has also been shown to be rich in proline and arginine residues 
corresponding to four overlapping Src homology 3 (SH3) domain structures (Fig. 9).  
These SH3 domains have been shown to interact with the catalytic subunit of the 
serine/threonine (Ser/Thr) protein phosphatase, PP2A.  The gpr-54/PP2A unit can then 
modulate phosphorylation of critical signalling intermediates.  As PP2A has been shown 
to be a tumour suppressor this may be a mechanism for gpr-54 mediated inhibition of 
metastasis, as PP2A is known to up regulate phosphatase and tensin homology (PTEN) 
protein to down regulate the tumour promoter Akt, via dephosphorylation of PIP2  




Figure 9. The C-terminal domain of gpr-54 contains a proline/arginine rich segment. (A). 
The C-terminus contains a region rich in Pro and Arg residues and few Ser and Thr residues. (B) 
The amino acid sequence of the Pro-Arg rich region contains four overlapping SH3 binding 
motifs. Diagram taken from Evans et al. Physical association of GPR54 C-terminal with protein 
phosphatase PP2A. Biochem Biophys Res Commun 2008. 377(4): p1067-1071.  
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GPCRs signal by interacting with heterotrimeric g-proteins to cause conformational 
changes and an exchange of guanosine diphosphate (GDP) with guanosine triphosphate 
(GTP), allowing dissociation of Gα from the βγ subunit to activate intracellular 
signalling.  Gpr-54 interacts with the Gαq/11 subunit to activate specific signalling 
mechanisms (Kotani et al., 2001).  Mutations in the receptor, have revealed that this 
interaction involves Leu148 of IL2 since dissociation of the g-protein subunits is 
disrupted by mutations at this residue (Wacker et al., 2008).  IL2 of a gpr-54/β2-AR 
model forms hydrophobic interactions with the Gα subunit that stabilises the switch II 
region of the g-protein.  This activates the subunit into a conformation that facilitates 
GDP-GTP exchange, allowing dissociation and maximising downstream signalling.  
Therefore, IL2 of gpr-54/β2-AR acts as a guanine nucleotide exchange factor (GEF).  
The Leu148 equivelant in β2-AR, Phe139, has been shown to dock in close proximity to 
the GTPase domain of the Gαq/11, where Pro
138 interaction causes a change in IL2 to 
allow Phe139 to fit into the hydrophobic groove created by α2/β4 and α3/β5 loops of the 
g-protein (Wacker et al., 2008).  Phe139 can then interact with Phe220, Val223, Trp263 and 
Phe264 of the switch II region to facilitate disociation of the Gα and βγ subunits (Fig. 10).  
This is now thought to be a mechanism common to all GPCR class A receptors.   
 
Figure 10. A model to suggest the involvement of IL2 in hydrophobic-hydrophobic 
interactions between GPCR and G-protein. (A) Docking analysis reveals that the IL2 of 
GPR54/β2-AR comes into close proximity to the GTPase domain of the activated G q subunit. 
(B) Pro138 of the β2-AR positions Phe139 so that a productive hydrophobic interaction face is 
formed with highly conserved Phe220, Val223, Trp263, and Phe264 residues of G q.  Diagram taken 
from Wacker et al. Disease-causing mutation in GPR54 reveals the importance of the second 
intracellular loop for Class A G-protein coupled receptor function. J Biol Chem 2008. 283(45): 
p31068-31078. 
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1.3.    Kisspeptin is a key regulator of puberty and the HPG axis 
 
1.3.1. Hypogonadotropic hypogonadism as a result of gpr-54 inactivating 
mutations. 
 
KiSS-1 was first shown to play a role in the reproductive axis in 2003, when two groups 
discovered that mutations in gpr-54 led to idiopathic hypogonadotropic hypogonadism 
(iHH) (de Roux et al., 2003), which is a deficiency of gonadotropin secretion from the 
pituitary. De Roux’s group found that in five affected siblings, from first cousin 
marriages, with normal GnRH receptor mRNA, a 155 nucleotide deletion in the gpr-54 
receptor was the cause of their impaired puberty (de Roux et al., 2003).  This deletion 
did not cause impaired migration of GnRH neurons from the olfactory bulb, so it could 
not be classified as Kallmann’s syndrome, but was classified as iHH and is therefore due 
to disrupted stimulation of GnRH production (de Roux et al., 2003).  Seminara et al 
found a separate gpr-54 mutation, L148S, in another family with 6 affected members 
also from first cousin marriages.  This mutation caused impaired signalling of the gpr-54 
receptor resulting in iHH.   In the same study, a non-related male with iHH was also 
found to have gpr-54 mutations, R331X and X339R, causing elongation of the receptor 
sequence due to a disrupted stop codon (Seminara et al., 2003).  Discovery of these 
mutations identified gpr-54 and kisspeptins as important regulators of puberty and the 
HPG axis. Since 2003, further mutations of the gpr-54 receptor have been found to cause 
iHH in humans.  Semple et al. found C223R and R297L mutations in one male patient 
and these gave rise to impaired signalling, with C223R causing a more severe phenotype 
than R297L in the impairment of kisspeptin stimulation of calcium release in vitro 
(Semple et al., 2005).  Another group reported that a base pair mutation 1001-1002insC 
caused iHH in association with cryptorchidism (Lanfranco et al., 2005). Then in 2007, 5 
iHH patients were shown to have a L102P mutation in gpr-54 (Tenenbaum-Rakover et 
al., 2006).  Gpr-54 mutations only account for about 2% of iHH cases (Pedersen-White 
et al., 2008) and all can be rescued by treating with GnRH or gonadotropins, which 
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induce puberty and normal reproductive function, allowing an affected individual to lead 




Table 2.  Activating and inactivating mutations of gpr-54. Table summarizing all inactivating 
and activating mutations of human gpr-54 reported to date.  The table shows the mutation, 
phenotype and effect the mutation has on receptor sequence or signalling. References are shown 
in the text. 
 
 
1.3.2. Precocious puberty as a result of gpr-54 and KiSS-1 mutations. 
 
As well as inactivating mutations of gpr-54, a mutation, R386P (Table 2), apparently 
caused prolonged signalling of the receptor leading to precocious puberty in a girl of 8 
years of age (Teles et al., 2008).  A KiSS-1 polymorphism prevalent in Chinese girls 
with precocious puberty, P110T, was also found to be statistically associated with the 
condition, although further evidence is needed to confirm that this substitution causes 
kisspeptin to constitutively activate the receptor (Luan et al., 2007).   
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1.3.3. KiSS-1 and gpr-54 knockout mice display characteristics of 
hypogonadotropic hypogonadism. 
 
At the same time as gpr-54 mutations were being found to cause iHH in humans, a gpr-
54 knockout mouse had been produced with similar findings to those from the patients 
described above. Gpr-54 -/- male mice had small testes, delayed puberty and reduced 
sexual behaviour and females had small ovaries and uteri, delayed vaginal opening, no 
maturation of follicles in the ovary and reduced sexual behaviour.  Both sexes were 
infertile and had low gonadotropin levels, although low magnitude pulses could still be 
detected, suggesting that gpr-54 signalling is not required for basal GnRH or luteinising 
hormone (LH) levels in the mouse. Gpr-54 -/- mice are still responsive to exogenous 
GnRH, showing that there is an impaired secretion of GnRH in these animals (Lapatto et 
al., 2007; Seminara et al., 2003).  The kisspeptin system, therefore appears to elevate 
GnRH pulse amplitude more than frequency (Seminara et al., 2003).  These results 
confirm the human observations and identify kisspeptins and gpr-54 as major regulators 
of puberty.  
 
More recently, KiSS-1 knockout mouse models have been developed that also display 
iHH characteristics, however the physiological effects are more variable than in the gpr-
54 knockout.  In one study, although infertile, only 50% of females had smaller uteri and 
ovaries with 50% being normal, however all had reductions in gonadotropins and sexual 
behaviour (Lapatto et al., 2007).  In a different study, all KiSS-1 -/- mice were infertile 
with delayed puberty. Female mice had delayed vaginal opening, small ovaries, thread 
like uteri, and no estrus cycle or follicle maturation due to decreased gonadotropin 
secretion.  The male mice also had delayed pubertal maturation, small testes, 
microphallus, spermatogenic arrest and decreased gonadotropins and sex steroids 
(d'Anglemont de Tassigny et al., 2007).  This shows the variability of the phenotype, as 
in one study the KiSS-1 knockout seems to be partially compensated for, but in the other 
the KiSS-1 knockout cannot be overcome by compensation.  However, both sets of 
animals were responsive to exogenous kisspeptin, showing that both active kisspeptin 
Chapter One  Literature Review 
 
 18
and gpr-54 are required for puberty to occur at the correct time.  The less complete 
phenotype in the KiSS-1 knockout mice than gpr-54 knockout mice suggests that other 
RFamide peptides may be able to partially compensate for loss of kisspeptin via 
activating gpr-54 or their own receptors. 
 
1.3.4. KiSS-1 mRNA and gpr-54 sensitivity in the hypothalamus increases 
with pubertal development. 
 
The realisation of the pivotal role of the KiSS-1/gpr-54 system in reproduction 
stimulated further research in a quest to elucidate mechanistic details.  KiSS-1 and 
possibly gpr-54 hypothalamic mRNA levels increase with pubertal maturation in mice 
(Han et al., 2005), rats (Sun et al., 2007) and primates (Keen et al., 2008; Shahab et al., 
2005).  In rodents, KiSS-1 mRNA increases in the anteroventral periventricular nucleus 
(AVPV) but not in the arcuate nucleus (ARC) during puberty (Fig. 11 and Table 3). 
There is also an increase in the number of GnRH neurons that are depolarized by 
kisspeptin during puberty.  In juvenile mice, only 27% of GnRH neurons depolarize with 
exogenous kisspeptin treatment, this increases to 45% in prepubertal mice and 90% in 
the adult.   This increase in the number of GnRH neurons that are depolarized appears to 
be due to the increase in gpr-54 sensitivity at this time and the increased kisspeptin 
neuron apposition with GnRH neurons (Han et al., 2005), along with the increase in 
kisspeptin mRNA levels, which is shown to occur throughout puberty. In the mouse, 
kisspeptin neurons show close association with GnRH neurons in the preoptic area 
(POA) and median eminence (ME) and an increase with puberty (Fig.11). These neurons 
appear from postnatal day (P) 25 and reach adult like proportions of 50% co-localisation 
in the POA at around P61 (Clarkson and Herbison, 2006). As mentioned above, another 
explanation for the increase in depolarization is that GnRH neurons and gpr-54 gain 
sensitivity to kisspeptin during puberty in the mouse.  Additionally, in prepubertal 
female rhesus monkeys, KiSS-1 mRNA increases nocturnally and by mid-puberty KiSS-
1 and gpr-54 mRNA increase 3-fold in the ARC.  In males, KiSS-1 mRNA increases 
with puberty but gpr-54 mRNA does not, suggesting that increasing KiSS-1 mRNA is a 
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controlling factor in males (Shahab et al., 2005). Also, in female rhesus monkeys, 
kisspeptin secretion increases during puberty in association with GnRH secretion and 
kisspeptin secretion in the ME becomes pulsatile with 60 minute intervals (Table 3). Of 
these pulses, 75% correlate with GnRH pulses (Keen et al., 2008). These pulses then 






Figure 11. Schematic diagram of Hypothalamus and Pituitary.  Diagram showing the layout 
of the hypothalamus in relation to the pituitary gland.  Kisspeptin neurons (red) and GnRH 
neurons (blue) are marked in the appropriate areas. 
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In order to examine the physiological consequences of increased kisspeptin during 
puberty, studies were undertaken to determine the effect of repetitive administration of 
exogenous kisspeptin to juvenile female rats (Navarro et al., 2004b) and primates (Plant 
et al., 2006).  This would reveal whether kisspeptin alone is sufficient to kick-start the 
onset of puberty.  In both studies, repetitive kisspeptin administration was able to 
advance puberty, measured in the mouse as early vaginal opening and increased uterine 
weight and in both species gonadotropins were elevated to adult levels (Navarro et al., 
2004b; Plant et al., 2006).  In both cases the advance in puberty onset appears to be due 
to kisspeptin stimulation of GnRH secretion, as GnRH antagonists completely abolished 
the advancement of puberty.   
 
These collective studies suggest that kisspeptin and gpr-54 are key regulators of puberty 
in mammals due to a programmed increase in KiSS-1 mRNA and increased gpr-54 
sensitivity to kisspeptin, possibly due to an increase in receptors at the cell surface.  
Activation of the kisspeptin system facilitates increased pulsatile release of GnRH, 
awakening the reproductive axis and bringing about pubertal maturation. 
 
1.4. Kisspeptin and gpr-54 regulate the HPG axis in adults via     
modulation of GnRH, LH and FSH production 
 
1.4.1. Acute kisspeptin stimulates secretion of luteinising hormone (LH) 
and follicle stimulating hormone (FSH) via GnRH. 
 
As mentioned above, the expression of both ligand and receptor in the hypothalamus and 
pituitary respectively, and their crucial role in puberty suggests that kisspeptins may also 
be key regulators of the HPG axis in adults.  In gpr-54 -/- and KiSS-1 -/- mice, LH levels 
were found to be significantly lower than in wild type (WT) mice even though GnRH 
receptor levels were normal and GnRH could elicit a robust LH stimulation.  This 
indicated a role for kisspeptins in LH regulation in the adult.  Kisspeptin-54 and 
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kisspeptin-10 rapidly increase plasma LH levels in adult mice (Gottsch et al., 2004), rats 
(Navarro et al., 2004a), sheep (Arreguin-Arevalo et al., 2006), cows (Kadokawa et al., 
2008), primates (Plant et al., 2006) and humans (Dhillo et al., 2005; Dhillo et al., 2007) 
in a dose-dependant manner.  Doses as low as 1fmol given centrally 
(intracerebroventricular (icv)) are effective (Gottsch et al., 2004), making kisspeptin the 
most potent stimulator of LH known to date.  Low doses of 10pmol to 1nmol have also 
been shown to be active systemically (intraperitoneal (ip) and intravenous (iv)) in 
rodents (Navarro et al., 2005b; Thompson et al., 2004).  The demonstration that 
kisspeptin stimulation of gonadotropins can be abolished by administering a GnRH 
receptor antagonist suggests that kisspeptin operates at the level of the hypothalamus to 
stimulate GnRH release rather than directly at the pituitary (Fig. 12) (Gottsch et al., 
2004; Navarro et al., 2005b). Castellano et al. have attempted to delineate the 
mechanism behind kisspeptin activation of gonadotropins in the rat.  Kisspeptin 
stimulation of LH could be blocked by PLC, calcium and MAPK inhibitors using 
hypothalamic explants pre-incubated for 60 min, however, no further evidence to 
support these pathways has been produced (Castellano et al., 2006b).   
 
In gpr-54 and KiSS-1 knockout mice, follicle stimulating hormone (FSH) levels also are 
lower than in controls (Lapatto et al., 2007).  Again, kisspeptin has been shown to 
stimulate release of FSH in adult rats (Navarro et al., 2005a), mice (Gottsch et al., 2004) 
and humans (Dhillo et al., 2005).  However, in the rat a 100-fold higher dose of 
kisspeptin is required to stimulate FSH than for LH secretion, with an EC50 of 400nmol.   
Activation of FSH secretion also occurs via GnRH, as GnRH antagonist again blocks the 
kisspeptin stimulation (Navarro et al., 2005a).  However, most studies have concentrated 
research on LH because FSH stimulation is of a much lower magnitude than that for LH.  
Further studies are required to fully elucidate kisspeptins effects on FSH production. 
 





Figure 12. Kisspeptin stimulates GnRH release in the hypothalamus. Diagram showing 
kisspeptin stimulates GnRH release within the hypothalamus.  This in turn causes secretion of 
gonadotropins from the pituitary into the circulation to act on the gonads.  
 
 
1.4.2. Chronic kisspeptin administration disrupts secretion of luteinising 
hormone (LH) and follicle stimulating hormone (FSH). 
 
As described above, acute injection of kisspeptin stimulates LH release and repeated 
injections produce LH pulses (Tovar et al., 2006).  Continuous iv injections of kisspeptin 
in rodents and primates over 4 days initially stimulate LH, but after 3-4 hours of 
stimulation this rise begins to fall, reaching control levels by 24 hours.  This has been 
attributed to desensitization of the gpr-54 receptor, as GnRH injection is still able to 
increase LH secretion during the last 3 days of kisspeptin infusion in adult male mice 
and primates (d'Anglemont de Tassigny et al., 2008; Ramaswamy et al., 2007). Also, 
after the infusion is completed, acute kisspeptin administration cannot induce LH until 
the receptor recovers about 2 hours later. However, in female adult rats, the elevation of 
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LH lasted for 48 hours during a 7 day infusion and in peri-pubertal female rats, 
desensitization did not occur, suggesting a change in gpr-54 sensitivity during puberty or 
an increase in inputs to gpr-54 from kisspeptin neurons (Roa et al., 2008d).  
Nevertheless, it is evident that gpr-54 desensitizes with time, so chronic administration 
may be a useful tool therapeutically for inhibiting gonadotropins and sex steroids as 
currently accomplished by GnRH agonists in treating hormone-dependant diseases.  
 
1.4.3. Kisspeptin neurons are located in the hypothalamus and directly 
contact GnRH neurons. 
 
KiSS-1 mRNA and protein have been localised in the ARC and the AVPV of the rodent 
hypothalamus, with a small group of neurons also being identified in the periventricular 
nucleus (PeN) (Clarkson and Herbison, 2006; Gottsch et al., 2004; Kauffman et al., 
2007a). However, in the ewe and in primates, kisspeptin neurons are not located within 
the AVPV (Franceschini et al., 2006; Rometo et al., 2007). The kisspeptin neurons 
project into the ME and POA regions within the hypothalamus, which also possess 
GnRH neurons (Franceschini et al., 2006; Pompolo et al., 2006). Double 
immunoflourescence has revealed that 85% of the GnRH neurons in the ME of rats 
contain gpr-54 on their cell surface and express increased levels of c-fos in response to 
kisspeptin-10 (Irwig et al., 2004; Matsui et al., 2004) .  There is also a close association 
between 70-90% of GnRH and kisspeptin neurons in mice (Clarkson and Herbison, 
2006), sheep (Pompolo et al., 2006) and rhesus monkey (Ramaswamy et al., 2008), 
suggesting that kisspeptin acts directly at the GnRH neurons to regulate the HPG axis.  
However, these associations differ in brain regions between different species. In the 
mouse, kisspeptin axons associate with GnRH cell bodies and dendrites in the POA 
(Clarkson and Herbison, 2006).  In the sheep, co-localization is seen in both the ME and 
POA (Pompolo et al., 2006), and in the primate, associations occur in the ME but this 
time between kisspeptin and GnRH axons (Ramaswamy et al., 2008).  However, it is yet 
to be determined if these differences are species related or simply due to differences in 
the primary and secondary fluorescent antibodies used in each study. 
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1.4.4. Kisspeptin and gpr-54  in the anterior pituitary. 
 
The role of kisspeptin in the pituitary has been debated, with conflicting results obtained 
in vitro on primary pituitary cell cultures.  Some groups have seen no effect of 
kisspeptin on rat anterior pituitary cells (Matsui et al., 2004), whereas another group 
showed increased Ca2+ in 10% of cells, along with stimulation of LH and growth 
hormone (GH) (Gutierrez-Pascual et al., 2007).  However, the doses used in this study 
were extremely high compared to other studies and the effects may be due to activation 
of other RFamide receptors.  LHβ-expressing cells within rat pituitary explants 
expressed KiSS-1 mRNA; however KiSS-1 mRNA was also detected in other pituitary 
cells, possibly somatotropes. Gpr-54 mRNA was located in a subset of these LHβ 
expressing cells, suggesting the machinery is present for kisspeptin to have direct 
pituitary effects. Pituitary KiSS-1 mRNA appears to be regulated by estrogen and gpr-54 
appears to be regulated by GnRH, making it plausible for direct effects to occur in the 
rat (Richard et al., 2008).  However, all of these studies have used highly sensitive PCR 
techniques that do not reveal whether expression of gpr-54 and kisspeptin is functionally 
significant.  Moreover, pharmacological doses of kisspeptin were required to elicit 
effects on the pituitary.   
 
In ovine anterior pituitary cells, gpr-54 mRNA is present in gonadotropes, somatotropes 
and lactotropes.  Administering kisspeptin to these cells when taken during the follicular 
phase causes an 80% increase in LH release. However, anterior pituitary cells taken 
from all other stages of the ovine cycle did not respond to kisspeptin administration. 
Also, in ovariectomised (OVX) ewes which were hypothalamus-pituitary disconnected 
(hence ablating effects of GnRH on the pituitary); no stimulation of LH by kisspeptin 
was seen at any time during the cycle (Smith et al., 2008).  Furthermore, although 
kisspeptin is present at low levels in the hypophysial blood, this was not affected by 
estrogen, even at LH surge levels (Smith et al., 2008).  Thus in vivo findings in contrast 
to in vitro findings indicate that direct pituitary effects of kisspeptin are not important 
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for LH release. Overall, there is no convincing data demonstrating that direct effects of 
kisspeptin at the level of the pituitary are important for regulation of the HPG axis. 
 
1.5. Kisspeptin and gpr-54 mediate steroid feedback on the HPG axis 
 
1.5.1. Kisspeptin and gpr-54 mediate negative steroid feedback within the 
HPG axis. 
 
It has been known for many years that the HPG axis is under the control of steroid 
hormone feedback from the gonads.  Steroid hormone levels fluctuate across the cycle in 
females (Almond and Dial, 1990; Gill et al., 2002; Karsch and Evans, 1996; Moenter et 
al., 2003).  However, the mediator of steroid hormone feedback has remained elusive for 
many years, as GnRH neurons only possess estrogen receptor β (ERβ) which does not 
play a role in feedback (Herbison and Pape, 2001).  Therefore, neurons upstream of the 
GnRH neuron, which possess estrogen receptor α (ERα), progesterone receptor (PR) and 
androgen receptor (AR) have been sought as possible mediators of steroid effects on 
GnRH release.   
 
Kisspeptin neurons express ERα, PR and AR and therefore have the potential to relay 
feedback effects onto the GnRH neuron. Regulation of KiSS-1 expression is likely be a 
mediator of negative feedback in mouse (Smith et al., 2005a; Smith et al., 2005b), rat 
(Adachi et al., 2007), ewe (Franceschini et al., 2006; Goodman et al., 2007; Smith et al., 
2006b) and human (Rance, 2008).  Evidence now suggests that reduced activity of 
kisspeptin neurons in the ARC of rodents, primates and sheep is responsible for 
translating estrogen negative feedback to GnRH neurons.  OVX female and castrated 
male mice (Smith et al., 2005a; Smith et al., 2005b), sheep (Pompolo et al., 2006; Smith 
et al., 2006b) and  rhesus monkeys (Rometo et al., 2007; Shibata et al., 2007) have an 
increased level of KiSS-1 mRNA in the neurons compared to controls (Table 3).  Also, if 
estrogen replacement is given to OVX female or testosterone is given to castrated male 
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mice, sheep and rats, then KiSS-1 mRNA levels are reduced to control levels (Pompolo 
et al., 2006; Rometo et al., 2007; Shibata et al., 2007; Smith et al., 2006b; Smith et al., 
2006c; Smith et al., 2005b).  This suggests that steroids are negatively regulating KiSS-1 
mRNA in the ARC, hence reducing stimulation of GnRH neurons.  KiSS-1 mRNA 
regulation by steroids is specifically mediated via the ERα isoform as PPT, a specific 
inhibitor for this ER isoform blocks the reduction of neuronal KiSS-1 mRNA in the 
ARC, but DPN an ERβ specific inhibitor does not affect these mRNA levels (Bateman 
and Patisaul, 2008).  Also ERα -/- mice do not have any steroid negative feedback on 
KiSS-1 mRNA levels in the hypothalamus (Smith et al., 2005a). 
 
This negative regulation of kisspeptin by steroids was also revealed by analyses of  
KiSS-1 mRNA regulation across the rat ovarian cycle in the ARC (Table 3), where levels 
increased at diestrus when estrogen levels are low and decreased at proestrus when 
estrogen levels are elevated (Adachi et al., 2007).  Further evidence for negative 
feedback is derived from females at the time of menopause, when estrogen is low due to 
reduced follicle numbers in humans and rhesus monkeys.  At this time, a rise in KiSS-1 
mRNA and in turn LH is seen accompanied by cellular hypertrophy, similar to the rise 
in OVX female rhesus monkey (Kim et al., 2008; Rance, 2008; Rometo et al., 2007), 
which is thought to be due to the lack of negative feedback from the follicles.   
 
However, kisspeptin cannot be the only factor effecting GnRH secretion, since in the 
gpr-54 knockout mouse, there are still basal pulses of LH (Colledge, 2009; Seminara et 
al., 2003).  It has been shown that KiSS-1 co-localises with two other groups of ERα, PR 
and AR positive peptidergic neurons; the dynorphin A neuron and the neurokinin B 
neuron (Goodman et al., 2007). Recently, a mutation in the neurokinin B receptor in 
man has been shown to affect the HPG axis and reproduction.  Therefore, it is possible 
that the different types of neuron work in concert to regulate negative feedback and the 
HPG axis in the ARC (Topaloglu et al., 2009).  However, this may not be the case in 
mice, where neurokinin B knockouts do not display a reproductive phenotype 
(Nordquist et al., 2008; Siuciak et al., 2007). 
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1.5.2. Kisspeptin and gpr-54 mediate positive steroid feedback via an 
anatomically distinct neuronal pathway. 
 
As well as eliciting negative feedback, estrogen also induces positive feedback on the 
HPG axis at the time of the pre-ovulatory LH surge in females.   The LH surge occurs 
when estrogen reaches a threshold level synchronising GnRH neuron secretory activity 
to stimulate the LH surge for ovulation, followed by a secondary FSH surge on the 
morning of estrus in rats (Roa et al., 2008a).  Again, due to the lack of ERα in GnRH 
neurons, estrogen appears to act upstream of these neurons.  Kisspeptin neurons are 
perfectly placed to mediate this response.  In mice and rats, positive feedback is 
regulated by a separate group of kisspeptin neurons in the AVPV, which are associated 
with the LH surge (Adachi et al., 2007; Smith et al., 2005a; Smith et al., 2006d).  This 
association can be demonstrated at the level of the neuron, where KiSS-1 mRNA is 
decreased in the AVPV of OVX female rats and its levels increase with estrogen 
replacement (Table 3) (Smith et al., 2005a).  Positive feedback on KiSS-1 mRNA in the 
AVPV can also be shown in intact female rats, where AVPV KiSS-1 mRNA increases 
on the afternoon of proestrus (Table 3) and expression of c-fos increases in kisspeptin 
neurons just before the LH surge when estrogen is at its highest levels (Adachi et al., 
2007). The kisspeptin neurons in the AVPV may project to the POA as kisspeptin 
blockade in the POA, using neutralising antibodies, inhibits the LH surge, proving the 
importance of kisspeptin neurons in positive feedback (Adachi et al., 2007). As with 
negative feedback, positive feedback is regulated through ERα, as blockade of this 
receptor completely inhibits the gonadotropin surge and ovulation in mice and rats 
(Adachi et al., 2007; Kinoshita et al., 2005; Roa et al., 2008c).   
 
In contrast to mice and rats, in sheep and primates kisspeptin neurons are only localised 
to the ARC and PeN and not the AVPV. Here, the ARC appears to be responsible for 
both negative and positive feedback (Estrada et al., 2006; Pompolo et al., 2006; Smith et 
al., 2007).  In adult ewe neurons, KiSS-1 mRNA in the caudal ARC rises during the 
follicular phase and in the rostal ARC at estrus when the LH surge occurs (Estrada et al., 
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2006).   This suggests the ARC is responsible for modulating the positive steroid 
feedback in the ewe.  In the intact ewe, during the estrus cycle, kisspeptin can 
synchronise LH surges and during anoestrus, administration of kisspeptin can cause 
ovulation to occur, suggesting that when kisspeptin levels are high enough they can 
stimulate the LH surge and they are therefore probably involved in relaying positive 
feedback to GnRH neurons (Caraty et al., 2007).  
 
1.5.3. Steroids are responsible for sexual dimorphism of KiSS-1 
expression in neurons in the rat AVPV. 
 
In the AVPV of rats, females have 12-fold higher KiSS-1 mRNA expression than males, 
probably in order to produce a synchronised LH surge.  This elevation appears to be due 
to steroid exposure during neonatal life. If female rats are exposed to testosterone 
neonatally, they develop male levels of kisspeptin in the AVPV and conversely male 
gpr-54 knockout mice develop female levels, due to low testosterone levels.  However,   
kisspeptin levels in the rat ARC are not affected (Kauffman et al., 2007a; Kauffman et 
al., 2007b) .   This suggests that testosterone in neonatal life, in both males and females, 
is important in developmental differentiation of kisspeptin neurons in the AVPV. 
 
 
Overall, it is apparent that kisspeptin neurons are important mediators of steroid 
feedback in many species, to regulate LH release throughout the oestrous cycle and to 
synchronise release at the time of the GnRH/LH surge (Fig. 13). Evidently, steroids are 
important regulators of kisspeptin neurons and play an important role in the regulation of 














Table 3. Regulation of KiSS-1 and gpr-54 within the hypothalamus. Table showing the 
effects on KiSS-1 and gpr-54 mRNA within the hypothalamus in response to different stimuli 
such as steroid hormones and puberty. 





Figure 13. Kisspeptin mediates positive and negative steroid feedback. Diagram showing 
positive and negative feedback inputs into the HPG axis through KiSS-1 neurons in the AVPV 
and ARC within the hypothalamus of rodents, which project to co-localise with GnRH neurons 
in the preoptic area and median eminence. In sheep and primates, the ARC but not the AVPV is 
involved in both negative and positive feedback. 
 
 
1.6. KiSS-1 neurons are influenced by environmental and metabolic factors 
 
1.6.1. Kisspeptin is regulated by photoperiod in seasonal breeders. 
 
Environmental factors such as photoperiod play a regulatory role in the HPG axis via 
regulation of GnRH production (Porkka-Heiskanen et al., 1997). In view of its major 
role in the regulation of the GnRH neuron, kisspeptin neurons were hypothesised to 
relay photoperiod effects on GnRH neurons in seasonally breeding species.  In seasonal 
breeders such as sheep, cattle and hamsters, activation of the reproductive axis is 
controlled by melatonin produced from the pineal gland, which is secreted at night only 
and therefore relays day-length to the body (Bittman et al., 1985). Three animal models 
have been employed to look at these effects, the Siberian and Syrian hamsters (long day 
breeders), and sheep (short day breeders; see Table 3). 
Chapter One  Literature Review 
 
 31
Female Siberian hamsters are sexually active during long days (LD), when melatonin 
secretion is reduced.  During this time KiSS-1 levels in the ARC are decreased, while 
AVPV KiSS-1 levels are increased, to give optimum conditions for conception (Mason 
et al., 2007).  However, during short days (SD) when female Siberian hamsters are in 
anoestrus the opposite occurs, with high KiSS-1 levels in the ARC and low levels in the 
AVPV (Table 3)  (Greives et al., 2006; Mason et al., 2007). In the Syrian Hamster, also 
a long day breeder, no staining was found in the AVPV, but an increase in KiSS-1 
staining was seen in the ARC during LD and a decrease was seen during SD.  This 
response to seasonal breeding appears to be a result of melatonin production as pineal 
gland ablation prevents the reduction in ARC KiSS-1 during SD (Revel et al., 2006). 
Thus melatonin is important for KiSS-1 regulation in both Siberian and Syrian hamsters 
but evidence of functional melatonin receptors on kisspeptin neuronal cells has not been 
demonstrated so far.  
 
In the ewe, which is a short day breeder and so responds to a long melatonin secretion 
period, KiSS-1 mRNA in the ARC is increased during SD when oestrus occurs, and 
ARC KiSS-1 expression is decreased during LD for anoestrus (Table 3) (Smith et al., 
2006b). This allows activation of the LH surge during oestrus but inhibition during 
anoestrus (a mechanism which has evolved to co-ordinate reproduction with seasonal 
availability of food).  However, seasonal endocrine physiology can be overcome with 
exogenous kisspeptin, which when given continuously for 30 hours can cause ovulation 
in 80% of ewes during anoestrus (Caraty et al., 2007).  This shows that kisspeptin is a 
potent regulator of the HPG axis, even when the system is dampened. 
 
Therefore, kisspeptin neurons represent a conserved mechanism for relaying 
photoperiodic cues in seasonal breeding animals (Fig. 14). The neuronal networks and 
melatonin actions are yet to be delineated.   
 





Figure 14. Kisspeptin mediates environmental and metabolic signals to GnRH.  Diagram 
showing that as well as mediating steroid feedback, KiSS-1 neurons also integrate 
signals from the environment via melatonin and from metabolism via leptin and then 
relay these signals to the GnRH neuron. 
 
 
1.6.2. Kisspeptin is regulated via Leptin signalling. 
  
Metabolic factors, such as body mass index (BMI) have profound effects on 
reproduction.  This is manifestly evident in female dancers and athletes when body 
weight declines to low levels during intense training, resulting in amenorrhea (Shade, 
1983).   Leptin, an adipose-derived hormone is known to affect metabolism, food intake 
and reproduction (Bluher and Mantzoros, 2007) and leptin increase is proposed to 
regulate the onset of puberty (Bluher and Mantzoros, 2007).  Around 40% of kisspeptin 
neurons in the mouse possess leptin receptors (Smith et al., 2006a); this implicates 
kisspeptin neurons as mediators of metabolic control of the HPG axis and puberty. 
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In order to examine the effect of leptin on KiSS-1, two models, the ob/ob mouse, which 
lacks leptin due to a spontaneous single base pair mutation, and states of under-nutrition 
have been studied.  In the ob/ob mouse, KiSS-1 expression in the ARC is reduced 
compared to controls (Table 3) and this is partially rescued by leptin replacement (Smith 
et al., 2006a).  The same is also true for gpr-54 mRNA, indicating that leptin can 
regulate KiSS-1 and gpr-54 mRNA (Luque et al., 2007).  In adult mice subjected to short 
term fasting, there is a rapid decline in both KiSS-1 and gpr-54 mRNA (Table 3) at 
around 12-24 hours followed by a decrease in GnRH at 48 hours (Luque et al., 2007).  In 
fasting prepubertal rats, KiSS-1 mRNA is still decreased but gpr-54 mRNA is increased 
at this stage (Castellano et al., 2005).  However, opposite gpr-54 responses are seen in 
underfed animals subjected to continuous kisspeptin infusion. In the presence of 
continuous kisspeptin infusion, underfed adult female rats, have a prolonged LH 
response to kisspeptin, which lasts 5 days, compared to 2 days in control rats and in 
underfed female peri-pubertal rats, LH responds for the entire seven days with no sign of 
receptor desensitization (Roa et al., 2008d).  These results suggest that leptin positively 
regulates gpr-54 mRNA in pubertal and adult life (Figure 13), as these responses were 
mimicked by leptin administration.  Induction of gpr-54 mRNA appears to be more 
sensitive to leptin during puberty than in adults.  The above evidence places kisspeptin 
and gpr-54 as major mediators of metabolic signals to GnRH and the HPG axis. 
 
1.7. Kisspeptin and gpr-54 may have direct actions at peripheral sites 
 
1.7.1. Kisspeptin expression and effects in the ovary. 
 
Expression of KiSS-1 and gpr-54 has been detected in peripheral tissues in addition to 
the hypothalamus and other brain regions.  Expression has been noted within the testis 
and the ovary.  No functional effect of kisspeptin has been found in the testis, but 
regulation of KiSS-1 mRNA around the time of ovulation has been noted in the ovary.  
In the rat ovary, KiSS-1 and gpr-54 mRNA expression is found in the ovarian surface 
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epithelium (OSE) and interstitial glands of the stroma at all stages of the cycle.  Whereas 
KiSS-1 and gpr-54 expression in the follicle was stage dependant, with staining in the 
theca layer of growing and preovulatory follicles from oestrus to early proestrus, which 
then switched to the granulosa cell layer of preovulatory follicles in late proestrus.  After 
ovulation, expression returned to the theca-lutein cells of the corpus luteum and 
decreased as the corpus luteum regressed.  Also expression levels fluctuated with the 
oestrus cycle with expression increasing on the afternoon of proestrus just preceding the 
LH surge and ovulation and then sharply decreasing thereafter.  The increase in KiSS-1 
mRNA seems to be directly associated with the increase in LH at the time of the surge. 
If the LH surge is absent then this rise does not occur.  Administration of human 
chorionic gonadotropin (hCG), to rats, increased KiSS-1 mRNA in the ovary, suggesting 
the ovarian rise in KiSS-1 mRNA is regulated by LH.  In prepubertal female rats, KiSS-1 
expression in the ovary is very low, due to low LH levels, but this can again be 
overcome by hCG administration (Castellano et al., 2006a). Therefore, kisspeptin and 
gpr-54 show spatial and temporal expression changes in the ovary during the oestrus 
cycle, which suggests a functional role.   
  
KiSS-1 and gpr-54 expression has also been reported in the human and marmoset ovary. 
In both species, KiSS-1 mRNA can be seen in the follicle, corpus luteum, interstitial 
glands and the OSE, whereas gpr-54 mRNA was only found in the thecal and luteal cells 
of the follicle.  The mechanism of KiSS-1 regulation in the ovary was also investigated 
in this study.  KiSS-1 mRNA but not gpr-54, cyclooxygenase (COX)-2 or progesterone 
mRNA was dramatically inhibited with the COX inhibitor, indomethicin. The decrease 
is due to inhibition of COX-2 as a specific inhibitor of this, NS398 but not a COX-1 
inhibitor, SC506, caused the same phenomenon.  The decrease could also be rescued by 
the prostaglandin, PGE2 (Gaytan et al., 2009).  This places the prostaglandin pathway as 
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1.7.2. Kisspeptin and the placenta 
 
One of the largest peripheral sources of kisspeptin in the human is the placenta. In the 
human placenta, KiSS-1 mRNA is located within the syncytiotrophoblast cells (Bilban et 
al., 2004; Horikoshi et al., 2003) and gpr-54 mRNA is located in the syncitio-, villous 
and extravillious trophoblast cells (Fig. 15), suggesting possible paracrine actions 
(Bilban et al., 2004).  KiSS-1 mRNA and protein are increased with pregnancy in 
humans, and in the placenta appears to be highest in the first trimester (Bilban et al., 
2004). However, in the maternal plasma KiSS-1 protein dramatically increases 
throughout pregnancy. In non-pregnant plasma the kisspeptin concentration is around 
1.3fmol/ml this increases to ~1230fmol/ml in the first trimester and rises to 
~9590fmol/ml at term.  After delivery kisspeptin levels return to normal within 5 days 
suggesting the source of kisspeptin is the placenta (Horikoshi et al., 2003),  this is in 
contrast to the decreasing levels within the placenta itself.   Gpr-54 mRNA and protein 
is also found in the placenta and levels are shown to be highest in the first trimester with 
a steady decline until term (Bilban et al., 2004).  This suggests a role in implantation and 
placentation.  Similar results are also seen in the mouse with KiSS-1 and gpr-54 
expression only found in the cytotrophoblasts. Again, gpr-54 is highest in the first 
trimester but KiSS-1 expression appears constant throughout the pregnancy, suggesting 
possible species differences (Janneau et al., 2002).  KiSS-1 appears to be a conserved 
regulator of placentation as it can also be located in the trophoblast giant cells within the 
rat placenta, were again KiSS-1 and gpr-54 is highest early in placentation at embryonic 
day (E) 12.5 but has been completely lost by E18.5 (Terao et al., 2004).  
 
The role of the kisspeptin system in the placenta is thought to be the regulation of 
trophoblast cell invasion. Trophoblast invasion of the uterine deciduum is important to 
allow remodelling of the maternal arteries, to provide sufficient blood flow to the 
developing foetus. This requires a balance of inhibitory and stimulatory signals to the 
invading trophoblast cell population. Kisspeptin-10, the form found in the placenta 
(Bilban et al., 2004) has been shown to inhibit migration of primary trophoblast explants 
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and primary cell cultures and this is related to a decrease in MMP expression (Bilban et 
al., 2004). Kisspeptin and gpr-54 may also be important in the pathophysiology of the 
placenta.  In pre-eclampsia, where trophoblast invasion is shallow, KiSS-1 mRNA and 
protein are elevated and these increase with disease severity.  This has been correlated 
with a decrease in the expression of MMP-9 and decreased birth weight (Qiao et al., 
2005).  KiSS-1 expression is also significantly higher in the placenta during pre-term 
labour but circulating levels do not change (Torricelli et al., 2008).  This suggests that 
during pregnancy, placental kisspeptin is very important and that its primary role is to 






Figure 15.  KiSS-1 and gpr-54 expression in the placenta.  (A) KiSS-1 expression within the 
syncytiotrophoblasts (ST) of the invading placenta (shaded cells).  (B)  Gpr-54 expression within 
the syncytiotrophoblasts (ST), villous (vCT) and extravillious (evCT) cytotrophoblasts of the 
invading placenta (shaded cells).  Diagram taken from Hiden et al., Kisspeptins and the 
placenta: Regulation of trophoblast invasion Rev Endocr Metab Disord, 2007. 8(1): p 31-39. 
 
 
Chapter One  Literature Review 
 
 37
1.7.3. Putative role of kisspeptin in cancer metastasis 
 
Kisspeptin was first discovered as an anti-metastatic factor in cancer tissues. However, 
since then data has been varied and at times contradictory.  In many cancer tissues such 
as clear cell ovarian cancer (Prentice et al., 2007), epithelial ovarian cancer (Hata et al., 
2007), pancreatic cancer (Katagiri et al., 2009; Masui et al., 2004; Nagai et al., 2009) 
and melanomas (Nash et al., 2007), kisspeptin and gpr-54 expression have been 
positively correlated with increased patient survival.  However in other cancers such as 
estrogen positive breast cancer (Marot et al., 2007), transition cell carcinoma of the 
bladder (Nicolle et al., 2006) and hepatocellular cancer (Schmid et al., 2007), kisspeptin 
and gpr-54 have been correlated with decreased survival. Yet, in estrogen positive breast 
cancers, kisspeptin is also associated with decreased invasion (Marot et al., 2007).  
Therefore, it would appear that even though kisspeptin is not always associated with a 
positive outcome, it does appear to inhibit cancer cell invasion. 
 
Different mechanisms of function have been hypothesised for this inhibition of 
metastasis. Some publications have shown an increase in ERK1/2 phosphorylation and a 
decrease in MMP-2 as described in the placenta (Masui et al., 2004; Ringel et al., 2002; 
Yoshioka et al., 2008). Other suggested mechanisms include antagonism of stromal cell-
derived factor-1 (SDF-1) signalling to inhibit the pro-metastatic properties of its 
chemokine receptor CXCR4. This may involve the up regulation of modulatory 
calcineurin-interactin protein-1 (MCIP-1), a chemokine capable of inhibiting the 
calcinuerin signalling pathway (Navenot et al., 2005; Stathatos et al., 2005).  Another 
hypothesis is that kisspeptin is regulated by Specificity Protein 1 (SP1) and its co-
activator DRIP130 which is located on chromosome region 6q16.3q23.  When Loss of 
hetrozygosity (LOH) occurs at this region KiSS-1 gene expression is frequently lost 
from tumours and allows metastasis to occur. This can be rescued by SP1 and DRIP130 
transcription factor which can lead to inhibition of invasion and migration (Mitchell et 
al., 2007; Shirasaki et al., 2001).   However, further research is needed to delineate the 
signalling pathways further and to evaluate an association with cancer prognosis. 
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1.7.4. Kisspeptin and gpr-54 are expressed in non-reproductive tissues 
 
The kisspeptin/gpr-54 system has been shown to have effects in other regions of the 
brain and periphery not connected with reproduction.  In the brain, KiSS-1 and gpr-54 
mRNA are located in the hippocampal dentate gyrus, where kisspeptin-10 can up 
regulate the excitatory post-synaptic current (EPSC) of the dentate granule cells by 
increasing the amplitude but not frequency of the current.  This increase in synaptic 
transmission is via a MAPK pathway, which may be regulated via camodulin-dependant 
kinase (CaMK) and tyrosine kinase mechanisms (Arai et al., 2005).  KiSS-1 mRNA is up 
regulated in kainite-induced seizures in the hippocampus of rats via a α-amino-3-
hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) dependant mechanism.  Kisspeptin 
can also increase brain-derived neurotrophic factor (BDNF) levels in the hippocampus, a 
factor that is critical for hippocampus function and correlates with the severity of 
seizures in this region (Arai and Orwig, 2008). 
 
In peripheral tissues, kisspeptin has a putative role as a vasoconstrictor in aortic smooth 
muscle. In addition KiSS-1 and gpr-54 mRNA have been localised to the vascular 
endothelial cells and atherosclerotic plaques of the coronary artery.  However, further 
work is needed to discover the relevance of this vasoconstriction and if this system is 
active in vivo (Mead et al., 2006).  In the adrenal gland, gpr-54 mRNA has been 
localised to the neocortex of human adrenals, with a 50% increase in foetal compared to 
adult adrenal glands.  In this gland, kisspeptin-54 can stimulate secretion of aldosterone 
into the kidney vasculature to regulate blood fluid levels and blood pressure (Nakamura 
et al., 2007).  In the pancreas, KiSS-1 and gpr-54 mRNA have been found in human and 
mouse islet cells of the endocrine pancreas, where kisspeptin can augment release of 
glucose-induced insulin in a high-glucose environment (20mmol/l) in humans and rats.  
This increase in insulin acts via receptors in the periphery as iv but not icv injection 
stimulates this increase and this has again been shown to involve the ERK1/2 pathway 
(Bowe et al., 2009; Hauge-Evans et al., 2006).  This set of studies indicates that 
kisspeptin may regulate a wide range of effects in the body. 
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1.8. Signalling Pathways activated by gpr-54 
 
To date a limited number of signalling pathways have been evaluated for involvement in 
the kisspeptin/gpr-54 pathway.  These evaluations have predominantly been in relation 
to two areas of kisspeptin action: GnRH secretion from the GnRH neuron and kisspeptin 
actions in cancer metastasis. This section will focus on the pathways activated in these 
two settings. As mentioned in section 1.1.2, kisspeptin signalling mechanisms were first 
investigated in CHO cells stably expressing gpr-54, where kisspeptin stimulation, 
through Gq/11, activated PLC to hydrolyse PIP2 to IP3, which increased intracellular 
calcium release and generated DAG, which activated PKC and this in turn activated the 
MAPK pathway. 
 
1.8.1. Kisspeptin signalling in GnRH neurons 
 
KiSS-1 neurons directly contact GnRH neurons expressing gpr-54 to cause secretion of 
GnRH into the hypophysial portal blood to act on the pituitary. The signalling 
mechanisms of this secretion have recently been delineated.  Using GnRH neurons from 
GFP-transgenic mice, it was shown that kisspeptin causes depolarisation of GnRH 
neurons in a dose-dependant manner.  This occurs via activation of sodium-dependant, 
non-selective cationic channels, possibly TRPC-like channels as the depolarisation is 
blocked by 2-APB an inhibitor of TRPC channels.  This activation is also accompanied 
by inhibition of inwardly rectifying (Kir) potassium channels (Liu et al., 2008; Zhang et 
al., 2008).  This inhibition may be due to a blockade of GABAB receptors, as kisspeptin 
has been shown to inhibit GABAB and the subsequent Kir potassium channel activation 
(Zhang et al., 2009).  This mechanism of cationic channel activation and potassium 
channel inhibition is dependant on PLC and the IP3 receptor, and therefore influences 
both plasma membrane and endoplasmic reticulum-driven calcium release (Fig. 16).  
Plasma membrane tetradotoxin-sensitive channels have also been implicated in GnRH 
neuronal depolarisation (Constantin et al., 2008). 






Figure 16. Kisspeptin signalling in the GnRH neuron.  Schematic diagram of the signalling 
pathways and ion channels operated by kisspeptin in the GnRH neuron to activate GnRH 
secretion.  This shows the importance of intracellular and extracellular calcium.  Diagram taken 
from Colledge, W. H., Kisspeptin and GnRH neuronal signalling Trends Endocrinol Metab, 




1.8.2. Kisspeptin signalling in cancer cells 
 
Researchers have utilised cancer cells to investigate the signalling pathways activated by 
kisspeptin and gpr-54.  In CHO cells, kisspeptin-10 desensitizes the chemokine receptor, 
CXCR4 response to SDF-1 causing a decrease in calcium release and inhibiting 
phosphorylation of Akt/PKB via cross-talk between the two GPCRs.  This in turn blocks 
chemotaxis mediated via CXCR4 in these cells as mentioned previously (Navenot et al., 
2005). Kisspeptin also activates the chemokine, MCIP-1 to inhibit calcineurin release in 
thyroid cancer cells (Stathatos et al., 2005).  Whereas, Sp-1 and its co-activator DRIP-
130 act to regulate KiSS-1 expression in melanomas cells via binding to a GC-rich 
region between amino acids 58 to 93.  This combination can decrease the invasive and 
migratory behaviour of the melanoma cells (Mitchell et al., 2007).   
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It appears that inhibition of Akt phosphorylation may be an important mechanism of 
kisspeptin in inhibiting migration and invasion as kisspeptin also down regulates Akt 
phosphorylation by tyrosine kinase receptors.  Kisspeptin abolishes EGF receptor- and 
insulin receptor-mediated phosphorylation of Akt in an ERK1/2-dependant manner. 
ERK1/2-dependant mechanisms also appear important for pro-apoptotic signalling as 
kisspeptin via this mechanism can up-regulate apoptosis genes TNFα and FasL.  
Kisspeptin also increases caspase expression and cleavage of PARP, all of which are 
involved in apoptosis (Navenot et al., 2009).  As well as Akt inhibition, reduction of 
MMPs has also been delineated as a mechanism for this inhibition of metastasis via 
kisspeptin.  Fibrosarcoma HT-1080 cells stably expressing KiSS-1 have decreased 
MMP-9 and invasiveness.  This is due to an up regulation of cytosolic IκBα, an inhibitor 
of NFκB, stopping its nuclear translocation.  This causes a decrease in MMP-9 
expression as NFκB needs to bind to the promoter of MMP-9 for activation (Yan et al., 
2001). This data suggests HT-1080 cells express gpr-54. Therefore, it appears 
kisspeptin/gpr-54 signalling inhibits a variety of pathways to decrease the invasiveness 





Figure 17. Signalling pathways activated by kisspeptin and gpr-54.  Schematic diagram of 
signalling pathways proposed to be activated by kisspeptin via gpr-54.  Dotted lines represent 
pathways that still need to be confirmed by further research.  Diagram taken from Castano et al., 
Intracellular signalling pathways activated by kisspeptins through gpr-54: do multiple signals 
underlie functional diversity? Peptides, 2009. 30(1): p 10-15. 
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GPCR mediated signalling pathways 
 
Since a substantial part of this thesis (chapters 4 and 5) addresses the signalling 
pathways activated by kisspeptin at gpr-54, the following section reviews signalling 
pathways activated by g-protein coupled receptors, with a focus on pathways modulating 
cell migration.  
 
1.9. Mitogen-activated protein kinase (MAPK) signalling pathway 
 
MAPKs are a family of protein kinases composed of 3 major groups: 1) Extracellular-
regulated kinases (ERKs), 2) jun N-terminally regulated kinases (JNKs) and 3) p38 
MAPKs.  Although each group has distinct functions and downstream mediators, they 
do share some common features. The MAPK family is activated by many receptor types 
such as receptor tyrosine kinases, GPCRs, cytokine and Ser/Thr kinase receptors.  This 
then leads to the activation of a three-tier phosphorylation process to activate the 
MAPK.  A cascade involving activation of MAPK kinase kinases (MAPKKK, MEKK 
or MAP3Ks) by small g-proteins such as RAS exists.  MAPKKK are serine/threonine 
kinases which phosphorylate MAPK kinases (MAPKK or MEK), which are dual 
specificity kinases.  MAPKKs dual phosphorylate MAPKs at a Thr-X-Tyr motif, 
allowing the MAPKs to phosphorylate downstream substrates on serine and threonine 
residues only when followed by a proline residue.   These downstream targets include 
p90RSK1-4, MSK1/2, MNK1/2 and MAPKAP2/3 (Fig. 18) (Krishna and Narang, 
2008).   
 
1.9.1.  Extracellular-regulated kinases (ERK1/2) 
 
The first MAPK members to be characterised were ERK1 and ERK2.  These are 
activated by the common three-tier system via the small g-protein, RAS.  The main 
MAPKKK in the ERK1/2 pathway is raf-1, which requires binding to RAS and 
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phosphorylation at multiple sites for activation. This leads to activation of the MAPKK, 
MEK1/2 followed by ERK1/2 dual phosphorylation at a Thr-Glu-Tyr motif (Fig. 18) 
(Boutros et al., 2008).   
 
Once activated ERK1/2 can target a variety of cytosolic (PLA2, calnexin), nuclear 
(NFAT, Elk-1, c-fos, c-jun, p90rsk) and cytoskeletal proteins (paxillin, neurofilaments) 
via phosphorylation.  One specific substrate of ERK1/2 is the p90rsk family of Ser/Thr 
kinases. Firstly, ERK1/2 docks at the C-terminal domain of p90rsk via a Leu-Arg-Gln-
Arg-Arg motif allowing phosphorylation of Thr573 in the N-terminal kinase domain 
(NTKD).  This activates the C-terminal kinase domain (CTKD), which is involved in 
autophosphorylation of Ser230 to create a site for PDK1.  PDK1 can then phosphorylate 
Ser221 to fully activate p90rsk, to phosphorylate downstream substrates at Arg-X-Arg-X-
X-pSer/Thr motifs.  This co-ordinated phosphorylation is completed by the NTKD 
domain phosphorylating Ser749 within the ERK1/2 binding motif.  Downstream 
substrates of p90rsk include transcription factors, CREB and NFAT and cytosolic 
proteins such as glycogen synthase kinase 3 beta (GSK3β).  These then regulate 
processes such as cell survival, cell migration and cell cycle progression (Anjum and 
Blenis, 2008).   
 
1.9.2.  Jun N-terminally regulated kinases (JNKs) 
 
JNKs were originally discovered as stress-activated protein kinases (SAPKs) but have 
since been shown to phosphorylate and activate members of the jun family of 
transcription factors.  JNKS are activated via stresses such as UV radiation or DNA 
damage as well as via cytokines and GPCRs, mainly within the innate immune system. 
JNKs are also activated by three-tier phosphorylation involving a variety of MAPKKKs 
such as MEKK1-4, MLK2/3, Tpl-2 and TAK1 depending on the stimulus.  The 
MAPKKK then phosphorylates MEK4 and 7, which dual phosphorylate JNK at its Thr-
Pro-Tyr motif (Fig. 18).  MEK7 phosphorylates Thr183 and MEK4 phosphorylates Tyr185 
allowing phosphorylation of downstream substrates (Boutros et al., 2008; Krishna and 
Narang, 2008).   






Figure 18.  MAPK signalling pathway. Schematic diagram of the MAPK signalling pathway 
showing the three-tier phosphorylation system.  Activators for each member and specific 
downstream mediators and biological responses are also shown.  Diagram taken from Krishna 
and Narang, The complexity of Mitogen-activated protein kinases (MAPKs) made simple Cell 




Once activated JNK targets a variety of downstream mediators, especially members of 
the Jun family such as c-jun, AFT-2 and c-fos.  However, JNK can also modulate 
cytoskeletal proteins (paxillin and Tau), transcription factors (NFAT, Elk-1, c-myc) and 
mitochondrial proteins (Bcl-2 family).  One area where JNK plays a significant role is in 
the control of cell migration.  JNK can phosphorylate paxillin a component of focal 
adhesions, on Ser178 which has been shown via mutagenesis to increase cell migration.  
JNK can also phosphorylate tau preventing the assembly of microtubules (Boutros et al., 
2008; Krishna and Narang, 2008).   
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1.9.3.  p38MAPK signalling 
 
The third major group of MAPK members is p38MAPK, which can also be activated via 
stress responses such as UV radiation, double stranded DNA breaks and osmotic shock 
as well as via cytokine receptors and GPCRs.  This activation is usually via the small g-
proteins Rho/Rac-1 which kick-start the three tier phosphorylation.  For p38MAPKs, the 
MAPKKK is MLK2/3, which then activates MEK3/6 to dual phosphorylate p38MAPK 
at its Thr-Gly-Tyr motif (Fig. 18).  This allows p38MAPK to phosphorylate downstream 
mediators of apoptosis, cell cycle and inflammation (Thornton and Rincon, 2009; 
Zarubin and Han, 2005). 
 
p38MAPK activates a wide range of downstream targets such as cytosolic proteins 
(GSK3β and PPA2), transcription factors (NFAT, ATF, Elk-1 and p53) and MAPK 
specific substrates (MK2/3).  For example, p38MAPK has been implicated as a mediator 
of cell survival after exposure to UV radiation and chemotherapy drugs.  The 
mechanism involves direct phosphorylation of the kinase, GSK3β at Ser389, a p38MAPK 
specific phosphorylation site in the C-terminus.  This allows accumulation of β-catenin 
in the nucleus to promote cell survival (Thornton et al., 2008; Thornton and Rincon, 
2009).  
 
1.10. Nuclear Factor kappa B (NFκB) signalling 
 
NFκB is a key mediator of inducible transcription within the innate immune response 
with a positive role in physiological immunity and pathological inflammation.  
Activation of NFκB by Toll-like receptor (TLR) adaptor proteins upon pathogen 
binding, promotes transcription of adhesion molecules in vascular endothelial cells 
leading to an initial increase of neutrophils infiltration followed by macrophage and 
other leukocyte infiltration (Ghosh and Hayden, 2008).  NFκB is also essential in the 
development of innate immune cells by regulating the expression of anti-apoptotic genes 
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upon TLR activation.  This promotes neutrophil survival to enhance the innate immune 
response (Hayden et al., 2006).  
 
1.10.1.  NFκBs: activation and inhibition 
 
The NFκB family consist of five related transcription factors that can regulate inducible 
gene transcription.  The five members are p50, p52, p65, RelA and RelB which are all 
encoded by separate genes.  All five family members share a common amino-terminal 
REL homology domain (RHD) within the immunoglobulin-like domain that is known to 
be involved in DNA binding. Each member also contains an N-terminal IgG-like domain 
which confers selectivity of transcriptional regulation and a hydrophobic C-terminus for 
dimerization.  Dimerization is essential for activation of NFκB and they can be homo- or 
hetro-dimers with the prototypical dimer being p50-p65.  When active, dimers can then 
bind to κB consensus sequences (GGGRNYYYCC, where Y = unspecified pyrimidine, 
R = unspecified purine and N = any nucleotide) within the promoters or enhancers of 
target genes, causing recruitment of co-activators and co-repressors (Ghosh and Hayden, 
2008; Hayden and Ghosh, 2008). 
 
NFκB dimers are usually kept in their inactive state by inhibitors of NFκB (IκBs) in un-
stimulated cells. The prototypical of these is IκBα and this mainly represses the p50/p65 
dimer of NFκB.  This occurs as IκBα masks the nuclear localization sequence (NLS) of 
the p65 subunit, but not the p50 subunit.  The NLS of p50 coupled with the nuclear 
export sequence (NES) on IκBα causes a constant shuttling of the inactive dimer 
between the cytoplasm and nucleus.  When cells are stimulated, IκBα is targeted for 
degradation by IκB kinase (IKKs) complexes. IKKβ is essential for degradation of IκBα 
via phosphorylation at Ser32 and Ser36 of a conserved IκB motif (DSGXXS), targeting it 
for proteasomal degradation.  This releases NFκB dimers to localise in the nucleus and 
regulate gene expression (Fig.19) (Hayden and Ghosh, 2008).   
 




Figure 19. NF-κB signaling pathways.   Following receptor ligation and recruitment of 
receptor proximal adaptor proteins, signalling to IKK proceeds through TRAF/RIP complexes 
leading to canonical NF-κB signalling. IKK activation results in IκB phosphorylation and 
degradation in the canonical pathway. Phosphorylated NF-κB dimers bind to κB DNA elements 
and induce transcription of target genes. Diagram taken from Hayden and Ghosh, Shared 
principles of NF-kappaB signaling Cell. 2008. 132(3): p344-362. 
 
1.11. GSK3β and β-catenin 
 
1.11.1.  β-catenin 
 
Catenins were originally identified via co-immunoprecipitation with cadherins and have 
three isoforms α-catenin, β-catenin and γ-catenin (Potter et al., 1999).  Catenins belong 
to the armadillo protein family characterised by a central domain consisting of a 
repeating 42 amino acid repeat (armadillo repeats) that act as a versatile protein 
interface.  Beta-catenin contains 12 armadillo repeats which are used to form three main 
complexes with TCF/Lef transcription factors, APC for targeted degradation and with 
cadherins to form adherens junctions (Daugherty and Gottardi, 2007; Gottardi and 
Gumbiner, 2001).  It has been proposed that β-catenin switches between cadherin and 
Chapter One  Literature Review 
 
 48
TCF/Lef binding via Tyr142, as phosphorylation of this residue by BCL-9 cause’s β-
catenin to dissociate from cadherins and move into the nucleus (Brembeck et al., 2004).   
 
As well as being an integral part of the canonical WNT signalling pathway, β-catenin 
can also associate with cadherins at the cell membrane to form intercellular junctions 
which regulate cell motility. Cadherins are calcium-dependant cell adhesion 
glycoproteins that contain an extracellular domain, a membrane spanning domain and an 
intracellular domain.  Beta-catenin can associate with Type 1 adhesions at adherens 
junctions to link E-cadherin or N-cadherin to microfilaments.  The cytoplasmic cadherin 
domain contains a catenin-binding sequence that can interact with β-catenin forming a 
salt bridge between Asp674/Glu682 of the cadherin and Lys435/312 of β-catenin.  This 
interaction is enhanced when E-cadherin is phosphorylated at Ser684/686/692.  Beta-catenin 
then binds with α-catenin which then links to the actin cytoskeleton to form a stable 
bond between the complex and cytoskeleton (Fig. 20).  This then promotes cell adhesion 




Figure 20. Adherens junctions. Diagram of an adherens junction: the connection of cadherins 
to the actin cytoskeleton.  Beta-catenin interacts with the cytoplasmic cadherin domain and α-
catenin, which then binds the actin cytoskeleton.  Diagram taken from Daugherty et al., Phospo-
regulation of beta-catenin adhesion and signalling functions Physiology (Bethesda), 2007. 22: 
p303-309. 
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1.11.2.   Glycogen Synthase Kinase 3 
 
Glycogen synthase Kinase 3 (GSK3) is a Ser/Thr kinase that contains an activation 
domain in the C-terminus and an ATP-binding site (Frame and Cohen, 2001; Pearl and 
Barford, 2002).  Of the two isoforms (α/β), GSK3β is better characterised and 
preferentially phosphorylates Ser/Thr residues with a pre-existing ‘primed’ phospho-
Ser/Thr site that is four amino acids C-terminal to the GSK3β phosphorylation site.  This 
allows for hyper-phosphorylation of substrates as most are primed at the last C-terminal 
Ser/Thr residue and then GSK3β can hyper-phosphorylate in a C- to N-terminal manner, 
with the previous residue acting as the prime for the next phosphorylation (Fig. 21). This 
prime site is recognised by GSK3β due to an oxyanion (phosphate)-binding site close to 
Val214 of the activation segment.  This causes a conformational change via interaction 
with Arg180/Lys205 of the C-terminus and Arg96 of the N-terminal α-helix forming a 
pocket that the primed Ser/Thr residue can interact with to regulate substrate specificity.  
This is the mechanism used to phosphorylate β-catenin within the (axin, adenomatous 
polyposis coli (APC), GSK3β) destruction complex of canonical WNT signalling.  This 
targets β-catenin for ubiquitination and degradation, however, if GSK3β is inhibited β-




Figure 21. GSK3β hyperphosphorylation of glycogen synthase and β-catenin.   Glycogen 
synthase (GS) and β-catenin undergo hyperphosphorylation when primed by casein kinases at 
the most C-terminal Ser/Thr.  GSK3β phosphorylates the Ser/Thr that is four residues N-
terminally to the primed site, this phosphorylation then acts as the prime for the next and so on.  
Diagram taken from Pearl and Bardford, Regulation of protein kinases in insulin, growth factor 
and Wnt signalling Curr Opin Struct Biol, 2002. 12(6): p761-767. 
Chapter One  Literature Review 
 
 50
However, GSK3β has a double life in mammals, in that it also regulates glycogen 
synthesis by insulin (Fig. 22), with no cross-talk between pathways.  In the insulin 
pathway, GSK3β is also constitutively active in resting cells via Tyr216 phosphorylation, 
where it hyper-phosphorylates glycogen synthase, when primed by CK2 to inhibit 
glycogen synthesis.  When stimulated by insulin, GSK3β is inhibited via 
phosphorylation at Ser9 by PKB/Akt through a PI(3)K-dependant pathway.  This 
promotes dephosphorylation of glycogen synthase and up-regulates glycogen synthesis 
(Pearl and Barford, 2002). This is critical for normal glycogen synthesis by insulin in 




Figure 22. Insulin signalling. Diagram of signalling via the insulin receptor to inhibit GSK3β 
via Ser9 phosphorylation by PKB/Akt via PI(3)K pathway.  This allows release of glycogen 
synthase to produce glycogen.  Diagram taken from Frame and Cohen, GSK3 takes centre stage 




PKB/Akt is not the only kinase that can phosphorylate this Ser9 residue, the ERK1/2 
specific substrate p90rsk can also phospho-inhibit GSK3β via this residue but is known 
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to target β-catenin to the plasma membrane to interact with cadherins, so increases 
adhesion and inhibits migration.  Inhibition by p90rsk is primed on GSK3β via ERK1/2, 
which can dock at an FKFP motif and phosphorylate the priming residue Thr43 (Fig. 23). 
This inhibition is usually regulated by growth factors such as fibroblast growth factor 
(FGF) or epidermal growth factor (EGF) (Ding et al., 2005; Frame and Cohen, 2001; 
Torres et al., 1999).  It is also known that PKA, PKC and p70s6k kinases can also 
phosphorylate this residue (Joshi et al., 2007). Inhibition of GSK3β by Ser9 
phosphorylation works in a similar manner to GSK3β hyperphosphorylation as this 
phosphorylation creates a primed pseudo-substrate in the N-terminus.  This can occupy 
the oxyanion-binding pocket and compete with primed substrates, however GSK3β is 
not then hyperphosphorylated as the residue four positions N-terminally is a proline, so 





Figure 23.  Regulation of GSK3β by p90rsk.  Model of GSK3β inhibition by p90rsk 
phosphorylation of Ser9 when primed by ERK1/2 allowing release of β-catenin.  Diagram taken 
from Ding et al., Erk associates with and primes GSK-3beta for its inactivation resulting in up 
regulation of beta-catenin Mol Cell, 2005. 19(2): p159-170. 
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1.11.3.  Regulation of GSK3β/β-catenin by g-protein coupled receptors  
 
More recently, it has been discovered that GPCRs can also regulate GSK3β and β-
catenin.  In 2001, the first GPCR shown to regulate these molecules was the prostanoid 
receptor FPB activated by the prostaglandin, PGF2α.  GPCR activation can cause 
dephosphorylation and nuclear accumulation of β-catenin, resulting in activation of 
TCF/Lef transcriptional activity (Fujino and Regan, 2001).  In reproductive tissues, 
GnRH receptor activation can inhibit GSK3β, stabilize β-catenin in the nucleus and 
activate TCF/Lef transcription of the pro-apoptotic genes c-jun, c-myc and Fra-1 
(Gardner et al., 2007).     
 
1.12.   Signalling at focal adhesions 
 
Integrins are transmembrane receptors that can bind to proteins within the extracellular 
matrix (ECM) such as collagen and fibronectin.  The integrins convey signals about the 
adhesion status of the cells to regulate cell survival, proliferation and migration.  
Integrins form heterodimers consisting of α and β subunits localized within the plasma 
membrane where their short cytoplasmic domains functionally link changes in the ECM 
to the actin cytoskeleton inside the cell.  The sites where integrins connect to the 
cytoskeleton are called focal adhesions and these are comprised of a multiprotein 
complex of scaffolding and signalling proteins (Fig. 24).  This complex contains protein 
tyrosine kinases and these are usually activated via integrin clustering, although this can 
also occur via GPCR, cytokine and growth factor receptor signalling (Lim et al., 2008). 
 
An important tyrosine kinase in focal adhesions is focal adhesion kinase (FAK).  FAK is 
a non-receptor tyrosine kinase that is targeted to focal adhesions upon integrin 
clustering.  FAK consists of an N-terminal FERM domain, a central kinase domain and a 
C-terminal focal adhesion targeting (FAT) domain (Fig. 25). The FAT domain is where 
FAK indirectly links to integrins via the binding protein, paxillin.  Paxillin binds to the 
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cytoplasmic domain of integrins and to vinculin, a focal adhesion associated protein.  
Paxillin can also interact with p21-activated protein kinase (PAK) when phosphorylated 
at Tyr31/118; this can then phosphorylate MEK to up regulate MAPK signalling. FAK 
also contains proline-rich domains that bind Src-homology 3 (SH3) containing proteins 
such as p130Cas and conserved phosphorylation sites which can serve as SH2 domains 
to bind Src, PI(3)K or adapter proteins such as Grb2 (Golubovskaya et al., 2009; Lim et 





Figure 24. Signalling at focal adhesions. Diagram showing the multiprotein complex involved 
in focal adhesion signalling involving integrins, FAK, Paxillin, Src and p130Cas.  This complex 
can facilitate downstream signalling to MAPKs, PAK and PI(3)K to effect actin polymerization 
and cell migration.  Diagram taken from Parsons, J.T., Focal adhesion kinase: the first ten years 
J Cell Sci, 2003. 116 (Pt. 8): p1409-1416. 
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FAK is activated in response to integrin clustering via autophosphorylation of Tyr397, 
creating a SH2 domain for binding with Src. Full activation of FAK can then occur via 
phosphorylation of Tyr567/577 by Src and FAK can enhance Src activity via 
phosphorylation at Tyr418.  FAK-Src complexes can bind to paxillin and p130Cas at 
focal adhesions or regulate downstream signalling cascades. For example, if Src 
phosphorylates Tyr925 of FAK this promotes binding of Grb2 and activates the MAPK 
cascade.  Inhibition of FAK occurs via its FERM domain, which can bind to the kinase 
domain and inhibit via an auto-inhibitory mechanism. This causes steric inhibition of 
target proteins at the catalytic cleft and Tyr397.  This inhibition is released when proteins 







Figure 25. Focal Adhesion Kinase. Schematic Diagram of focal adhesion kinase representing 
the cytoplasmic FERM domain, the kinase domain containing three phosphorylation sites and 
the N-terminal domain (also known as FRNK domain) containing the FAT domain and two 
phosphorylation sites. Src binds to the auto-phosphorylated Tyr397 to then phosphorylate the 
other two sites within the kinase domain.  Paxillin can then bind to the FAT domain and 
p130Cas to the N-terminal domain. Diagram taken from Parsons, J.T., Focal adhesion kinase: 
the first ten years J Cell Sci, 2003. 116 (Pt. 8): p1409-1416. 
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1.13.  Summary  
 
In this chapter, kisspeptin/gpr-54 and MAPK, NFκB, β-catenin, GSK3β and FAK 
signalling pathways have been reviewed.  A review of the recent literature suggests that 
kisspeptin and gpr-54 are critical for hormonal control of reproductive tissue function 
via regulation at multiple levels including initiation of puberty, steroid feedback to the 
hypothalamus and within different cell types of the ovary and placenta.  However, the 
evidence implicating the importance of kisspeptin and gpr-54 in these tissues is so far 
indirect, creating a need for antagonists of this system to determine direct regulation of 
these pathways via gpr-54.  This will be addressed as part of the research within this 
thesis where I aim to define the structural elements of kisspeptin required to bind to and 
activate gpr-54 using synthetic peptide analogues. These analogues will also be used to 
screen for in vitro receptor antagonism and then selected analogues will be evaluated via 
in vivo models.  
 
This review covered the signalling pathways activated by kisspeptin known to date, 
including signalling pathways involved in the regulation of cell migration.  The literature 
on signalling by kisspeptin is limited and needs further investigation and will therefore 
be encompassed within the remainder of the research in this thesis.  Here I aim to 
delineate the signalling pathways activated by gpr-54 in vitro using stably transfected 
CHO and GT1-7 cells and a trophoblast cell line.  The effects of kisspeptin and analogues 






Materials and Methods 
 





This chapter details the materials and laboratory techniques used throughout this 
research.  The source of all materials is provided and any work not carried out by myself 
acknowledged.  All chemicals where a manufacturer is not stated in the text were 




Human kisspeptin-10 and peptide analogues 186-191, 200-203, 206-213, 228-248 and 
271-278 were custom synthesized by EZBiolabs, USA. Chinese hamster ovary (CHO) 
cells stably expressing gpr-54 were obtained from Prof. G Vassart (Univ. Brussels); 
mouse GT1-7 and LβT2 cells were obtained from Dr Pamela Mellon (Univ. California, 
USA); human HTR8SVneo cells were obtained from Dr G. Pare (Queen’s Univ., 
Ontario, Canada);  HUVEC cells were obtained from Dr Rebecca Reynolds (Edinburgh, 
UK); BeWo choriocarcinoma cells were obtained from the American Type Culture 
Collection (ATCC) and COS-7, JAR, JEG-3, MCF-7 and rat GH3 cells were obtained 
from the European Collection of Cell Cultures (ECACC).  The Src inhibitor PP2, the 
PI(3)K inhibitor LY294002, the PKC inhibitor Go6983, a second PKC inhibitor Ro-31-
8220, the specific MEK inhibitor PD98059, the PI(3)K specific inhibitor PI-103, the 
specific Src-Inhibitor 1 and the specific EGFR inhibitor AG1478 were obtained from 
Calbiochem (Nottingham, UK).  A specific Akt1/2 inhibitor was obtained from Sigma, 
UK.  The specific GSK3β inhibitor CT99021 and the specific p90rsk inhibitor BI-D1870 
were obtained from Dundee University, UK. The specific Gq/11 inhibitor YM254890 was 
kindly provided by Dr Masatoshi Taniguchi (Astellas Pharmaceuticals Inc, Japan).  The 
RGDS and RGES tetrapeptides were obtained from Sigma, UK. D-[myo-3H]-inositol 
was obtained from GE Healthcare (Buckinghamshire, UK).  The mouse gpr-54 cDNA 
expression construct was produced in the laboratory by Dr Kevin Morgan. The pSRE-
luciferase and renilla constructs were obtained from Dr Elena Faccenda (Edinburgh). 
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2.2. Preparation of plasmid DNA 
 
A scrape of bacteria from a glycerol stock was added to a starter culture of 10ml fresh 
terrific broth medium containing selective antibiotic (Ampicillin – stock solution 
50mg/ml, Sigma) and grown for a period of 10 hours. 2ml were then used to inoculate a 
250ml terrific broth medium culture and this was grown for a further 16 hours.  Plasmid 
DNA was purified using Qiagen maxi-preparation columns and eluted using TE Buffer 
(10mM Tris-HCL (pH8), 1mM EDTA) according to the manufacturer’s instructions.  
DNA concentration and quality was determined using the nanodrop (Nanodrop 
technologies, Delaware). 
 
2.3. Preparation of glycerol stocks of transformed bacteria 
 
Glycerol stocks of transformed E.coli were made by adding 400ul of 80% glycerol to 
600ul of bacterial culture that had been grown for a period of 10 hours.  Vials were 
inverted to mix the glycerol and stored at -80ºC.  To recover the bacteria, a sterile 
inoculating loop was used to scrape the surface of the frozen culture, keeping the 
bacteria on dry ice.  The plasmid DNA was then prepared as described in section 2.2. 
 
2.4. Agarose gel electrophoresis 
 
1% agarose gels were prepared in TAE buffer (40mM Tris, 320mM acetic acid, 1mM 
EDTA, pH 7.2).  Plasmid DNA and PCR products were separated at 120V for 30 
minutes, stained with ethidium bromide and visualised under ultraviolet light using a 
transilluminator.  To obtain size of fragment, either a 1kb DNA or DNA step ladder was 
utilized (Promega, Madison, WI, USA) 
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2.5. Design and synthesis of peptide analogues 
 
Peptide analogues were designed based on the sequence of kisspeptin-10, the final ten 
C-terminal amino acids of kisspeptin. Firstly, kisspeptin-10 was systematically truncated 
at the N-terminus to 5 and 7 amino acid lengths in order to determine the shortest C-
terminal peptide capable of binding and activating the receptor.  Then amino acid 
substitutions of the residues within the truncated and full length peptides were 
performed, firstly the C-terminal amino acids were substituted, then the N-terminal 
residues to find amino acids important for receptor binding or activation.  The peptide 
analogues were synthesized by EZBiolabs, USA.  Peptide analogues for preliminary 
studies were synthesized to a purity of >80% (range 83-99% measured by HPLC) and 
peptides 234, 271 and 273, which were selected for detailed studies were synthesized at 
a purity of >95%.  The authenticity of peptides was confirmed by mass spectrometry.  
Once synthesized analogues were tested for antagonism and agonism using the methods 
described. 
 
2.6. Cell Culture 
 
2.6.1. Cryopreservation and thawing of cell lines 
 
Stocks of each cell line were stored at -196ºC under liquid nitrogen in cryoprotectant 
(10% dimethylsulphoxide (DMSO) (v/v) in fetal calf serum).  Cells were recovered from 
liquid nitrogen store and rapidly warmed to 37ºC.  They were then gently re-suspended 
in media and seeded into flasks.  Frozen stocks were preserved by banking cells for the 
first few passages after they were resuscitated. Confluent cultures were passaged as 
described below (section 2.6.2), and cells collected by centrifugation at 2000rpm for 3 
minutes.  The medium was then decanted and the cell pellet gently re-suspended in 
cryoprotectant, aliquoted into vials and frozen at -80ºC in a cryo 1ºC freezing container 
(Nalgene).  Vials were then transferred to liquid nitrogen for long term storage. 
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2.6.2. Stable and immortalized cell lines 
 
Chinese hamster ovary cells stably expressing the human gpr-54 receptor (CHO/gpr-54); 
LβT2 cells stably expressing mouse gpr-54 (LβT2/gpr-54) and GT1-7 cells stably 
expressing the mouse gpr-54 receptor (GT1-7/gpr-54) were maintained in Dulbecco’s 
modified Eagles medium (DMEM, Sigma) supplemented with 10% fetal calf serum, 2% 
Glutamine, 1% Penicillin (10,000units/ml)/Streptomycin (10,000mg/ml) and 500µg/ml 
geneticin (G418; PAA Laboratories,  Somerset, UK) at 37ºC in a humidified 5% CO2 
atmosphere. COS-7, GH3, Ishikawa, JEG-3, JAR and MCF-7 cells were maintained as 
above minus the geneticin. BeWo choricarcinoma cells were maintained in F-12 HAM 
medium (Invitrogen) supplemented with 10% fetal calf serum, 2% Glutamine, 1% 
Penicillin (10,000units/ml)/Streptomycin (10,000mg/ml) at 37ºC in a humidified 5% 
CO2 atmosphere. HTR8SVneo immortalized trophoblast cells were maintained in RPMI 
1640 medium (Invitrogen) containing glutamine and supplemented with 5% fetal calf 
serum and 1% Penicillin (10,000units/ml)/Streptomycin (10,000units/ml) at 37ºC in a 
humidified 5% CO2 atmosphere.  HUVEC cells were maintained in EGM2 medium 
(Lonza) supplemented with hydrocortisone, VEGF, rhEGF, rhFGF, R3-IGF-1, heparin, 
ascorbic acid, GA-1000 and 2% fetal bovine serum at 37ºC in a humidified 5% CO2 
atmosphere. 
 
Cells lines were routinely passaged twice weekly by enzymatic dispersal with trypsin.  
The medium was removed from confluent cells and cells washed with Dulbecco’s 
phosphate buffered saline (PBS; Lonza).  Then 2ml of 1x trypsin were added to each 
162cm2 flask (Corning) and flasks returned to incubator at 37ºC for 3-5 minutes until 
cells were easily detached.  8ml of media were then added to inhibit the trypsin and all 
cell lines were routinely split 1:5 with appropriate antibiotics added.  Flasks were then 
returned to the incubator at 37ºC in a humidified 5% CO2 atmosphere.  Dispersed cells 
were then diluted 1:10 in PBS and counted using a Nebauer haemocytometer. Cells were 
counted in all four counting areas and an average taken to give the cell number x 105 per 
ml.  The cells were then seeded onto plates/dishes for experiments as needed. 
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COS-7 cells were seeded into 150cm2 dishes (Corning), to be 80% confluent at time of 
transfection.  Confluent cells had medium removed and cells were washed three times 
with PBS.  Then 2ml of 1x trypsin were added to each dish and dishes returned to 
incubator at 37ºC for 10 minutes until cells were easily detached.  8ml of medium were 
then added to each dish to inhibit the trypsin.  Dispersed cells were collated and then 
collected by centrifugation at 2000 rpm for 3 minutes. The medium was decanted and 
the pellet gently re-suspended in 25ml of Optimem-1 (Gibco, Invitrogen, UK) 
electroporation medium.  The cells were again collected by centrifugation at 2000 rpm 
for 3 minutes.  The medium was decanted and the pellet re-suspended in 0.7ml/dish 
Optimem-1 electroporation medium (Gibco).  Then 0.7ml cell suspension was added to 
each pre-chilled electroporation cuvette (Bio-rad) containing 10ug DNA and mixed with 
gentle pipetting.  Each cuvette was placed in the electroporation shocking chamber (Bio-
rad Gene Pulsar Xcell) and pulsed at 0.22kV and 960μF with an average time constant 
of 21ms.  Cuvettes were then left to settle for 10 minutes at room temperature.  
Transfected cells were then seeded into 12-well plates at 1x105 cells/well for 
experiments as needed.  
 
2.7.2. Chemical Transfection – Fugene 6 reagent 
 
Cells were seeded at 1x105 cells/well in 12-well plates (Costar) as needed.  The 
transfection medium was prepared as follows for each 12-well plate and left to 
equilibrate at room temperature for 30 minutes: 
 
  10μg DNA 
  316.6ul Fugene 6 transfection reagent (Roche) 
  9.5ml Optimem-1 
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After 30 minutes, 9.5ml of complete media was added to transfection medium to stop 
the reaction.  Cells then had medium removed and were washed once with PBS.  Then 
1ml/well of Fugene 6 transfection medium was added to cells and plates incubated 
overnight at 37ºC in a humidified 5% CO2 atmosphere. 
 
2.7.3. Chemical Transfection – Superfect reagent 
 
Cells were seeded at 1x105 cells/well in 12-well plates as needed. The transfection 
medium was prepared as follows for each 12-well plate and left to equilibrate at room 
temperature for 30 minutes: 
 
  10μg DNA 
  240ul Superfect transfection reagent (Qiagen)  
  2.3ml DMEM 
 
After 30 minutes, 2.3ml complete media was added to the transfection medium to stop 
the reaction.  Cells then had medium removed and were washed once with PBS.  Then 
400ul/well of Superfect transfection medium was added to cells and cells incubated at 
37ºC in a humidified 5% CO2 atmosphere for 4 hours.  Transfection medium was then 
removed and cells were washed once with PBS.  Lastly, 2ml/well of culture medium 
was added to cells and cells incubated overnight at 37ºC in a humidified 5% CO2 
atmosphere. 
 
2.8. Preparation of pharmacological inhibitors and ligands 
 
Stock solutions of inhibitors were prepared in DMSO or as per manufacturers’ 
instructions, aliquoted and stored at 4ºC or -20ºC.  Stock solutions of kisspeptin-10 and 
kisspeptin analogues were prepared in 20% polyethylene glycol, aliquoted and stored at 
-20 ºC.  After aliquots were defrosted they were diluted further in 20% polyethylene 
glycol as needed. 
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2.9. Whole cell receptor binding 
 
Kisspeptin-10 was prepared at 1:100 dilution in HEPES modified DMEM supplemented 
with 0.1% Bovine Serum albumin and 125I-labelled Kisspeptin-10 (100,000 cpm/0.5mls).  
Cell monolayers seeded at 1x105 cells/well in 12-well plates were placed on ice and 
exposed to 0.5ml peptide/well (10pM-10uM); the cells were then incubated at 4ºC for 4 
hours.  After 4 hours, cells were washed twice with ice cold PBS (with Calcium and 
Magnesium) and then 0.5ml 0.1M Sodium Hydroxide (NaOH) were added to cells for 
20 minutes, while shaking. Lysates were transferred to plastic tubes and bound 
radioactivity counted on the Wallac 1470 Wizard gamma counter (PerkinElmer and 
Analytical Sciences (UK) Ltd, Buckinghamshire, UK) for 60 seconds.  
 
2.10. Inositol phosphate (IP) assay 
 
Cell monolayers seeded at 1x105 cells/well in 12-well plates as needed, were labelled 
overnight with 1µCi/ml D-[myo-3H]-inositol in inositol-free DMEM supplemented with 
1% dialyzed fetal calf serum, 2% glutamine and 1% penicillin/streptomycin. Cells were 
then incubated in 0.5ml HEPES modified DMEM supplemented with 1% 
Penicillin/Streptomycin and 10mM Lithium Chloride (LiCl) for 30 minutes at 37ºC.  
Cells were then stimulated with 0.5ml/well kisspeptin-10 (10pM-10uM) ± peptide 
analogues for 1 hour at 37ºC, then placed in 1ml of 10mM formic acid at 4ºC for 1 hour.  
Lysates were then transferred to plastic tubes containing 0.5ml Dowex AG1-X8 ion 
exchange resin (Bio-rad). The resin was then washed with 1ml of water followed by 1ml 
of 60mM ammonium (NH4) formate/5mM sodium tetraborate and finally 1ml of 1M 
ammonium (NH4) formate/0.1M formic acid.  Then 800µl of the radioactive solution 
were transferred to scintillation vials (Zinsser analytic) containing 2.5ml scintillation 
fluid (Fischer Scientific) and radioactivity counted on a Wallac Microbeta Trilux β-
counter (PerkinElmer and Analytical Sciences (UK) Ltd, Buckinghamshire, UK) for 60 
seconds. 
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2.11. Fluorescence Intensity Plate Reader (FLIPR) calcium 4 assay 
 
Cell monolayers were plated in black, clear bottomed 96-well view plates (PerkinElmer, 
UK) overnight. Cells were then incubated in serum-free media at 37ºC for 1 hour prior 
to stimulation with FLIPR calcium 4 reagent (Molecular Devices, USA).  Cells were 
then incubated for 1 hour at 37ºC while ligands were prepared in a separate flat 
bottomed 96-well plate (Costar).  Cells were then tested for intensity of fluorescence on 
the Novostar (BMG Labtech, UK) over 60 seconds with ligands being added 1:10 after 
11 seconds in reading mode.   
 
2.12. Preparation of whole cell lysates and nuclear/cytoplasmic fractions  
 
2.12.1. Whole cell lysates 
 
Cells were seeded at a density of 3x105 cells/well in 6-well plates (Costar) and allowed 
to attach overnight before being incubated in serum-free media (DMEM, 2% Glutamine, 
1% Penicillin/Streptomycin and 10mM HEPES) for 16 hours. Agonist stimulations were 
performed in serum-free media at 37ºC after appropriate incubation with chemical 
inhibitors, as described in figure legends.  After stimulation, cell monolayers were 
placed on ice, washed with ice-cold PBS and lysed in a Nonidet-P40-based 
solubilisation buffer (250mM NaCl, 50mM HEPES, 0.5% Nonidet P-40, 10% glycerol, 
2mM EDTA pH 8.0) supplemented with 1mM Sodium orthovanadate, 1mM 
phenlymethlsulphonyl fluoride and 1mg/ml leupeptin. Cell lysates were clarified by 
centrifugation at 13000 rpm for 10 minutes.   
 
100ul clarified whole cell lysates were mixed with an equal amount of 2x Laemmli 
sample buffer (LSB) and samples were resolved by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). To give a measurement of the size of proteins pre-stained 
broad range SDS-PAGE standards were utilized (Bio-Rad). The gels were 4-20% Tris-
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glycine gels (invitrogen) and a Novablot semi-dry transfer apparatus (Amersham 
Pharmacia Biotech) was utilised.  Polyvinylidene difluoride (PVDF) membrane (NEN 
Life Sciences, Buckinghamshire, UK) was soaked in 100% ethanol for 5 minutes, 
followed by 3x 5 minute washes in distilled water and then equilibrated in semi-dry 
transfer buffer (20mM Tris, 192mM glycine, 20% methanol and 0.1% SDS).  Blotting 
paper pads were soaked in semi-dry transfer buffer and 1 pad place on either side of the 
gel on the transfer apparatus: blotting paper, PVDF membrane, gel then blotting paper.  
Air bubbles were removed by applying pressure with a glass tube and then the cathode 
plate was placed on top. The proteins were then transferred to the membranes at 0.2A for 
1 hour. PVDF membranes were then blocked in 4% BSA (50mM Tris-HCl, pH 7.0, 
0.05% Tween-20 and 0.05% Nonidet-P40) blocking solution for 1 hour, while shaking 
on a rocker.  The blocking buffer was then discarded and primary antibody added for 
either 1 hour or left overnight. 
 
2.12.2.  Nuclear/cytoplasmic fraction lysates 
 
Cells were seeded at a density of 3x105 cells/well in 6-well plates and allowed to attach 
overnight before being incubated in serum-free media for 16 hours.  Agonist 
stimulations were performed in serum-free media at 37ºC after appropriate incubation 
with chemical inhibitors, as described in figure legends.  After stimulation, cell 
monolayers were placed on ice, washed with ice-cold PBS and lysed in a Nonidet-P40-
based solubilisation buffer (250mM NaCl, 50mM HEPES, 0.5% Nonidet P-40, 10% 
glycerol, 2mM EDTA pH 8.0) supplemented with 1mM Sodium orthovanadate, 1mM 
phenlymethlsulphonyl fluoride and 1mg/ml leupeptin.  Cell nuclei were crudely 
extracted from solubilised lysates by centrifugation at a low spin of 2900 rpm for 10 
minutes.  The cytoplasmic fraction was then removed to a fresh eppendorf and further 
clarified by centrifugation at 13000 rpm for 10 minutes (approximate concentration 
1mg/ml of total protein).  Then 100ul of clarified cytoplasmic lysate was mixed with an 
equal amount of 2x LSB in fresh eppendorf tubes.  
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The nuclear pellet was washed with Nonidet-P40-based solubilisation buffer four times, 
to remove contaminating cytoplasmic proteins.  The nuclear pellet was then re-
suspended in 100ul of Nonidet-P40-based solubilisation buffer and the nuclear 
membrane ruptured by sonification. Insoluble material was sedimented by centrifugation 
at 13000 rpm for 10 minutes. Then 60ul of clarified nuclear lysate was mixed with an 
equal amount of 2x LSB in fresh eppendorf tubes. Both nuclear and cytoplasmic lysates 
resolved by SDS-PAGE and then processed the same as for whole cell lysates (section 
2.12.1.).   
  
2.13.  Immunoblotting and detection 
 
Immunoblotting was performed at a 1:1000 dilution.  Immunoblotting of pERK1/2, 
pJNK, p38MAPK (New England Biolabs, USA), pNFKB, pAkt (T308), β-catenin, 
pGSK3β (Ser9), pFAK (Y925; Cell Signaling Technology, USA), pSrc (Y418; 
Invitrogen Ltd, Paisley, UK), Rac-1, pIκBα, RhoA (Santa Cruz Biotechnology Inc., 
USA) and RAS (Upstate Biotechnology, USA) were visualised by rabbit anti-human 
antibodies. Cdc42 (Santa Cruz Biotechnology Inc., USA) was visualized by mouse anti-
human antibodies. Each antibody was used for a maximum of 10 times then replaced. 
Immunoblots were then washed three times for 10 minutes with 1x TBS-T to remove 
excess antibody. The proteins were then visualized by addition of a 1:10000 dilution of 
alkaline phosphatase-conjugated polyclonal anti-rabbit or anti-mouse IgG as a secondary 
antibody for 1 hour. The antibodies raised against ERK1/2 were used as a loading 
control. Immunoblots were then again washed with 1x TBS-T to remove excess 
secondary antibody. Each alkaline phosphatase labelled protein was visualized using an 
enzyme-linked chemifluorescence reaction (GE Healthcare, Buckinghamshire, UK) and 
quantified using a Typhoon 9400 Phosphoimager and Imagequant TL software 
(Molecular Dynamics, Amersham Biosciences).    
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After immunoblots were scanned, membranes were washed in 40% methanol for 30 
minutes to remove the ECF substrate and then washed three times with 1x TBS-T for 10 
minutes.  Antibodies were then stripped from the membrane by incubating in 10ml of 
25mM Tris-HCl (pH 7), 8% (w/v) SDS, 0.72M β-mercaptoethanol for 30 minutes at 
80ºC followed by three 10 minute washes with 1x TBS-T.  The membranes were then 
either probed with another antibody or dried and stored at room temperature. 
 
2.14. Dual light reporter gene luciferase assay 
 
Transient transfections were performed using Superfect reagent for CHO/gpr-54 and 
LβT2/gpr-54 cell lines.  Fugene 6 reagent and electroporation were also utilized for the 
CHO/gpr-54 cell line.  Cells were seeded at 1x105 cells/well in 12-well plates, as needed 
and the next day transfected with a SRE-luciferase reporter construct as well as a Renilla 
luciferase construct to control for transfection efficiency. Cells were then placed in 
starving media, overnight before stimulations were performed for 24 hours. Luciferase 
activity was assayed using a Dual-light luciferase assay kit (Promega) in a FLUOstar 
Optima luminometer (BMG Lab technologies).  Luciferase activity was expressed in 
arbitrary units relative to activity observed in non-stimulated control.  The results were 
then expressed as fold over basal as indicated in figure legends. 
 
2.15. RNA Purification 
 
Confluent cells monolayers had media removed and were washed once with PBS.  The 
cells were then lysed with Tri-reagent (Phenol; Guanidine thiocynate), which also 
inhibits any ribonucleases.  Once detached cells were placed in fresh eppendorf tubes 
and 200ul chloroform added, causing the mixture to separate into different phases with 
RNA at the top, then a protein layer and DNA at the bottom.  The RNA layer was then 
isolated and placed in a fresh eppendorf tube to which 600ul isopropanol was added 
along with glycogen.  The RNA was then precipitated at 10000 rpm for 10 minutes.  The 
pellet was then frozen at -80ºC until needed. 
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2.16. Reverse Transcription for real time - polymerase chain reaction (RT-
PCR) 
 
RNA precipitate was thawed at room temperature and then clarified at 13000 rpm for 10 
minutes.  The supernatant was decanted and the pellet gently re-suspended in 1ml of 
70% ethanol (700ul ethanol and 300ul Diethylpyrocarbonate (DEPC) water).  This was 
also clarified at 13000 rpm for 10 minutes and the supernatant decanted.  The pellet was 
then dried at room temperature.  The RNA pellet was then dissolved in DEPC water to 
give 1μg/ml.  The following reagents were then mixed: 
 
  3.5μl Water 
  2.5μl Random Primers 
  1.0μl 10mM dNTPs 
  5.0μl RNA 
 
The master mixture was heated to 65ºC for 5 minutes in the PCR machine (PCRSprint, 
Thermohybaid, UK), then cooled to room temperature and clarified at 13000 rpm for 1 
minute.  Then the following reagents were added to the above mastermix: 
 
  4.0μl 5x Buffer 
  2.0μl 0.1M DTT 
  1.0μl RNAse inhibitor 
  1.0μl Reverse transcription enzyme 
 
The master mixture was then mixed and incubated at 42ºC for 1 hour in the PCR 
machine for reverse transcription to occur.  The reaction was then stopped by heating the 
master mixture to 95ºC for 3 minutes before being placed on ice.  Finally the reverse 
transcription cDNA product was mixed then diluted with 80μl DEPC-water.  The cDNA 
was then kept at -80ºC until needed for RT-PCR. 





The PCR master mixture was prepared as follows: 
 
  33.25μl water 
  5.0μl 10x Buffer 
  2.5μl DMSO 
  2.0μl Magnesium Chloride 
  1.5μl Forward Primer 
  1.5μl Reverse Primer 
  1.75μl 10mM dNTPs 
  2.0μl cDNA 
  0.5μl enzymes 
 
The master mixture was then mixed and heated to 94ºC for 90 seconds then left to 
progress through the following PCR cycle for 30-40 repeats: 
 
  94ºC for 30 seconds to denature the cDNA 
  55ºC for 60 seconds to allow attachment of primers 
  72ºC for 60 seconds for translation to occur 
 
Once complete the PCR product was heated to 72ºC for 10 minutes to complete the 
reaction.  The PCR products were then cooled at room temperature then 20ul of PCR 
product was added to 2ul blue dye.  This was then loaded onto an agarose gel and run at 
120V for 30 minutes and visualised under ultraviolet light using a transilluminator.  To 
obtain size of fragment, either a 1kb DNA or DNA step ladder was utilized (Promega, 
Madison, WI, USA).  The primers used for RT-PCR were a mouse gpr-54 forward 
primer - ATG GCC ACC GAG GCG ACA TTG GCT and reverse primer - AAG TGA 
GGC AGT GCG TTC ACT CTG. 
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2.18. Cell Migration assay 
 
Confluent cell monolayers were scratched with a yellow pipette tip and were then 
washed three times with PBS at 37ºC to remove any loose cells.  Cells were then 
stimulated with kisspeptin with or without inhibitors.  Cells were incubated at 37ºC with 
5% CO2 in air for 22hrs.  Cell scratches were photographed at 0 and 22hrs and the width 
of the scratch recorded at each using the Axiovert 200 microscope. Migration was 
evaluated by the distance refilled between the furthest migrated cell and the scraped 
edge on both sides. 
 
2.19. Silver Nitrate gel staining 
 
15μl of whole cell lysate samples were mixed with an equal amount of sample buffer 
(5% Glycerol, 10mM Tris and bromophenyl blue).  Samples were then separated by 
PAGE using 4-20% Tris-glycine gels at 0.45mA for 45 minutes.  Gels were then soaked 
in fixing solution (75ml EtOH, 25ml acetic acid and 150ml water) for 2 hours, while 
shaking on a rocker.  The gel was then moved to a sensitizing solution (75ml EtOH, 
10ml sodium thiosulphate, 17g sodium acetate and 150ml water) for a further 2 hours, 
while shaking on a rocker.  The gel was then washed five times for 15 minutes with 
water prior to the silver nitrate solution (25ml silver nitrate, 225ml water ant 0.1ml 
formaldehyde) being added for 2 hours under constant shaking on a rocker.  After 2 
hours, the gel was given four 1 minute washes with water then a developing solution 
(6.25g sodium carbonate, 250ml water and 0.2ml formaldehyde) was added, while 
shaking on a rocker, for 6 minutes or until bands became detectable.  The reaction was 
then stopped by adding a stopping solution (3.65g EDTA-Na2 and 250ml water), which 
the gel was left in overnight.  The gel was then recorded by photography. 
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2.20. Statistical analysis 
 
Each experiment was performed in duplicate for western blotting and in triplicate for all 
other assays.  Each experiment was repeated 3-5 times on separate days.  Western blots 
were analyzed using a two-way ANOVA followed by Bonferroni post-tests.  Inositol 
phosphate, FLIPR calcium 4, cell migration, luciferase and receptor binding assays were 
analyzed using a two way ANOVA followed by a student’s t-test.  Statistical 
significance was set at p<0.05 with * = p<0.05, ** = p<0.01 and *** = p< 0.001. 
 
2.21. Collaborator methods 
 
The following methods were performed by collaborators at other institutions for 
kisspeptin antagonist studies, since facilities and materials needed for these studies were 
not available within the MRC Human Reproductive Sciences Unit. 
 
2.21.1. GnRH neuron firing (Moenter Laboratory, USA) 
 
The effects of the selected antagonist peptide 234 on kisspeptin-10 (1nM) stimulation of 
GnRH neuron firing (loose patch) was examined using loose patch recordings as 
previously described in procedures approved by the Animal Care and Use Committee of 
the University of Virginia (Nunemaker et al., 2002; Pielecka and Moenter, 2006; Suter 
et al., 2000).  Positive control cells were recorded for a 10 minute stable baseline, and 
then treated with 1nM kisspeptin-10 for 10 minutes followed by a washout.  To test for 
antagonist activity peptide 234 was added for 10 minutes at 1nM, 10nM or 100nM and 
then 1nM kisspeptin added along with 234 for 5 minutes. 
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2.21.2. Microdialysis monitoring of GnRH release in pubertal female 
rhesus monkeys (Terasawa Laboratory, USA) 
 
The source, care, ethical approval and handling of monkeys, surgical procedures and 
microdialysis monitoring of GnRH were as previously described (Frost et al., 2008; 
Keen et al., 2008).  Peptide 234 (10nM) in CNS perfusion fluid or vehicle alone were 
infused for 30 minutes through a semi-permeable membrane in four pubertal female 
rhesus monkeys in random order and the dialysate collected for GnRH assay.  The 
infusion was preceded by a 90 minute control collection period and followed by 60 
minute collection. Two of the 4 animals were examined twice in separate experiments 
totalling 6 experiments. 
 
2.21.3.  LH studies in intact and castrated rats (Tena-Sempere Laboratory, 
Spain) 
 
The source, care, ethical approval, surgical procedures, experimental protocol and LH 
and testosterone assays were as previously described (Castellano et al., 2005; Navarro et 
al., 2005b; Navarro et al., 2004b).  In intact adult males 5µl of 1nmol peptide 234 or 271 
was injected icv or ip at 60 minute intervals over 180 minutes.  The last injection was 
accompanied by an icv injection of 100pmol kisspeptin-10 in test animals.  Blood 
samples were collected for LH and testosterone assay at 15 and 60 minutes after each 
injection and also at 120 minutes after the last injection.  The same protocol was 
employed for castrated rats except the kisspeptin-10 injection was omitted. 
 
2.21.4. LH studies in intact and castrated mice (Steiner Laboratory, USA) 
 
The source, care, ethical approval, handling, surgical procedures, experimental protocol 
and LH assays were as previously described (Gottsch et al., 2004; Smith et al., 2005b).  
In initial experiments castrated mice were infused icv twice with doses of 1nmol, 5nmol 
and 15nmol peptide 234 and blood collected 30 minutes after the second infusion.  This 
study was repeated at 5nmol and 15nmol with a single infusion and collection of blood 
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30 minutes later.  To demonstrate that peptide 234 was specifically inhibiting kisspeptin 
stimulation of LH, intact male mice were infused icv with peptide 234 (100pmol) or 
vehicle, followed 5 minutes later by infusion of 100fmol kisspeptin-10 or vehicle alone 
and blood collected after 30 minutes. 
 
2.21.5. LH pulsatility studies in ovariectomised ewes (Clarke Laboratory, 
Australia) 
 
The source, care, ethical approval, handling, surgical procedures, experimental protocol 
and hormone assays were as previously described (Barker-Gibb et al., 1995; Iqbal et al., 
2006).  Blood samples were collected every 10 minutes for LH assay.  From 180-240 
minutes, four ovariectomised ewes were infused icv with vehicle or peptide 234 at 
40µg/h after a loading dose of 10µg.  Each ewe served as its own control, randomly 
receiving peptide 234 or vehicle on two occasions. 
 
2.21.6. Puberty Studies in female pre-pubertal rats (Tena-Sempere 
Laboratory, Spain) 
 
Peptide 234 was chronically infused to pubertal females. As general procedure for 
central delivery of the antagonist, pre-pubertal females (n=15/group) were implanted 
intradermally with osmotic minipumps (1 μl/h delivery rate X 7 days, Alzet mini-
osmotic pump model no. 2001; Durect, Cupertino, CA) that were connected to icv 
cannulae, as previously described (Roa et al., 2008d). Antagonist concentration per 
mini-pump was adjusted to 10 nmol/24 μL. Pair-aged females infused with vehicle 
served as controls. The treatment spanned from postnatal d-30 to d-36. Along treatment, 
the animals were monitored for daily food intake, body weight gain and vaginal opening. 
On d-36, the animals were killed by decapitation, trunk blood was collected for LH and 
FSH assays. Ovarian and uterine tissues were also dissected out and weighed. A 
statistical analysis was performed as an ANOVA followed by Student-Newman-Keuls 
multiple range test, or Student t-test –for bar graph data. 
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2.21.7. LH surge activation in female rats (Tena-Sempere Laboratory, 
Spain) 
 
A similar protocol of central infusion of peptide 234 was implemented in adult, cyclic 
female rats. The animals (n=9) were implanted with osmotic mini-pups in the morning of 
estrus, and infusion was continued until the following estrus. On the afternoon of 
proestrus, blood samples (250 L) were obtained by jugular vein-puncture at two hour 
intervals, from 12:00 onwards, following previously published procedures (Roa et al., 
2008a; Roa et al., 2008c). Additional blood samples were taken from each animal 
between 9:00 and 10:00 of the following estrus. A group of cyclic female rats (n=11) 







Development and characterisation of potent 
kisspeptin antagonists using in vitro and in 
vivo analyses to delineate physiological 
mechanisms affecting gonadotrophin 
secretion 





GnRH neurons are the final conduit through which the brain can control the 
reproductive system.  GnRH neuron function is thought to be regulated by an 
afferent network of kisspeptin-producing neurons.  Kisspeptin is released to act on 
its receptor (gpr-54) situated on GnRH neurons to stimulate GnRH secretion.  
However, the evidence supporting this hypothesis to date is indirect.  Therefore 
kisspeptin antagonists were produced to analyse the structure-activity properties of 
kisspeptin-10 (kp-10) and elucidate the role of kisspeptin on gonadotropin 
production.  Synthetic analogues were created by introducing amino acid changes 
to human kp-10 and were tested for their ability to bind to and activate or 
antagonise human gpr-54.  A number of antagonists were identified and some of 
these were subjected to in vivo testing to elucidate functional roles for kisspeptin.  
Structure-activity studies of the analogues indicated that Asn2, Trp3, Phe6, Arg
9 and 
Phe10 were important for the peptide to bind to the receptor.  Two other residues, 
Tyr1 and Leu8 were found to be critical for receptor activation.  In addition to 
deciphering functionally important residues within kp-10, these studies also 
identified four antagonists with the following consensus sequence for potent 
antagonism, X1-N-W-N-X5-F-G-X8-R-F-NH2 were X
1 = D-Ala or D-Tyr, X5 = Gly or 
D-Ser and X8 = D-Trp or D-Leu.  One of these antagonists, peptide 234 was 
extensively tested in vivo where it was shown to inhibit GnRH neuron firing in mice 
and GnRH secretion in monkeys.  This inhibition of GnRH secretion is a result of 
decreased pulse amplitude, and the same effect is seen on LH pulses in rodent and 
sheep models, confirming kisspeptin as a direct regulator of the HPG axis.  
However, peptide 234 had no effect on basal secretion of GnRH or LH in any 
species, suggesting differential mechanisms for regulation of basal and pulsatile 
secretion of these hormones.  Peptide 234 also inhibited the post-castration rise in 
LH levels observed in male rats and mice, providing direct evidence that increased 
kisspeptin mediate the LH rise resulting from removal of steroid negative feedback.  
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The antagonist also ablated the ovulatory LH and FSH surges in female rats and 
delayed vaginal opening in peri-pubertal rats, confirming further roles for 
kisspeptin in positive steroid feedback on the LH/FSH surge and influencing the 
timing of the onset of puberty.  In summary, kisspeptin antagonists have been 
developed and utilised to delineate the functionally important structural features of 




The HPG axis regulates reproduction via the modulation of GnRH production as a 
consequence of multiple pathways acting within the hypothalamus (Centeno et al., 2007; 
Millar, 2005; Porkka-Heiskanen et al., 1997).  Kisspeptin via gpr-54 has been shown to 
be one of the most potent regulators of this system known to date with doses as low as 
1fmol (icv) capable of stimulating GnRH secretion in vivo.  Kisspeptin and gpr-54 have 
also been implicated to have roles in puberty onset, regulation of the pre-ovulatory LH 
surge and integration of other regulatory pathways that affect the axis such as steroid 
hormone feedback and seasonal breeding stimuli (Popa et al., 2008; Roseweir and 
Millar, 2009).  The kisspeptin system was first discovered to be involved in the 
regulation of reproduction when two groups found that mutations in gpr-54 caused 
delayed or absent puberty with similar results evident in knockout mouse studies (de 
Roux et al., 2003; Seminara et al., 2003).  Since then many studies have emerged 
examining the effect of kisspeptin on GnRH secretion and the onset of puberty, with a 
major focus on how kisspeptin and gpr-54 are regulated by sex steroids, metabolic cues 
and photoperiod.  The latter factors can negatively regulate KiSS-1 mRNA levels within 
the ARC throughout the female reproductive cycle (Pompolo et al., 2006; Rance, 2008; 
Shibata et al., 2007; Smith et al., 2007; Smith et al., 2005b). Estrogen can also positively 
regulate KiSS-1 mRNA within either the ARC in sheep and primates or the AVPV in 
rodents at the time of the pre-ovulatory surge in LH production which initiates ovulation 
(Adachi et al., 2007; Estrada et al., 2006; Smith et al., 2005a).  However, most of the 
data concerning the role of the kisspeptin system to date is indirect (such as 
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measurement of changes in mRNA levels or altered patterns of immunohistochemical 
staining). 
 
To directly elucidate the importance of kisspeptin and gpr-54 in biological processes, the 
development of kisspeptin antagonists is a crucial requirement. The development of 
these synthetic analogues can be undertaken via two different strategies of structure-
function analysis; the more logical approach is to introduce systematic residue changes 
(e.g. Alanine screening).  This would involve each residue being systematically changed 
to Alanine, resulting initially in 10 synthetic peptide analogues.  Although this would 
assess the function of each residue, this system is not very cost-effective (with these 10 
peptides costing ~ £3300) and this cost would be amplified if any double-residue 
changes were then examined.  The second approach, as used in this study, is to make 
more intuitive amino acid changes based on knowledge of the peptide structure of 
kisspeptin (Fig. 26).  This involves making either conservative changes at positions of 
interest such as changing the side chain but not the overall charge of a residue, or 
changing L- amino acids to D-amino acids to assess the positioning of side chains.  
Finally, radical structural changes can also be made to change the charge or flexibility of 
the analogue.  This approach was chosen for this study as it is more cost-effective and 
potentially more rapid than the systematic approach. Any antagonists identified would 
be very useful tools, to investigate whether blockade of the system directly affects 
puberty onset, GnRH/LH secretion, steroid feedback and the pre-ovulatory LH surge.  
Antagonists may also be useful medicines with potential application as novel 
contraceptives, potential for management of polycystic ovarian syndrome (PCOS) 
patients (where there is often elevation of gonadotropin levels) or for treatment of 
children with precocious puberty. 
 
The results within this chapter cover the development and in vitro characterisation of 
synthetic kisspeptin-10 peptide analogues, enabling identification of a number of potent 
antagonists.  Selected antagonists were then characterised using in vivo experiments. 
Kisspeptin antagonists caused inhibition of GnRH and LH pulses and decreased FSH 
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secretion in rodents, sheep and primates.  An antagonist also caused a delay in pubertal 




Figure 26. Schematic diagram showing kisspeptin-10 primary structure. Amino acid side 
chains and carbon backbone for kisspeptin-10 are indicated.  Both the side chains and the carbon 
backbone may be important for establishing interactions with gpr-54. 
 
 





3.2.1. Kisspeptin analogues developed using intuitive amino acid changes 
bind with similar affinity to native kisspeptin-10 at human gpr-54 – 
Truncated peptides 
 
Analogues were synthesised based on the structure of human kisspeptin-10 (kp-10) as 
this is the smallest fragment needed to bind to and activate the receptor (Muir et al., 
2001; Ohtaki et al., 2001). Analogues were tested using CHO cells stably expressing 
human gpr-54 for their ability to bind to the receptor via a competition binding assay. A 
4 hour time point was used to test the binding of analogues to human gpr-54 since initial 
time course studies over 5 hours, revealed this to be the time point were unlabelled 
kisspeptin-10 and selected analogues maximally displaced 125I-labelled kisspeptin-10 




Figure 27. Time course of binding to assess maximal displacement. Time course assessing 
the time taken for unlabelled kisspeptin-10 or peptide 271 to maximally displaced 125I-labelled 
kisspeptin-10 from human gpr-54. (A) Kisspeptin-10 maximally displaces labelled peptide at all 
time points tested. (B) Peptide 271 maximally displaces labelled peptide from 4 hours. 
 
The results of the competition binding assays were quantified for comparison by 
calculating the half maximal inhibitory concentration for each analogue, known as the 
IC50.  This is the concentration of competing ligand, which displaces 50% of the specific 
binding of the radioligand in a competition assay and can therefore be compared 
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between kp-10 analogues.  This IC50 value for an analogue is variable between assays 
and can therefore be converted to the absolute inhibitory constant (Ki) using the Cheng-
Prusoff equation which states: 
     Ki =      IC50 
              1 + [S]/Km 
where [S] is the analogue concentration and Km is the analogues affinity for the receptor.   
This gives the concentration of competing ligand which would occupy 50% of the 
receptors if no radioligand was present. However, since the aim of this study was to 
compare a large number of analogues to Kp-10 and the Km for each analogue was not 
able to be calculated; only the IC50 was determined.  The dissociation constant or Kd 
may also have been estimated, to give an accurate measurement of the binding affinity 
for each analogue.  The Kd is based on the law of mass action which proposes a dynamic 
equilibrium exists for a reaction, e.g. between the number of unoccupied receptors/free 
ligand concentration and the number of occupied receptors.  The Kd is the concentration 
of ligand at which 50% of receptors are occupied and therefore the concentration at 
which this equilibrium occurs.  The Kd can be calculated using the law of mass action 
equation: 
 
Receptor + ligand ↔ Receptor.ligand 
 
Where Kon is the association rate constant and Koff is the dissociation rate constant.  
These are both proportional to the concentration of ligand and the number of unoccupied 
receptors.  At equilibrium, the rate of association should equal the rate of dissociation 
giving the following equation: 
 
  [ligand].[receptor].Kon = [ligand.receptor].Koff  
 
The Kd can then be calculated as follows: 
 
   Kd =  Koff = [ligand].[receptor] 
    Kon    [ligand.receptor] 
Kon 
Koff 
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However, within the scope of this thesis the rate of association and dissociation where 
not measured, and therefore the rate constants and Kd could not be calculated.  The IC50 
value was therefore used as a measure of the apparent binding affinity for analogues. 
 
Firstly, experiments tested whether all 10 amino acids were required for binding to the 
receptor using N-terminally truncated peptides possessing 5 or 7 amino acid residues. 
These were named peptides 188 (acFGLRF) and 186 (acNSFGLRF), respectively (Fig. 
28; for continuity the amino acid residues are numbered to correspond to positions in the 
full length kisspeptin-10). Each of these truncated peptides had a reduced binding 
affinity for the receptor compared to kp-10. This is calculated as the IC50, which is the 
concentration of peptide needed to displace the radiolabelled ligand by 50%. Peptide 188 
(acFGLRF) had an IC50 of 1.4x10
-7M for gpr-54 and peptide 186 (acNSFGLRF) had an 
even lower IC50 of 1.8x10
-6M (Fig. 28 and Table 5).  Therefore, it appears that binding 
of truncated peptides is less effective than kp-10, for which the IC50 is 7.7x10
-9M; based 
on a representative graph of the mean binding curve for kp-10 (Fig. 28 and Table 5).  
The reduction in binding affinity seen for the 5aa and 7aa truncated analogues suggests 
that more than 7aa are needed to bind effectively to gpr-54. Therefore, this implies that 
all 10aa are needed for binding to human gpr-54 and that at least one of the N-terminal 
residues must be involved in this process.   
 
Nevertheless, amino acids within the 5 amino acid truncated peptide were substituted to 
see if the binding affinities could be increased.  These are peptides 189, 190, 191 and 
200-203, and 206-207.  All of these analogues had reduced affinity for human gpr-54 
(Table 5); however, these analogues did highlight some residues important for binding 
interactions with the receptor.   
 
As the RFamide motif at the C-terminus is hypothesised to be critical for receptor 
binding, we firstly investigated substitutions at these two residues.  Trp10 was introduced 
into peptide 189 to assess the effects of introducing a bulkier and polar side chain into 
the RFamide motif.  The use of Trp10 also introduces rigidity to the phenyl ring and 
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some steric hindrance thus reducing flexibility of the C-terminus. Peptide 189 
(acFGLRW) had an IC50 of 9.5x10
-7M for human gpr-54 (Fig. 29 and Table 5). The 
results imply that introducing a more rigid polar residue into the RFamide motif 
decreases the ability to bind the receptor.  Next a D-Arg9 was substituted in place of the 
normal L-Arg9 in conjunction with the Trp10 substitition (peptide 200).  This substitution 
of both residues of the RFamide motif ablated kisspeptins ability to binding to the 
receptor. These results confirm the importance of both the residues within this motif for 




Figure 28.  Truncated analogues of kp-10 have decreased binding affinity for gpr-54. (A) 
Kp-10 binds strongly to gpr-54 with an IC50 of 7.7nM. (B) Truncation of this peptide to five 
amino acids decreases the IC50 for gpr-54 to 140nM.  (C)  Increasing the length of the analogue 
to seven amino acids actually decreases the binding further to an IC50 of 1.8μM.  Primary 
structures for each analogue are shown. 








Figure 29.  Substitution of both Arg9 and Trp10 of the RFamide motif in truncated 
analogues ablates binding.  (A) Kp-10 binds strongly to gpr-54 with an IC50 of 7.7nM. (B) 
Substitution of Phe10 with Trp10 reduces receptor binding to an IC50 of 950nM. (C) Substitution 
of both Phe10 to Trp10 and Arg9 to D-Arg9 ablated the analogues ability to bind to human gpr-54. 
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Arg9 and Phe10 have been shown to be important for receptor binding in truncated 
peptides, and one further residue was also shown to be involved in this interaction within 
the N-terminus (peptides 202-203). The first residue of the truncated 5 amino acid 
analogue is a bulky aromatic and hydrophobic phenylalanine6; this is usually within the 
core of the peptide structure and may evade exposure to an aqueous environment.  
Therefore, two substitutions were made at this position; firstly within peptide 202 an 
alanine is substituted for Phe6.  Alanine is smaller than phenylalanine and possesses a 
hydrophobic methyl side chain.  This substitution should inform about the need for 
longer side chains at this position.  The second substitution is a D-Phe6 (peptide 203) to 
determine if the position of the side chain in the peptide is important for binding.  
Peptide 202 could no longer bind the receptor (Fig. 30 and Table 5) suggesting that the 
side chain of phenylalanine is important for kp-10 to interact with gpr-54 along with 
Arg9 and Phe10, possibly via hydrophobic interactions.  Peptide 203 could also not bind 
to gpr-54, confirming the need for the side chain and revealing that the positioning of the 
side chain is important for interactions to occur (Fig. 30 and Table 5).   
 
As none of the above truncated peptides could bind the receptor with the same or higher 
affinity than kp-10, this confirms that more than five residues are needed to fully bind to 
the receptor.  Therefore further studies with truncated peptides were abandoned and full-
length 10-residue analogues were developed and tested. 
 
It was noted from studies using the truncated peptides, that neither kp-10 nor the 
truncated analogues could completely displace the radiolabelled ligand in the whole cell 
binding assay. This problem was subsequently shown to be due to the radiolabelled 
ligand binding to the plastic ware. Binding of 125I-labelled kp-10 to the plastic ware, 
results in a relatively high amount of non-specific binding when kp-10 and the analogues 
are tested for binding to the receptor in a displacement assay.  This makes it difficult to 
accurately determine the specific binding for some peptides due to overlap with the high 
non-specific binding. The best way to analyse this data would be to subtract non-specific 
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binding at each displacement point, however this would be difficult as the results would 
need to be compare to non-transfected cells plated at the same density.   
 
The high non-specific binding seen for some analogues may also be due to some 
peptides aggregating or forming secondary or tertiary structural lattices, since this would 
impair the ligand binding interactions giving a false level of non-specific binding.  To 
try to combat these effects a variety of solvents such as weak acids, DMSO, detergents 
and distilled water were utilised to try to inhibit formation of secondary structures, but 
this approach had limited success.  The temperature of analogue stock solutions was also 
varied to try to break down any hydrogen bonding within potential lattices but this also 
failed to cause a significant effect.  These results suggest that lattices are not being 
formed in these analogues but this could to be investigated using light scattering 
spectroscopic techniques (e.g. infrared spectroscopy or circular dichroism).  In this 
assay, any peptides undergoing aggregation would cause a higher amount of light 
scattering than disaggregated peptides. 
 
Other factors may also affect the assay conditions for ligand binding interactions such a 
purity and solubility which might reduce the effective ligand concentration and specific 
receptor activity and receptor dimerisation when over-expressed.  It is important to know 
that the ligand solubility exceeds the concentration of the peptide under investigation.  
The concentration is determined using the molecular weight and weight of peptide per 
millilitre (mg/ml), which can then be used to calculate the molarity (M).  If the peptide 
does not fully dissolve then the mg/ml will be incorrect giving an inaccurate calculation 
of the concentration. Another problem related to concentration determination is the 
purity of the peptide, the lower the purity of the analogue. This may lead to an 
overestimation of the concentration of the peptide solution which leads to an 
underestimation of the binding affinity for the peptide.  The amount of peptide per 
millilitre and therefore the concentration may therefore be confirmed in several ways 
such as using a nanodrop spectrometer to determine the absorbance at 280nm if the 
peptide contains tryptohans or tyrosines.  Based on the known extinction coefficients 
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and the number of the two absorbing amino acids, the molar concentration can be 
determined with much better accuracy compared to weighing in a sample of low mg 
amounts.  HPLC chromatography using absorbance or fluorescence detection combines 
the concentration determination with the measurement of the sample purity.    As for 
receptor dimerisation, this requires specialised fluorescence resonance-energy transfer 
(FRET) techniques using tagged receptors or immunoprecipitation with specific 
antibodies to determine if any receptor dimerisation actually occurs.  However, as 
tagged receptors are not yet available and no reliable specific antibodies have been 
made, it is not known whether gpr-54 forms dimers.  However, as only IC50 were 
calculated within this thesis, as assay condition dependent relative estimation of affinity, 




Figure 30. Position 6 amino acid changes are not tolerated. (A) Kp-10 binds strongly to gpr-
54 with an IC50 of 7.7nM. (B) Substitution of Phe
6 with Ala6 abolishes receptor binding due to 
the absence of the aromatic side chain. (C) D-Phe6 is also not tolerated confirming the side chain 
properties.  
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3.2.2. Kisspeptin analogues developed via intuitive amino acid changes 
bind with similar affinity to native kisspeptin-10 at human gpr-54 –  
 Full length peptides 
 
For the first full-length substitutions the six most C-terminal residues were substituted, 
as it had been hypothesised that these residues were involved in binding to the receptor 
due to the high level of conservation of these residues between vertebrate species and 
the RFamide motif within this family; peptides 208-213 and 288 (Table 4).   
 
 
Table 4. Primary sequences for RFamides including kisspeptin. Primary sequences for 
RFamides showing species where discovered.  Sequences are also shown for kisspeptin-1/2 in a 




In order to increase the flexibility of the peptide Ser5 was substituted with the achiral, 
glycine in peptide 208. Due to the small hydrogen atom in place of a side chain, this 
allows glycine to create flexibility within the peptide, to promote conformational 
changes. This substitution retained binding to the receptor with an IC50 of 1.2x10
-7M 
(Fig. 31 and Table 5). As this replacement was well-tolerated by the peptide, it was 
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included in the majority of subsequent analogues.  Next, amino acid changes at Leu8 
were attempted (Fig. 32). Leu8 is a hydrophobic and aliphatic residue found in the 
peptide core, likely to be involved in interactions with other hydrophobic residues. 
Peptide 209 had a D-Leu8 substitution, to check if the specific location of side chains 
was important for binding. Peptide 210 and 228 had D-Trp8 in place of Leu8 to test the 
effect of steric hindrance due to a bulky side chain within the C-terminal region upon 
binding.  However, as this is combined with Gly5 this will still allow flexibility within 
the central region. Peptide 228 also had an acetyl group added to the N-terminus to try to 
extend the half-life of the peptide when exposed to amino-peptidases in a biological 
environment. Peptide 209 had decreased ability to bind the receptor, with an IC50 of 
2.8x10-6M, but exhibited similar capacity to displace radiolabelled ligand compared to 
kp-10.  Peptide 210 was, however, able to bind the receptor with an IC50 close to that of 
kp-10 at 6x10-9M. The results were similar for peptide 228 although the IC50 was higher 
at 1x10-11M (Fig. 32 and Table 5).  Therefore, it appears that changes within residue 8 
that increase steric hindrance do not significantly affect the binding properties of kp-10. 
However, changing the steric position of the Leu8 side chain is not tolerated. Also 
although displacement of radiolabelled ligand seems lower all the analogues (Peptides 
208, 209 and 228) displace to a similar percentage as kp-10, the higher non-specific 
background is probably due to increase binding to plastic ware when total counts are 
increased due to a higher cell number (Fig. 32). 
 
The contribution of Phe6 was next investigated in the full-length analogues since 
changes to this residue had ablated binding in the truncated peptides.  Two substitutions 
were made at this position in conjunction with Gly5, firstly in peptide 211, this residue 
was replaced with D-Phe6 as in the truncated peptides the steric orientation of the large 
side chain appeared important for receptor binding.  The second change incorporated a 
D-Trp6 residue in peptide 212, again to test for the effects of steric hindrance but as this 
residue is close to Gly5 this may also affect the flexibility of the central region. All of the 
above changes to Phe6 caused a significant shift in binding affinity to IC50 values around 
1μM (~10-6M).  This suggests that Phe6 is critical for receptor binding via interactions 
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between its side chain and gpr-54, since even changing the position of the side chain 
ablates binding (peptide 211, Fig. 33 and Table 5).   
 
The above results examining the effects of substitutions of C-terminal residues suggest 
that binding involves Phe6, Arg9 and Phe10, this is in line with data published after this 
work was completed describing the pharmacophore created by these residues for binding 






Figure 31. Glycine substitution at Ser5 retains binding. (A) Kp-10 binds strongly to gpr-54 
with an IC50 of 7.7nM. (B) Peptide 208, with a Glycine at position 5 binds the receptor with an 
IC50of 120nM and effectively displaces the labelled ligand by 75% at 10µM. Amino acid 














Figure 32.  Amino acid changes at Leu8 retain receptor binding.  (A) Kp-10 binds strongly to 
gpr-54 with an IC50 of 7.7nM. (B) D-Leu
8 decreases binding affinity, with an IC50 value of 
2.8μM. (C) D-Trp8 retains a binding affinity an IC50 of 6nM similar to kp-10. (D) Acetylation of 
peptide 210 increases affinity, but decreases displacement. (E, F) Amino acid structures of 














Figure 33. Phe6 is critical for receptor binding. (A) Kp-10 binds strongly to gpr-54 with an 
IC50 of 7.7nM. (B) Replacement of Phe
6 with D-Phe6 significantly reduces the IC50 to 4.3μM. (C) 
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Following demonstration that the C-terminal residues of kisspeptin are involved in 
binding to receptor, attentions were turned to the five N-terminal residues to examine if 
receptor binding also involved N-terminal interactions.  As peptide 210 could bind with 
a similar affinity to kp-10 (Fig. 32), the D-Trp8 substitution was incorporated into all 
further analogues in conjunction with glycine at position five. However, as Phe5 has 
been demonstrated to tolerate a glycine substitution to promote flexibility, the next 
changes examined if other residues would also be acceptable.  Three more substitutions 
were tried; these were D-Trp5 (Peptide 229); D-Ala5 (peptide 233) and D-Ser5 (Peptide 
273).  D-Trp5 was used for the opposite reasons to glycine, to hinder conformational 
changes rather than increase flexibility and the D-Ala5 and D-Ser5 substitutions may 
cancel any interactions made at this position, due to a decrease in the side chain length.   
Peptide 229 was unable to bind to gpr-54, suggesting flexibility is needed in this region.  
Peptide 233 and 273 could still bind with an IC50 value of 7.9x10
-9M and 1.4x10-10M, 
respectively, but again the displacement of radiolabelled ligand is lower (Fig. 34 and 
Table 5) implying that glycine at this position allows the greatest amount of receptor 
binding and that side chain interactions are not important within this residue.  Therefore, 
flexibility is more important at this position than side chain interactions. 
 
Substitutions were then made for the three most N-terminal residues in combination with 
Gly5 and D-Trp8; however Asn4 was not substituted in these studies.  Two changes were 
made at Tyr1; firstly this residue was replaced with D-Tyr1 (Peptide 230) to test side 
chain positioning and then with D-Ala1 (Peptide 234) to test the importance of side chain 
interactions for binding.  Peptide 230 was still able to bind to the receptor but the 
displacement of radiolabelled ligand was decreased, whereas peptide 234 could bind the 
receptor with similar binding affinity to kp-10 and exhibited a greater amount of 
displacement compared to peptide 230 (Fig. 35 and Table 5).  Therefore, we can assume 
that Tyr1 is not important for binding to the receptor.  Two similar substitutions were 
made in place of Asn2.  Peptide 232 incorporated a D-Asn2 and peptide 236 had a D-Ala2 
in place of the asparagine removing the basic charge at this position.  Peptide 232 and 
peptide 236 could not bind to the receptor (Fig. 36 and Table 5). These results imply that 
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Asn2 interacts with the receptor to assist binding probably via hydrogen bonding and that 
the presence and positioning of the side chain is critical to this interaction.  The results 
also suggest that a basic residue is needed at this position for receptor binding to take 
place. Finally, the same substitutions were made for Trp3 giving peptide 231 with D-Trp3 
and peptide 235 with D-Ala3.  Peptide 231 and peptide 235 could not bind to gpr-54 (Fig. 
37 and Table 5).  This suggests that Trp3 may also form interactions with the receptor 
and that the presence and positioning of a side chain is again important for this 
interaction and binding to occur. 
 
These results from examining the effects of residue substitutions within full-length 
kisspeptin-10 suggest that the main binding residues lie within the C-terminal domain 
via Phe6, Arg9 and Phe10, as was proposed within truncated analogues, and within the N-
terminal domain via Asn2 and Trp3. This would account for the reduced binding in 
truncated peptides where Asn2 and Trp3 were removed. The study of the full-length 
analogues also suggests that the functional peptide conformation requires flexibility in 
the centre of the peptide as bulky residues at position 5 ablate receptor binding. The 
introduction of rigidity via D-Trp8 within the C-terminus is tolerated well suggesting that 
this residue does not contribute to receptor binding interactions. Similar results were 
seen with Tyr1 substitutions, again suggesting this residue has no involvemet in receptor 
binding. 
 
Although further analogues were made, these were used to investigate receptor 
activation and to screen for kisspeptin antagonists, since most residues within kp-10 










Figure 34. Amino acid changes at Ser5 need flexibility. (A) Kp-10 binds strongly to gpr-54 
with an IC50 of 7.7nM. (B) D-Trp at position 5 abolishes binding. (C) D-Ala
5 retains binding with 
an IC50 of 7.9nM as does (D) D-Ser
5 with an IC50 of 140pM.  Amino acid composition is also 
shown for each analogue. 
 
 










Figure 35. Tyr1 is not involved in receptor binding. (A) Kp-10 binds strongly to gpr-54 with 
an IC50 of 7.7nM. (B) D-Tyr at position 1 retains ability to bind to the receptor with an IC50 value 
of 7.3nM. (C) Peptide 234 with a D-Ala1 binds with a similar IC50 value to kp-10 of 2.8nM.  












Figure 36. Asn2 amino acid substitutions affect binding. (A) Kp-10 binds strongly to gpr-54 
with an IC50 of 7.7nM. (B) D-Asn at position 2 cannot bind the receptor. (C) Similarly, D-Ala at 












Figure 37.  Trp3 interacts with the receptor.  (A) Kp-10 binds strongly to gpr-54 with an IC50 
of 7.7nM. (B) D-Trp3 at this position cannot bind to the receptor and (C) substitution with D-Ala3 










Table 5. Diagram of amino acid substitution effects on receptor binding. Flowchart for 
amino acid substitutions within truncated and full-length peptide analogues showing the effects 
of each substitution on binding.  The IC50 for analogues that exhibit binding is shown in brackets 
and peptide number in blue. 
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3.2.3. Some kisspeptin analogues inhibit kisspeptin-10 induced inositol 
phosphate production and intracellular calcium release 
 
After testing for receptor binding, analogues were tested for receptor activation via 
phospholipase C-mediated inositol phosphate (IP) production and antagonistic properties 
via inhibition of kisspeptin-stimulated inositol phosphate production.  An antagonist 
should bind to the receptor but not activate it and ideally should inhibit kisspeptin-
stimulated IP production by >80%.  Kisspeptin activates the receptor with a mean EC50 
of 3.9x10-9M; therefore a dose of 10nM was used for antagonist studies.  For logistical 
reasons, experiments for each analogue were not always performed on the same day and 
although cells were routinely plated at 1x10-5 cells/well, variation in lengths of cell 
culturing causing variation in cell numbers can account for inter-experimental 
differences in basal and kp-10-induced levels of IP. Large variations were seen with 
some analogues and this may be due to the need to handle multiple plates per analogue 
for each experiment.  
 
Effects on inositol phosphate production 
Truncated peptides were tested first even though they had little receptor binding.  All of 
these analogues could activate the receptor except peptides 201 and 206-7, which all had 
substitutions of Leu8. Truncating the receptor to 5 amino acids retained its agonistic 
properties (peptide 188-9). Changes to position 6 (peptide 202-3) had no antagonistic 
effects and changes to position 9/10 (peptide 200) could not bind, activate or antagonise 
the receptor. However, position 8 changes did not intrinsically activate IP production 
and had weak antagonistic properties.  Peptide 201 possessing Ala8 could antagonise the 
kp-10 stimulation by 67% with an IC50 of 7x10
-9M, peptide 206 with a D-Trp8 could 
also antagonise the kp-10 stimulation by 71% with an IC50 of 5x10
-9M but peptide 207 
with a D-Phe8 could only antagonise by 53% with an IC50 of 3x10
-9M (Fig. 38 and Table 
6).  These results suggest that Leu8 is important for activation of gpr-54 and that large 
residues are the most effective residues for antagonism. However, as none of these 
truncated kisspeptin-10 analogues could antagonise by more than 70% they were not 
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tested further and attentions were turned to the full-length analogues.  Also the dose 
response curves where peculiar with low doses sometimes more effective than higher 




Figure 38. Truncated peptides with changes at position 8 create antagonism. Graphs 
showing both intrinsic IP release (light grey) and antagonism of kp-10 stimulated IP release 
(dark grey). IP is the concentration at which stimulation reached 50% of the maximal (EC50) and 
Ant is the percentage for maximal antagonism at micromolar doses. (A) Ala6 can stimulate IP 
release and cannot antagonise gpr-54. (B) D-Phe6 also stimulates IP but can antagonise by 40%. 
(C) Ala8 does not produce an intrinsic IP response and antagonises by 67% with an IC50 of 7nM. 
(D) D-Trp8 further antagonises to 71% with an IC50 of 5nM.  (E) D-Phe
8 is less effective and only 
antagonises by 52%.  (F) Amino acid changes to Arg9 disrupt binding and activation of the 
receptor with little antagonism. 






Table 6. Truncated kisspeptin-10 analogues.  Table showing IC50 values for binding and  
antagonism, and EC50 values for intrinsic IP release.  The percentage of maximal inhibition at 
micromolar concentration are given along with an indication for possible antagonists.  Blue 




Amino acid changes within the C-terminal region were focused on, to determine 
residues within this region involved in receptor activation or creation of antagonism. 
Ser5 to Gly5 substitution in kp-10 (peptide 208) inhibited kp-10 stimulation of IP by 54% 
with an IC50 of 1x10
-8M (Fig. 39 and Table 7). Therefore, this change was incorporated 
into subsequent analogues. However, as this analogue could still stimulate an intrinsic IP 
release with an EC50 of 4.5x10
-8M it implies that this substitution alone is insufficient for 
antagonism.  Analogues comprising Gly5 and substitutions at Phe6 exhibited some 
antagonism but could still activate the receptor at high concentrations.  Peptide 211, 
containing D-Phe6 and, peptide 212 containing D-Trp6 could not antagonise any further 
than peptide 208 (Fig. 39 and Table 7).  This implies that a Phe6 substitution is not 










Figure 39. Gly5 causes antagonism and this is not enhanced by position 6 substitutions. 
Graphs showing both intrinsic IP release (light grey) and antagonism of kp-10 stimulated IP 
release (dark grey). IP is the concentration at which stimulation reached 50% of the maximal 
(EC50) and Ant is the percentage for maximal antagonism at micromolar doses. (A) Substitution 
of Ser5 to Gly5 enhances antagonism at high doses but still activates the receptor at 45nM.  (B, 
C) Additional substitutions at position 6 also stimulate IP release but D-Phe6 and D-Trp6 do not 
increase the antagonism over peptide 208. 
 
 
As Leu8 had been shown to create antagonism in the truncated peptides, changes at this 
residue were tested next in combination with Gly5.  D-Leu8 (peptide 209) did not activate 
the receptor but could not antagonise any further than Gly5 alone, whereas D-Trp8 
(peptides 210 and 228) again elicited no intrinsic IP release but caused further 
antagonism to 64% with an apparent IC50 of <1x10
-10M. The acetylated version of this 
peptide could also inhibit kp-10 stimulation of IP by 69%. Combination of changes at 
positions 6 and 8 with Gly5 (peptide 213) appeared to disrupt the structural conformation 
of the peptide as it could no longer bind, activate or antagonise the receptor (Fig. 40 and 
Table 7). This suggests that Leu8 is important for receptor activation and that appropriate 
substitutions in the C-terminal region promote antagonism.  Therefore, D-Trp8 was 
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incorporated into further analogues along with Gly5.  To test if Gly was the best residue 
for antagonism at position 5, changes were made in combination with D-Trp8.  D-Trp5 
(peptide 229) slightly decreased the antagonism, however, D-Ala5 (peptide 233) 
increased the antagonism to 71% but the IC50 was reduced to 7x10
-7M.  Therefore, Gly5 







Table 7. Full length kisspeptin-10 analogues. Table showing apparent IC50 for binding and 
antagonism, and EC50 values for intrinsic IP release.  The percentage of maximal inhibition at 
micromolar concentration are given along with an indication for possible antagonists. Yellow 
indicates a potent antagonist and blue indicates an analogue with antagonistic potential. 





Figure 40.  Gly5 combined with Leu8 substitution increases antagonistic effects. Graphs 
showing both intrinsic IP release (grey) and antagonism of kp-10 stimulated IP release (blue). IP 
is the concentration at which stimulation reached 50% of the maximal (EC50) and Ant is the 
percentage for maximal antagonism at micromolar doses. (A) D-Leu8 does not enhance 
antagonism over Gly5 alone. (B) D-Trp8 increases antagonism to 64% with an IC50 of less than 
100pM. (C) Acetylation of peptide 210 further increases the antagonism to 69%. (D) Combining 
substitutions at Ser5, Phe6 and Leu8 completely ablates the antagonistic effect seen with Gly5 and 
D-Trp8. 






Figure 41. Small amino acid side chains and flexibility are critical for antagonists 
containing substitutions at Ser5. Graphs showing both intrinsic IP release (grey) and 
antagonism of kp-10 stimulated IP release (blue). IP is the concentration at which stimulation 
reached 50% of the maximal (EC50) and Ant is the percentage for maximal antagonism at 
micromolar doses. (A) Gly5 promotes flexibility of peptides and in conjunction with D-Trp8 
antagonises by 69%.  (B) Substitution of Gly5 with a bulky D-Trp5 reduces this antagonism to 
50%.  (C) However, substitution with the small amino acid, D-Ala5 retains the antagonistic 
properties of peptide 228. 
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It was now clear that Gly5 in combination with D-Trp8 could antagonise receptor 
activation and that Leu8 was involved in receptor activation.  Therefore, to try to 
enhance this antagonism further, substitutions within the N-terminal region were tested 
in combination with these C-terminal region modifications.  Changes were made at 
positions 1, 2 and 3. All of these analogues (peptides 230-236 and 243-4) failed to 
stimulate IP release and do not have intrinsic agonist activity.  Position 1 substitution to 
D-Tyr1 (peptide 230) significantly improved antagonism to 81%; however D-Ala1 
(peptide 234) significantly increased antagonism further to 93% with an IC50 of 7x10
-
8M. However, D-Trp1 (peptide 243) or D-Phe1 (peptide 244) at this position could not 
increase the antagonism (Fig. 42 and Table 7). This suggests that removing the charge 
and hydrogen bonding from this position is important for antagonism and that steric 
hindrance at this position is detrimental to antagonistic events.  As for amino acid 
changes at position 2; D-Asn2 (peptide 232) and D-Ala2 (peptide 236) could not increase 
the antagonistic effects over peptide 228, therefore substitution of this residue does not 
appear important for antagonism of the receptor.  Finally substitutions of position 3 to D-
Trp3 (peptide 231) or D-Ala3 (peptide 235) also had no further antagonistic effect on the 
receptor (Fig. 43 and Table 7).  Therefore, Tyr1 is the only residue within the N-terminal 
region that appeared important for receptor activation and antagonism. 
 
Next, to test whether antagonism was due to a combination of all three substituted 
residues or whether one was more critical, we took the two position 1 analogues and 
removed or changed the Gly5 or D-Trp8 substitution to examine the effect on the 
antagonistic properties of the peptide. For analogues with D-Tyr1, modification of either 
of these residues completely ablated any antagonistic effect (peptides 237-8), indicating 
that the D-Tyr1 has relatively little effect on the receptor antagonism alone.  However, 
for D-Ala1 analogues, conversion of Gly5 back to Ser5 (peptide 247) slightly reduced the 
antagonism to 78% and changing of D-Trp8 to L-Trp8 (peptide 248) reduced antagonism 
further to 65%.  However, D-Leu8 at this position (peptide 276) increased antagonism to 
85%, suggesting a D-amino acid is needed at this position for antagonism; however 
peptide 276 does have intrinsic agonist activity (Fig. 44 and Table 7).  The results 
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indicate that D-Ala1 and D-Trp8 are the most important residues for antagonism. 
However, Gly5 must also play a role by keeping the peptide flexible since other 
substitutions at this position within peptide 234 has drastic effects except when D-Ser5 
(peptide 273) is substituted here, keeping antagonism high at 80% with an IC50 of 1x10
-
10M.  Replacement with Pro5 (peptide 274), D-Pro5 (peptide 275) or D-Ala5 (peptide 277) 
reduces antagonism to 24%, 45% and 24%, respectively (Fig. 45 and Table 7).   
Therefore, flexibility, possibly to allow receptor engagement appears to be the key factor 
in this position.  Now that substitution of position 1, 5, and 8 had been shown to produce 
antagonists, combinations of these with position 2 substitutions were tested (peptides 
239-242). However, all of these reduced antagonism.  Also, introduction of D-Trp6 into 
peptides 230 and 234 to increase steric hindrance at the C-terminal region (peptides 245 
and 246) also reduced antagonism to around 60% (Fig. 46 and Table 7).  The above data 
shows that amino acid changes to D-Ala1, Gly5 and D-Trp8 (peptide 234) are the most 
critical for antagonism.  However, other residues are tolerated at these positions such as 
D-Trp1 in peptide 230, D-Ser5 in peptide 273 or D-Leu8 in peptide 276.  
 
Effects on levels of intracellular calcium 
To further investigate the effects of these antagonists, stimulation of intracellular 
calcium release was measured.  Peptide 234 did not stimulate calcium release alone, but 
did antagonise kisspeptin-stimulated calcium release by 89% with an IC50 of 1x10
-10M, 
further confirming its potency.  Peptide 273 could also antagonise intracellular calcium 
release to 63% with no intrinsic stimulation and peptide 276 completely inhibited the 
intracellular calcium secretion (Fig. 47/Table 8). To confirm these were specific effects, 
three analogues that had reduced antagonism of IP were also tested, peptides 274, 275 
and 277 only antagonised by 28%, 27% and 22%, respectively, confirming the effects 
above are specific (Table 8).  Overall, four antagonists have been created (peptide 230, 
234, 273 and 276) from this research and it has identified the residues important for 
receptor binding (Asn2, Trp3, Phe6, Arg9 and Phe10) and for receptor activation (Tyr1 and 
Leu8).  As peptide 234 was the most potent antagonist created in vitro this was taken 
forward into in vivo testing. 





Figure 42.  Amino acid substitutions at position 1 increase antagonism. Graphs showing 
both intrinsic IP release (grey) and antagonism of kp-10 stimulated IP release (blue). IP is the 
concentration at which stimulation has reached 50% of the maximal (EC50) and Ant is the 
percentage for maximal antagonism at micromolar doses. (A) D-Tyr at position 1 increases 
antagonism to 81% with no intrinsic IP release. (B) D-Ala at position 1 increases antagonism to 
93% with and IC50 of 70nM and no intrinsic IP production.  (B) D-Trp
1 and (C) D-Phe1 does not 
increase antagonism showing steric hindrance in this area is not tolerated. 





Figure 43. Positions 2 and 3 are not involved in receptor activation. Graphs showing both 
intrinsic IP release (grey) and antagonism of kp-10 stimulated IP release (blue). IP is the 
concentration at which stimulation has reached 50% of the maximal (EC50) and Ant is the 
percentage for maximal antagonism at micromolar doses. (A) D-Asn and (B) D-Ala at position 2 
do not increase antagonism over peptide 228. (C) D-Trp and (D) D-Ala at position 3 do not 
increase antagonism over peptide 228. 







Figure 44. Removal of Gly5 or D-Trp8 reduces antagonism. Graphs showing both intrinsic IP 
release (grey) and antagonism of kp-10 stimulated IP release (blue). IP is the concentration at 
which stimulation has reached 50% of the maximal (EC50) and Ant is the percentage for 
maximal antagonism at micromolar doses. (A, B) Removal of D-Trp8 or Gly5 from analogues 
with D-Tyr1 completely ablates antagonism. (C, D) Removal of Gly5 or D-Trp8 form D-Ala1 
analogues reduce antagonism to 78% and 65%, respectively. (E) This can be increased by 
introducing D-Leu8 to 85%. 





Figure 45. Glycine is the most effective residue at position 5. Graphs showing both intrinsic 
IP release (grey) and antagonism of kp-10 stimulated IP release (blue). IP is the concentration at 
which stimulation has reached 50% of the maximal (EC50) and Ant is the percentage for 
maximal antagonism at micromolar doses. (A) D-Ser at position 5 is tolerated and antagonises by 
80% with an IC50 of 0.1nM.  (B, C) Pro or D-Pro at position 5 reduces antagonism to 24% and 
45%, respectively. (D) D-Ala at position 5 reduces antagonism to 24%. 





Figure 46. Double substitutions in the N-terminus and D-Trp6 reduce antagonistic effects.  
Graphs showing both intrinsic IP release (grey) and antagonism of kp-10 stimulated IP release 
(blue). IP is the concentration at which stimulation has reached 50% of the maximal (EC50) and 
Ant is the percentage for maximal antagonism at micromolar doses. Peptides were substituted 
with D-Tyr1 and D-Asn2 (A) without Gly5 or D-Trp8 completely ablating antagonism. (B) 
Introduction of D-Trp8 increased antagonism to 47% and (C) introduction of Gly5 also increased 
antagonism to 32%.  (D) When both Gly5 and D-Trp8 were added back, antagonism increased to 
44%. (E, F) Introduction of D-Trp6 into peptides 230 and 234 decreased antagonism to 67% and 
64%, respectively. 




Figure 47. Effects of selected peptides on the elevation of intracellular calcium by kp-10 in 
CHO/gpr-54 cells.  Graphs show antagonism of kp-10 stimulated calcium at 60 seconds. Ant = 
the maximal antagonism achieved at micromolar concentrations. (A) Raw calcium transients for 
kisspeptin-10 showing 60 minute time point (dotted line).  (B) Quantification of kisspeptin 
calcium transients.  (C) Peptide 234 calcium transients showing antagonism of kp-10 stimulated 
calcium (D) Quantification of peptide 234 transients showing 89% antagonism. (E) Peptide 273 
calcium transient showing partial antagonism of kp-10 stimulated calcium by 63%. (F) 
Quantification of peptide 273 calcium transients. (G) Peptide 276 calcium transients showing 
complete antagonism of kp-10 stimulated calcium. (H) Quantification of peptide 276 calcium 
transients showing 100% antagonism. 




Table 8. Table detailing all kisspeptin-10 peptide analogues used in this study. Table 
showing the peptide analogues tested with results for binding and stimulation of IP and Calcium 
release.  Antagonistic results for IP and Calcium are also shown.  The four antagonists found are 
highlighted in yellow and other promising analogues in blue. 
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3.2.4. Kisspeptin antagonist inhibits GnRH pulses in rodents and monkeys 
 
Selected antagonists characterised in vitro, where then tested for in vivo activity by 
collaborators with specialised models. For these studies the antagonist with the highest 
potency and efficiency in vitro was utilised, this is peptide 234. Firstly, the effect of 
peptide 234 on GnRH neuron firing was investigated in mouse brain slices. These 
studies were performed by Sue Moenter and Justyna Pielecka-Fortuna in the University 
of Virginia, USA.  Then the effects on GnRH pulsatility in the female rhesus monkey 
were investigated by Ei Terasawa and Kathryn Guerriero in the University of 
Wisconsin-Madison, USA.   
 
As has been demonstrated previously (Han et al., 2005; Pielecka-Fortuna et al., 2008), 
1nM kisspeptin-10 markedly increased GnRH neuron firing activity in mice with GFP-
labelled GnRH neurons (Fig. 48). Under these experimental conditions, there was no 
effect on GnRH neuron firing activity of peptide 234 alone (1nM pre 0.2 ± 0.1 Hz, post 
0.3 ± 0.1Hz, n=5, P>0.05; 10nM pre 0.3 ± 0.2 Hz, post 0.3 ± 0.2Hz, n=6, P>0.05; 
100nM pre 0.5 ± 0.1Hz, 0.6 ± 0.1 Hz, n=7, P>0.05, paired t test). In contrast to the lack 
of effect of peptide 234 on basal firing, pre-treatment with peptide 234 blocked the 
response to 1nM kisspeptin-10 (P<0.001 for all doses) compared to cells treated with 
kisspeptin-10 alone (Fig. 48).  
 
Since peptide 234 inhibited GnRH neuronal firing we investigated with collaborators 
whether it also inhibited GnRH release in pubertal female rhesus monkeys using 
methods previously described (Frost et al., 2008; Keen et al., 2008). Infusion of 10nM 
peptide 234 over 30 min through a microdialysis probe located in the stalk-median 
eminence region promptly and consistently suppressed GnRH pulses as well as mean 
GnRH levels but did not affect basal levels (Fig. 49). In contrast, vehicle infusion 
through the probe did not cause any significant changes in GnRH release (Fig. 49). The 
peptide 234-induced GnRH suppression was significantly different from values prior to 
peptide 234 infusion as well as those from the vehicle control (for both p<0.05). Based 
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on previous assessment that the dialysis membrane passes ~10% of peptides with a 
similar size to 234 (Frost et al., 2008), it is estimated that the concentration of peptide 
234 in the stalk-median eminence region was 1nM. 
 
These results show for the first time that endogenous kisspeptin via gpr-54 can directly 
influence GnRH neuron firing and can effect GnRH secretion by regulating pulse 
amplitude. These results confirm the findings of the previous studies using exogenous 
kisspeptin delivered via central and peripheral methods, which showed that kisspeptin 
could stimulate GnRH neuron firing and GnRH secretion. As the antagonist effects 
occur at doses as low as 1nM this confirms the potency of the antagonist, peptide 234 in 
vivo. 
 
3.2.5. Kisspeptin antagonist reduces LH levels in rodents and sheep 
 
Having shown peptide 234 inhibits GnRH neuron firing and release of GnRH, we 
investigated if this translated into an inhibition of LH secretion.  Two rodent models 
were utilised to investigate LH secretion into the circulation and a sheep model was used 
to investigate LH pulsatility.  Firstly, intact rats were used to investigate the effect of 
kisspeptin on LH secretion and secondly castrated rats were utilised to investigate 
negative feedback effects by Manuel Tena-Sempere and Rafael Pineda at the University 
of Cordoba, Spain.  These effects on LH secretion were also investigated in intact and 
castrated mice by Robert Steiner, Alexander Kauffmann and Michelle Gottsch at the 
University of Washington, USA. 
 
 








Figure 48. Peptide 234 antagonises kisspeptin-10 excitation of mouse GnRH neurons. 
Representative traces of GnRH neuronal firing rate over time for patch-clamped GFP-labelled 
GnRH neurons within slices of mouse brain. (A) Increased GnRH firing rate after 1nM 
kisspeptin-10 (bar). Downward spikes are individual action currents. (B) Inhibition of 
kisspeptin-10 (1nM) stimulation by peptide 234 (1nM, bar). (C) Summary bar graph showing 
mean ± SEM fold change in firing rate during baseline (white bars) and kisspeptin-10 
(black/blue bars) kisspeptin-10 significantly increased firing activity of GnRH neurons (n=7, * 
p< 0.002). Response to kisspeptin-10 was significantly reduced with the presence of 1, 10, 
100nM peptide 234 (1nM n=5, 10nM n=6, 100nM n=7, p<0.001 all groups). 





Figure 49. Peptide 234 suppresses GnRH release in vivo in female rhesus monkeys. 
Representative cases from the effects of peptide 234 on GnRH release and group mean (±SEM, 
n=6) are shown. (A) Pulsatile GnRH release in the hypothalamus was suppressed by 10nM 
peptide 234 infusion to the stalk-median eminence regions (dark shaded bar). Short arrows 
indicate GnRH peaks identified by the PULSAR algorithm (Merriam and Wachter, 1982). (B) In 
contrast, vehicle infusion as a control did not cause any significant changes in GnRH release 
(light shaded bar). (C) Data analysis indicated that peptide 234 significantly (p<0.05) suppressed 
GnRH release compared to levels prior to peptide 234 as well as to the vehicle control. (D) 
Vehicle infusion did not cause any significant changes. The estimated concentration of peptide 
234 in the stalk-median eminence region was 1nM, based on previous assessment that the 
dialysis membrane passes ~10% of peptides with a similar size. * p<0.05 vs. before peptide 234; 
a p<0.05 vs. control at corresponding time period.  
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Effects on LH secretion in the intact and castrated rat 
In rats, pharmacological tests involved repeated (x3) intracerebro-ventricular (icv) 
injections of 1nmol peptide 234 and serial blood sampling, in order to assess potential 
effects of antagonists on basal LH levels. The third injection was accompanied by co-
administration of a submaximal dose (100pmol) of kisspeptin-10 and a 1nmol dose of 
peptide 234, to monitor the ability to inhibit kisspeptin-10 stimulation of LH and 
testosterone via activation of GnRH neurons. Administration of 1nmol peptide 234 icv 
did not significantly modify basal LH levels at anytime tested after injection. Central 
injection of 100pmol kisspeptin-10 to vehicle-treated animals (at 120 minutes) evoked 
the expected rise in serum LH levels with a net LH secretory mass (Area under curve; 
AUC) of 527 ± 43. In spite of its lack of effect on basal LH levels, co-administration of 
peptide 234 blunted the LH secretory responses induced by kisspeptin-10, with a 
significant (P<0.01) reduction in the net LH secretory mass (AUC) to 328 ± 56 during 
the 120 minute period following co-injection of peptide 234 and kisspeptin-10 (Fig. 50). 
As for LH, testosterone levels at 60 minutes after combined injection of peptide 234 and 
kisspeptin-10 (1.58 ± 0.1) were significantly (P<0.01) lower than in animals injected 
with kisspeptin-10 alone (2.17 ± 0.2). 
 
LH levels were elevated in castrated rats over the 240 minute monitoring period due to 
lack of negative feedback. Administration of 1nmol peptide 234 at 0, 60 and 120 
minutes tended to reduce serum LH levels in castrated males; a reduction that reached 
statistical significance at 240 minutes (Fig. 50).  
 
Effects on LH secretion in the intact and castrated mouse 
In mice, peptide 234 showed strong antagonistic actions on LH levels. As with the 
studies in male rats, peptide 234 did not significantly alter plasma LH levels in intact 
male mice (p>0.30 versus vehicle controls; data not shown). However, two infusions of 
peptide 234 at 15nmol inhibited LH levels in castrated males compared with the elevated 
LH levels of vehicle-treated castrated males (p<0.05; Fig. 51). The low dose (15pmol) 
was ineffective. The subsequent dose-response study confirmed this finding, with all 
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three doses of peptide 234 (1nmol, 5nmol, 15nmol) reducing LH levels of castrated 
males to levels observed in intact males (p<0.01) relative to vehicle-treated castrates 
(Fig. 51). Similar to two infusions of peptide 234, a single infusion of peptide 234 
(5nmol or 15nmol) eliminated the post-castration rise in LH (p<0.05) relative to vehicle-
treated castrates (Fig. 51). The inhibition of LH levels in castrated mice after treatment 
with peptide 234 appears to be due to specific inhibition of kisspeptin signalling (rather 
than non-specific effects or effects on other neuroendocrine systems) because pre-
treatment of intact mice with peptide 234 completely blocked a kisspeptin-induced rise 
in LH (p<0.05; Fig. 51).  
 
Figure 50. Peptide 234 effects on basal and kisspeptin-10-stimulated plasma LH in intact 
and castrated male rats. Peptide 234 (A) inhibits kisspeptin-10 induced LH secretion in intact 
male rats. The animals were infused icv with 1nmol peptide 234 at 0 and 60 minutes, followed 
by infusion of 100pmol kisspeptin-10 with 1nmol peptide 234 at 120 minutes. The peptide 
significantly inhibited LH production over the following 2 hours (n=10; * = p<0.05).  (B) 
Castrated male rats were given three infusions of 1nmol peptide 234 at 0, 60 and 120 min, which 
significantly inhibited LH secretion after 240 minutes with 1nmol peptide 234 (n=10; p<0.05).  
Bars show mean ± SEM. 
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Effects on LH pulsatility in the sheep 
Since peptide 234 was able to inhibit kp-10 stimulated and castration increased LH 
secretion in rat and mouse models, the next step was to discover if this was due to a 
decrease in pulse amplitude or frequency. This work was carried out by Iain Clarke and 
Jeremy Smith at Monash University, Australia. For these studies an ovariectomised 
sheep model was used since sheep exhibit clearly detectable LH pulses. Major secretory 
episodes of LH were distinguishable in control ovariectomised ewes and in treated ewes 
prior to peptide 234 administration (Fig. 52). LH pulse amplitude was reduced after icv 
administration of peptide 234 (P<0.05); this reduction in amplitude was so marked in 
some ewes that it made pulse detection difficult and precluded determining if there was 
an additional effect on pulse frequency. Mean LH levels were similar before and during 
the infusion, but reduced following peptide 234 infusion (P<0.05). Peptide 234 had no 
effect on the concentrations of prolactin or cortisol before, during or after infusion (data 
not shown). 
 
The above results confirm that kisspeptin and gpr-54 via GnRH can regulate the 
secretion and pulsatility of LH.  The differences in the time taken for peptide 234 to take 
effect (240 and 30 minutes)  and the amount of inhibition between the rat and mouse 
studies may be attributable to the differences in doses used as only a low dose was 
utilised in the rat studies.  The studies on castration where negative feedback of LH 
secretion has been eliminated also confirm that kisspeptin is the mediator of negative 
feedback since peptide 234 can completely block the increase in LH which usually 






















Figure 51. Peptide 234 inhibition of plasma LH in male mice. (A) Two infusions of 15nmol 
of peptide 234 inhibit the elevated LH levels of castrated male mice after 30 minutes.  (B) Dose 
response graph for castrated male mice given two infusions of peptide 234 indicates that all 3 
doses tested are able to inhibit the post-castration rise in LH after 30 minutes. (C) Likewise, a 
single infusion of 5nmol or 15nmol of peptide 234 potently inhibits LH levels of castrated mice 
after 30 minutes. (D) Exogenously administered kisspeptin (100fmol) is unable to stimulate LH 
levels in intact male mice when 100pmol peptide 234 is infused 5 minutes beforehand (n=6-8). 
Bars show mean ± SEM. 
 




Figure 52. Central infusion of peptide 234 inhibits the secretory pulses of LH in OVX ewes. 
Concentrations of LH are shown in ewes treated with peptide 234 (closed bars) or control aCSF 
(artificial cerebrospinal fluid; opened bars). Arrows indicate LH pulses as defined in the 
supporting materials and methods. Analysis revealed a significant reduction in the mean LH 
concentration and pulse amplitude after peptide 234 infusion.  
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3.2.6. Kisspeptin antagonist blocks puberty and the LH surge in rodents 
 
As peptide 234 had been shown to act as a potent antagonist at gpr-54, the effects of this 
antagonist on puberty onset and the pre-ovulatory surge in rats were investigated, to 
confirm a direct role for kisspeptin in physiological processes. This work was performed 
by M Tena-Sempere, R Pineda, D Garcia-Galiano, M Romero, MA Sanchez-Garrido, F 
Ruiz-Pino and L Pinilla at the University of Cordoba, Spain. 
 
In order to directly assess the functional relevance of kisspeptin signalling in the central 
networks controlling puberty onset, a protocol of icv infusion of the antagonist, peptide 
234, was applied in peri-pubertal female rats, using established methodology (Roa et al., 
2008d). Thus, osmotic mini-pumps were implanted intradermally and connected to an 
icv cannulae into the brain to deliver a constant rate of 10nmol/24h peptide 234 during 7 
days, from P30 to P36. Phenotypic and hormonal analyses were applied to monitor the 
progression of puberty. Infusion of peptide 234 failed to induce any noticeable changes 
in body weight gain throughout the period of study (Fig. 53). In contrast, icv 
administration of peptide 234 to peri-pubertal female rats evoked a marked delay in the 
timing of puberty, measured by vaginal opening. On day 36, 80% of animals infused 
with vehicle displayed complete canalization of vagina, whereas only 13% of the 
females treated with peptide 234 showed complete vaginal opening (Fig. 53). In good 
agreement, central infusion of peptide 234 had caused a significant reduction of ovarian 
and uterus weights by the end of treatment (Fig. 53). However, no significant differences 
in mean LH and FSH levels were detected in the circulation between controls and 
antagonist-treated animals on the morning of the last day (P36) of infusion (Fig. 53). 
 
A similar protocol of central infusion of peptide 234 was applied to adult, cycling female 
rats in order to further define the importance of kisspeptin signalling in the generation of 
the pre-ovulatory surge of gonadotropins. Regularly cycling female rats, showing at least 
three consecutive 4-day ovarian cycles, were implanted in the morning of estrus with 
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osmotic mini-pumps to allow icv delivery of peptide 234, at a constant rate of 
10nmol/24h. The infusion was continued until the afternoon of the following proestrus, 
when the animals were subjected to serial blood sampling throughout the 
afternoon/evening of proestrus and the morning of estrus, as described in previous 
experiments (Roa et al., 2008b; Roa et al., 2008c). In cyclic females infused with 
vehicle, 10 out of 11 animals displayed the expected pre-ovulatory surge of LH along the 
afternoon of proestrus, with a progressive rise of its serum concentrations between 16:00 
and 20:00, followed by a drop in LH levels at the morning of estrus (Fig. 54). In striking 
contrast, 7 out of 9 females icv infused with peptide 234 failed to display the typical 
peak of LH levels at proestrus (Fig. 54).   The average of the results from all animals, 
excluding any outliers, show a complete blockade of the pre-ovulatory LH surge in 
peptide 234 infused cyclic rats compared to controls (Fig. 54). LH secretion (AUC) 
along the afternoon/evening (14:00 to 20:00) of proestrus shows a five-fold decrease in 
the net secretory mass of LH during the pre-ovualtory period in animals infused with 
peptide 234 (Fig. 54).   
 
FSH level (AUC) along the pre-ovulatory surge was also monitored. Animals infused 
with vehicle displayed a detectable increase in serum FSH levels between 16:00 and 
20:00 of proestrus (primary surge), which was followed by persistently elevated FSH 
concentrations at the morning of estrus (secondary surge). Infusion of peptide 234 
abrogated in primary FSH surge and blocked the secondary rise in FSH on the morning 
of estrus (Fig. 55). 
 
These results give direct evidence for regulation of puberty onset and the LH surge by 
the kisspeptin system in rats.  These confirm that kisspeptin and gpr-54 can regulate the 
timing of puberty as peptide 234 can delay vaginal opening in these animals.  Peptide 
234 also inhibited the LH and FSH pre-ovulatory surge in the majority of animals tested, 
placing kisspeptin as the main signal that regulates this process in this species.  Further 
tests are now needed to confirm these effects in other species such as primates. 





Figure 53. Effects of continuous infusion of kisspeptin antagonist on puberty onset in 
female rats. The impact of chronic icv. infusion of the antagonist of kisspeptin, peptide 234, to 
pubertal female rats (d-30 to d-36) on different indices of puberty onset is documented. Body 
weights (BW; A), vaginal opening (V.O., B), uterus and ovarian weights (C), and terminal serum 
LH and FSH levels (D) are presented for animals infused with vehicle or the antagonist. * 
P<0.05; ** P<0.01 vs. control (vehicle) group (Student t- test). 




          Time of Day     
Figure 54. Effects of continuous infusion of kisspeptin antagonist on pre-ovulatory surge of 
LH. Individual hormonal profiles of LH secretion along the proestrus-to-estrus transition are 
presented from representative female rats centrally-infused with either vehicle (A,C,E) or peptide 
234 (B,D,F,H). In addition, mean serum LH levels in both groups (G), as well as integrated LH 
secretion between 14:00 and 20:00 of proestrus (AUC; bar graph in I), are also shown. 9-E = 
estrus at 9am next day. For further details, see text. ** P<0.01 vs. corresponding control group. 




          Time of Day 
Figure 55. Effects of continuous infusion of kisspeptin antagonist on pre-ovulatory surge of 
FSH.  Mean serum FSH levels along the proestrus-to-estrus transition female rats centrally-
infused with either vehicle or peptide 234. In addition, integrated FSH secretion between 14:00 
and 20:00 of proestrus (AUC) is also shown as bar graph. 9-E = estrus at 9am next day. For 
further details, see text. ** P<0.01 vs. corresponding control group 
 
3.2.7. Penetratin-tagging of peptide 234 
 
All of the above results were obtained via icv injection with peptide 234.  To potentially 
enhance systemic activity, peptide 234 was modified by the addition of a penetratin tag 
in order to increase its permeability at the blood-brain barrier and this was named 
peptide 271.  Penetratin is a 16 amino acid cationic cell-penetrating peptide with the 
sequence RQIKIWFQNRRMKWKK-NH2.  This was derived from the homeodomain of 
Antennapedia protein, a drosophila transcription factor, known to be internalised and 
cross the cell membrane and blood-brain barrier (Derossi et al., 1998). It has since been 
shown that only the final seven C-terminal amino acids (RRMKWKK-NH2) are needed 
for this peptide to be able cross the cell membrane and blood-brain barrier (Fischer et al., 
2000). For these reasons, it was these seven amino acids, RRMKWKK, that were joined 
to peptide 234 via a Tyr residue to create peptide 271. 
 
Peptide 271 was first tested in vitro to examine if adding the tag had affected the 
peptides ability to bind and antagonise the receptor. Peptide 271 was found to bind to 
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gpr-54 with an IC50 of 1.56x10
-8M, which is similar to peptide 234.  As for activation of 
the receptor, peptide 271 did not induce IP production as expected for an antagonist.  
Finally, peptide 271 could antagonise the receptor in vitro by 62% (Fig. 56 and Table 6).  




Figure 56. Penetratin tagging does not affect binding or antagonistic properties of peptide 
234. (A) Peptide 271 can still bind with an IC50 of 15nM.  (B) Peptide 271 has no intrinsic IP 
stimulation but can antagonise Kp-10 stimulated IP production by 62% with an IC50 of 1μM. 
 
 
To test if peptide 271 could inhibit LH and FSH secretion when given systemically (ip) 
in vivo, a rat model was utilised by M Tena-Sempere, R Pineda, D Garcia-Galiano, M 
Romero, MA Sanchez-Garrido, F Ruiz-Pino and L Pinilla at the University of Cordoba, 
Spain.  Using a similar method to that describe previously, peptide 271 (5nmol) or 
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vehicle were injected three times via ip injection to male rats.  The third injection was 
accompanied by a sub-maximal injection of kisspeptin (100pmol) given icv to evoke a 
rise in LH or FSH.  In animals given vehicle, kisspeptin was able to evoke a robust rise 
in LH from 120-180 minutes.  FSH increased steadily over the three hour period with 
maximal stimulation at 240 minutes.  In contrast, the animals given peptide 271 via 
intraperitoneal (ip) injection exhibited a reduced LH rise by around 60% and a 
significant decrease in the amount of FSH secretion over 2 hours (Fig. 57). 
 
 
              Time (min) 
 
Figure 57. Effects of systemic kisspeptin antagonist on gonadotropin responses to icv Kp-
10.  LH and FSH secretory profiles are shown from adult male rats receiving three consecutive ip 
injections (5 nmol/each) of the antagonist of kisspeptin, peptide 271 (denoted by arrows); the last 
injection was associated with an icv bolus of Kp-10 (100 pmol). Integrated secretory responses 
following Kp-10 administration, calculated as area under the curve (AUC), are also depicted as 
bar graphs. ** P<0.01 vs. corresponding control group 





This research has been successful in identifying residues in kisspeptin critical to receptor 
binding and activation.  It is clear that to bind to the receptor the pharmacophore 
involving Phe6, Arg9 and Phe10 is crucially important; however Asn2 and Trp3 also 
appear to be needed.  To activate gpr-54 the residues Tyr1 and Leu8 play a critical role, 
probably via stabilisation of the active conformation of the peptide and receptor.  This 
suggests that residues in kp-10 required for receptor binding and for receptor activation 
overlap. Also, the conformation of the peptide is probably fundamental to peptide 
function as steric hindrance within the C-terminus disrupts receptor binding and 
activation.  
 
The pleiotropic effects of kisspeptin make the gpr-54 receptor an attractive therapeutic 
target.  Until now the emphasis has been on developing kisspeptin agonists as anti-
metastatic agents (Clements et al., 2001; Orsini et al., 2007; Tomita et al., 2006).  
However, the development of kisspeptin antagonists would allow detailed analyses of 
the role of kisspeptin in the HPG axis and peripheral tissues.  The ability to inhibit the 
actions of this system would facilitate examination of processes involved in regulation 
of puberty and the role of feedback mechanisms both in vitro and in vivo.  Kisspeptin 
antagonists may also have useful therapeutic roles in pathophysiological conditions such 
as PCOS (where LH is over-expressed (Armeanu et al., 1992; Blank et al., 2006)), in 
precocious puberty to delay onset of sexual maturation (Navarro et al., 2004b), as 
putative novel contraceptive agents and for treating hormone-dependant diseases such as 
endometriosis and prostatic cancer.   
 
To address the development of kisspeptin antagonists, a structure-activity study was 
undertaken of kisspeptin-10 analogues created by intuitive substitution of amino acid 
residues and by truncation of the peptide length.  As the RFamide motif is highly 
conserved among species and members of the RFamide family, it was hypothesised that 
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this may be critical to receptor binding and activation.  Therefore, the arginine and 
phenylalanine residues of the motif were substituted with D-Arg and Trp in both 
truncated and full-length analogues. Both peptides were unable to bind to or activate the 
receptor, confirming that this moiety is critical for peptide function.  It has also been 
hypothesised that kp-10 is the smallest fragment able to bind and activate the receptor. 
To address this hypothesis, the receptor was truncated to five and seven amino acid 
fragments; both of which had severely reduced receptor binding, however the five amino 
acid fragments could still activate the receptor. Within the five residue fragments, if 
Leu8 was inactivated by substitution with alanine or large amino acids, the peptide could 
no longer activate the receptor, suggesting Leu8 of kp-10 may configure the receptor 
activation conformation. Furthermore, if Phe6 was substituted then binding was ablated, 
suggesting a role for this residue in receptor binding. It has been suggested that the 
binding domain is in the C-terminus of kp-10 and the activation domain in the N-
terminus (Ohtaki et al., 2001); however results within truncated peptides suggest that 
these functional domains overlap, with binding (Phe6, Arg9 and Phe10) and activating 
residues (Leu8) located throughout the length of the 10 amino acid sequence.   
 
Results obtained with truncated peptides were confirmed with full-length 10 residue 
analogues, where substitution of Phe6 with large D-amino acids dramatically reduced the 
peptides ability to bind to the receptor.  This suggests that Phe6 along with the amino 
acids of the RFamide moiety are critical for binding to the receptor, these observations 
have now been published by Orsini et al. who showed that these three residues (Phe6, 
Arg9 and Phe10) form a binding pharmacophore that interacts with the receptor upon 
binding (Orsini et al., 2007).  This research also showed that alanine substitution of Asn2 
and Trp3 ablates receptor binding.  This implicates Asn2 and Trp3 as additional residues 
that interact with the receptor upon binding.  This is probably via formation of hydrogen 
bonds as asparagine and tryptophan are known to be capable of hydrogen bonding in 
other ligand-receptor scenarios (e.g. Trp3 in GnRH with Asn98 of the receptor (Zhou et 
al., 1995)).   
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The role of Leu8 in activating the receptor was also confirmed in studies with full-length 
kisspeptin-10 analogues, where substitution with either D-Leu or D-Trp inhibited 
receptor activation measured by production of inositol phosphate (IP) and intracellular 
calcium.  These substitutions at position 8 also caused antagonism of the receptor, with 
D-Trp8 being the most effective, suggesting that this residue is important for receptor 
activation.  Tyr1 was also shown to be involved in receptor activation in conjunction 
with Leu8, as substitution of this residue with D-Trp or D-Ala increased the degree of 
antagonism.  The need for flexibility around position 5 is suggested by amino acid 
residue changes made to Ser5.  When this side chain is altered by alanine substitution or 
introduction of a tight turn by substitution with proline occurs, the degree of antagonism 
is decreased.  However, when Gly5 or D-Ser5 is introduced, there is greater flexibility of 
the centre of the peptide and this enhances antagonism, with Gly5 being the more 
effective substitution.  The need for Gly5 and D-Trp8 within the more potent antagonists 
was shown to be crucially important as substitution of either residue decreases the 
amount of antagonism at the receptor. 
 
From the above research, a consensus sequence for the design of kisspeptin-10 
antagonists was arrived at:  X1-N-W-N-X5-F-G-X8-R-F-NH2 where X
1 = D-Tyr or D-
Ala, X5 = Gly or D-Ser and X8 = D-Trp or D-Leu.  The most potent amino acid changes 
for antagonism are present in peptide 234 where X1 = D-Ala, X5 = Gly and X8 = D-Trp, 
however three other antagonists were also developed in peptides 230, 273 and 276.  
 
Peptide 234 was then selected for ex vivo and in vivo studies.  Since the role of 
kisspeptin within the HPG axis is thought to be the stimulation of GnRH release from 
the hypothalamus (Gottsch et al., 2006; Irwig et al., 2004) the ability of peptide 234 to 
inhibit kisspeptin-10 stimulation of firing in GnRH neurons was recorded in acutely 
prepared brain slices from the mouse.  Peptide 234 was found to block kisspeptin-10 
stimulation of GnRH neuron firing at 100nM, 10nM and 1nM.  The low doses need to 
inhibit the firing of this neuron suggested that peptide 234 would also act as a potent 
antagonist in vivo.  
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The inhibitory effect of peptide 234 on the firing of GnRH neurons suggested that this 
peptide would also be able to inhibit the pulsatile GnRH secretion from the median 
eminence. It was therefore examined whether peptide 234 administered directly to the 
stalk-median eminence region of pubertal female rhesus monkeys would suppress the 
amplitude or frequency of GnRH pulsatility. The suppression of GnRH pulse amplitude 
seen during peptide 234 infusion provides the first direct evidence that signalling from 
kisspeptin neurons in the hypothalamus is required for GnRH pulsatile secretion.  This 
had previously been suggested through observations that kisspeptin-54 pulses coincide 
with GnRH pulses 75% of the time (Keen et al., 2008). However, as patients with 
mutations in gpr-54 have been shown to retain some GnRH pulsatility (indirectly 
through recording LH pulses) within the hypothalamus with normal frequency (de Roux 
et al., 2003; Seminara et al., 2003; Tenenbaum-Rakover et al., 2006), it has been 
questioned whether inputs from the kisspeptin neuron are responsible for the 
development of GnRH pulsatility or if kisspeptin neurons regulate GnRH pulse 
amplitude.   The dampening of spontaneous GnRH pulses in the monkey model suggests 
that kisspeptin is required for the amplitude of GnRH pulsatile secretion.  However, it 
remains unclear whether frequency is also affected.  Work with peptide 234 within 
Kevin O’Byrne’s laboratory at Kings College London, has suggested the antagonist can 
delay pulse frequency, however, further work is still to be completed to confirm these 
findings. 
 
Peptide 234 also blocked kisspeptin-10 stimulation of LH secretion in adult male rats 
and mice presumably by blocking kisspeptin-10 effects on GnRH secretion.  In rats the 
inhibition was incomplete at 1nmol peptide 234 suggesting that the dose may be sub-
optimal in relation to the size of the rats used.  Interestingly, the same dose completely 
inhibited the kisspeptin-10 stimulation of LH secretion in mice as did 5nmol and 
15nmol. Ovariectomised sheep were then used to examine if the inhibitory effect was 
due to a reduction in LH pulse amplitude as with GnRH. In these animals, LH pulse 
amplitude was markedly reduced by administration of peptide 234. This is consistent 
with the finding that peptide 234 inhibited GnRH neuron firing rate in mice and reduced 
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GnRH pulse amplitude in rhesus monkeys.  These effects of peptide 234 appear to be 
specific to the regulation of gonadotropins since the antagonist had no effect on either 
prolactin or cortisol secretion in ovariectomised ewes.  
 
One unexpected result from this research was the lack of effect that peptide 234 had on 
basal levels of GnRH and LH. This suggests that kisspeptin is responsible for the 
pulsatile secretion of GnRH but other factors underlie the basal secretion. This 
hypothesis is supported by the fact that peptide 234 did not lower the basal firing rate of 
the mouse GnRH neurons and had no effect on basal GnRH secretion in the female 
rhesus monkey.  This was also the case in studies on LH secretion, where peptide 234 
failed to inhibit LH secretion below intact basal levels in rodents and ewes.  Further 
confirmation is still needed to establish that kisspeptin is not responsible for the basal 
secretion of LH in females as well as males.  This would be an important discovery as 
the ability to inhibit the ovulatory LH surge but not basal LH in females might provide a 
novel contraceptive that does not ablate endogenous estrogen yet blocks ovulation.  
(Lapatto et al., 2007).  To investigate this further, peptide 234 was administered to cyclic 
female rats on the morning of estrus and was shown to completely ablate the expected 
pre-ovulatory LH and FSH surges compared to controls.  However, the basal levels of 
LH and FSH were not affected, suggesting that kisspeptin does not regulate basal 
secretion of GnRH in female rodents as well as males.  These observations directly 
implicate kisspeptin in the production of the LH surge and mediation of positive 
feedback mechanism, and provide further evidence for the use of peptide 234 as a novel 
contraceptive, which can ablate the LH surge but will not affect basal levels of 
gonadotropins and steroids. 
 
In male mice peptide 234 blocked the increase in LH that ensues following castration.  A 
similar result was observed in castrated rats but the inhibition was less pronounced and 
delayed probably due to the lower dosage per g/bodyweight employed and the 
consequent requirement for an accumulation of peptide 234 in the brain over the 3 
injections.  These findings suggest that KiSS-1 neurons are a target for steroid hormone 
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action and involved in the negative steroid feedback mechanism within the 
hypothalamus, relaying effects to GnRH neurons. This had previously been suggested in 
view of increased KiSS-1 gene expression in the arcuate nucleus in gonadectomised 
male and female rats (Gottsch et al., 2006; Irwig et al., 2004) which was hypothesised to 
be due to a negative feedback mechanism (Smith et al., 2005b). However, changes in 
mRNA do not always reflect functional changes in the biosynthesis and secretion of 
kisspeptin within the arcuate nucleus. The studies with the novel kisspeptin antagonist 
provide direct evidence for kisspeptin modulation of the GnRH neuron in negative 
feedback and emphasize the value of kisspeptin antagonists for elucidating physiological 
mechanisms.   
 
The inhibition of GnRH and LH pulses in pubertal female rhesus monkeys and OVX 
ewes by peptide 234 suggests a role for kisspeptin in the initiation of puberty.  The 
demonstration that kisspeptin-10 administration advanced the age of vaginal opening in 
female rats has previously implicated kisspeptin in the onset of puberty (Navarro et al., 
2004b). Further studies with peptide 234 in peri-pubertal female rats over 7 days were 
conducted to confirm a role for kisspeptin in puberty onset.  Administration of peptide 
234 to these rats delayed vaginal opening and reduced ovarian and uterine weights, 
directly implicating kisspeptin in puberty onset. 
 
However, as peptide 234 had to be delivered icv in all of the above experiments, this 
would not be suitable for taking forward into human trials on precocious puberty until 
systemic efficiency can be demonstrated.  Therefore, a penetratin tag was added to 
peptide 234 to increase permeability at the blood-brain barrier and potentially extend its 
half-life.  This modified peptide inhibited LH and FSH secretion in the rat when 5nmol 
were delivered by ip injection, a method that would be better translated into clinical 
studies. 
  
As well as the development of gpr-54 antagonists, the other aim of the structure-activity 
studies was to identify residues within kp-10 important for binding to gpr-54 or for 
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receptor activation.   This would then facilitate interpretation of the secondary structure 
of kp-10 and give an insight into the types of bonds formed within the binding 
interactions.  This information would facilitate the receptor binding pocket being 
modeled.  From the structure activity study of kp-10 within this chapter, it was shown 
that Phe6, Arg9 and Phe10 were critical for kp-10 to bind to gpr-54 and this has 
subsequently been confirmed by another group within the field (Orsini et al., 2007).  
These residues can therefore be investigated using the NMR structures for kp-10 (Lee et 
al., 2009; Orsini et al., 2007).  The first NMR model was a helical structure and within 
this model the phenyl rings of Phe6 and Phe10 are stacked on top of each other with the 
positive charge of Arg9 in the middle.  The second model suggests a tight turn structure 
for kp-10, but again the positioning of these three residues supports a similar 
pharmacophore with the two stacked rings flanking the positively charge arginine.  Both 
models therefore suggest that two types of bonds may be formed between the ligand and 
receptor, firstly, ionic bonds may be formed between the positive charge of Arg9 and 
negatively charged amino acids within the receptor binding pocket and secondly, 
stacking interactions may occur between the two phenyl rings of Phe6 and Phe10 and any 
aromatic residues within the receptor binding pocket.  However, the ionic bonds may be 
more important than the stacking interactions as this bond is stronger than the van der 
waals forces involved in the stacking interactions.  This possibility is consistent with the 
structure-activity data, where moving the positioning of the side chains of Phe6, 10 ablates 
the binding to the receptor signifying that the side chain position is critical, whereas 
moving the side chain of Arg9 only slightly reduces the binding suggesting that the 
charge is the important factor. 
 
Now that the binding pharmacophore for kp-10 is known, this can be used along with 
further structure-activity studies to examine the binding pocket within gpr-54.  This 
binding pocket is likely to be in the following area: juxtamembrane, within a structure 
formed by the extracellular loops and cell surface regions of the transmembrane 
domains.  The position of the pocket can be addressed using two methods, mutation of 
specific amino acids within gpr-54 or by constructing a homology model based on the 
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tertiary structure of other GPCRs.  Receptor mutations are useful to provide information 
on the specific residues involved in the binding of kp-10 and the types of inter-molecular 
bonds involved.  However, this is a time consuming process and would benefit from a 
homology model of gpr-54.  A homology model of the receptor could be based on the 
primary sequence of gpr-54 and a template of the likely tertiary structure taken from a 
related protein, such as the β2 –adrenergic receptor (a class A GPCR).  The results are 
more accurate if the sequence alignment between the two receptors is > 50%, with the 
most sequence divergence within the loop regions.  For less conserved areas, constraints 
can be applied such as internal co-ordinates and dihedral angles.  The model may then 
be used to virtually dock the ligand to access the most likely location of the binding 
pocket. 
 
A ligand docking homology model has been prepared for gpr-54 by Zhi-liang Lu (MRC 
HRSU, Edinburgh) but is still in its infancy (Fig. 58).  However from the model it is 
possible to see that the predicted binding pocket lies within the hypothesized site 
interacting with the extracellular loops (ECL) and the cell surface regions of the 
transmembrane (TM) domains.  Specific binding residues within the receptor are still to 
be deciphered but the regions for these interactions can be predicted.  The kp-10 binding 
pharmacophore seems to interact at two sites, firstly Phe6, 10 are situated close to the cell 
surface region of TM6/7 and Arg9 is in the vicinity of TM2/3.  These are the only 
residues of kp-10 which project into the TM domains, which may provide a protective 
environment for binding to occur and suggests that the main gpr-54 binding pocket is 
close to the core of the peptide. Other residues were also shown to be involved in 
binding within this chapter, mainly Asn2 and Trp3.  These both lie close to the ECLs of 
gpr54, specifically ECL1, although Trp3 may also interact with the N-terminal region.  
The two residues not examined in this thesis, Asn4 and Gly7 are also situated close to the 
ECL regions with Asn4 near to ECL2 and Gly7 in the vicinity of ECL3.  This suggests 
that some residues may be involved in positioning of the peptide to allow the binding 
pharmacophore to interact with the TM domains.  However, as modeling is a complex 
process the exact interactions are still to be examined. 






Figure 58. Homology model of gpr-54 showing the docking of kp-10.  Homology 
model showing the predicted structure for gpr-54 (white).  Within this model kp-10 
(orange) has been virtually docked to gpr-54 to assess the possible binding interaction.  
This model was designed by Dr Z Lu at the MRC HRSU in Edinburgh. 
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In conclusion, this part of my research has been successful in elucidating the residues in 
kisspeptin-10 important for receptor binding and activation, with the creation of four 
potent antagonists.  One of these antagonists has been characterised extensively in vivo 
and has been shown to inhibit both GnRH neuron firing and pulstatile secretion with 
subsequent inhibition of LH pulse amplitude, supporting a role for kisspeptin in 
modulation of the HPG axis.  This antagonist has also provided direct evidence of a role 
for kisspeptin in modulating both negative and positive steroid feedback from the 
gonads in males, the production of the LH surge in females and regulation of the onset 








Intracellular signalling pathways activated 
by kisspeptin-10 and gpr-54 





Kisspeptin and gpr-54 have been placed at the centre of the reproductive axis since 
it was discovered that kisspeptin neurons can directly innervate GnRH neurons, on 
which the gpr-54 receptor has been located.  Kisspeptin neurons have since been 
implicated in relaying multiple environmental, metabolic and steroidal cues to 
GnRH neurons to control GnRH secretion and hence reproductive tissue function. 
Kisspeptin has also been implicated as a key regulator within the placenta to 
control the invasion of trophoblast cells into the maternal uterine deciduum.  The 
major focus to date has been to delineate physiological actions of the kisspeptin 
system using in vivo models, with less attention focussed on the molecular 
mechanisms effecting these kisspeptin/gpr-54 actions.  Therefore, in the following 
chapter, the molecular signalling pathways utilised by kp-10 upon activation of 
gpr-54 have been studied, firstly in a transfected CHO cell line.  Gpr-54-activated 
signalling pathways found in this cell line were then tested in mouse embryonic 
GnRH neuronal cells (GT1-7), human breast cancer cells (MCF-7) and a human 
first trimester extravillious trophoblast cell line (HTR8SVneo).  In CHO cells, 
kisspeptin stimulated phosphorylation of members of the MAPK pathway 
occurred, with a robust activation of ERK1/2 via an EGFR transactivation 
pathway.  ERK1/2 phosphorylation was also evident in the neuronal, cancer and 
trophoblast cell lines. Also within three cell types (CHO/gpr-54, GT1-7 and 
HTR8SVneo), phosphorylation of NFκB occurred via PKC.  In the CHO and 
trophoblast cell line, the most robust signal was the inhibition of GSK3β by 
phosphorylation, causing release of β-catenin into the cytoplasm.  In both cell types, 
GSK3β inactivation occurred by Ser9 phosphorylation, mediated by the ERK1/2 
target, p90rsk, PKC and the PI(3)K/Akt pathways.  GSK3β inhibition and release 
of β-catenin was further amplified by a feedback loop involving FAK 
phosphorylation at Tyr925. This facilitates binding of the Grb-SOS complex to then 
activate RAS, further phosphorylating ERK1/2 and p90rsk.  Elevated levels of 
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cytoplasmic β-catenin may interact with cadherins to inhibit cell movement, 
suggesting a possible mechanism for kp-10-mediated inhibition of trophoblast 
migration.  In summary, the signalling pathways within trophoblast cells and 
GnRH neurons have been investigated and show cell-specific activation of 




Kisspeptin/gpr-54 signalling has emerged as a linchpin in the neuroendocrine regulation 
of reproduction (Popa et al., 2008), since it was discovered that kisspeptin-producing 
neurons directly innervate GnRH neurons and that kisspeptins are potent secretagogues 
for GnRH and LH (Gottsch et al., 2004; Irwig et al., 2004; Popa et al., 2008). Moreover, 
kisspeptin neurons have been implicated as conduits that relay humoral and 
environmental signals to GnRH neurons (Castellano et al., 2005; Estrada et al., 2006; 
Greives et al., 2006; Revel et al., 2006; Smith et al., 2005b). Kisspeptins were  originally 
identified as inhibitors of metastasis and trophoblast invasion (Bilban et al., 2004; 
Kotani et al., 2001). However, the intracellular signalling events by which kisspeptin 
modulates cell migration are poorly understood. 
 
In the GnRH neuron, calcium influx through sodium-dependant cationic channels in the 
plasma membrane and from intracellular stores is needed to stimulate secretion of GnRH 
in response to kisspeptin (Liu et al., 2008; Zhang et al., 2008). Kisspeptin-10 also 
inhibits trophoblast cell migration and NFκB signalling has been implicated in this 
process via regulation of matrix metalloproteinase-9 (MMP-9) gene expression (Yan et 
al., 2001). Finally some mechanisms for kisspeptins effects on metastasis have been 
identified such as desensitization of CXCR4 responses to SP-1 to decrease calcium 
release and Akt/PKB phosphorylation, in turn blocking chemotaxis (Navenot et al., 
2005).  In epithelial-like CHO cells it has also been shown that the receptor couples to 
the Gq/11 class of G-proteins to classically activate phospholipase C which hydrolyses 
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phosphatidyl bisphosphate (PIP2) in the cell membrane to diacyl glycerol (DAG) and 
inositol triphosphate (IP3), which activate PKC and modulate intracellular calcium, 
respectively.  This leads to phosphorylation of ERK1/2 and p38MAPK, cellular 
reorganisation of stress fibres and focal adhesion complexes. Effects on the cytoskeleton 
and cell adhesion molecules are thought to be important for kisspeptin inhibition of 
cancer cell metastasis and trophoblast invasion (Hori et al., 2001; Kotani et al., 2001). 
However, a detailed signalling study of the mechanisms downstream of gpr-54 
activation especially those relating to cell migration are yet to be undertaken. 
 
In order to examine the signalling pathways induced by kp-10, a variety of cell types 
were utilised to examine the likely existence of differential signalling between tissues 
such as neurons and the placenta and between cell types such as epithelial versus 
neuronal cells.  In this study, these differences were examined using an epithelial CHO 
cell model, malignant epithelial MCF-7 breast cancer cells, epithelial Ishikawa uterine 
cancer cells, GnRH neuronal cells (GT1-7), B35 neuroblastoma cells, GH3 
neuroendocrine somatolactotroph cells, choriocarcinoma trophoblast cells, and 
HTR8SVneo immortalised trophoblast cells (Table 9). Some of these cells were 
transfected with gpr-54 expression construct in order to highlight any differences 





Table 9. Cell types utilised to analyse kp-10 mediated signalling.  Table showing origin and 
phenotype for each cell line and if the receptor is transfected or endogenous to the cells.   
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This approach should also allow examination of cell type specific signalling, which may 
account for the wide variety of processes mediated by kisspeptin, for example, GnRH 
secretion may involve a different signalling network to kisspeptin-mediated inhibition of 
cell migration. These pathways may be completely distinct from one another or may 
involve common components to regulate gene expression, remodel the cytoskeleton, or 
regulate the secretion of hormones in different tissues (Fig. 59).  Overall, cell type 
specific signalling is important to allow a single ligand to have a variety of actions 







Figure 59. Possible cellular processes mediated by gpr-54 signalling.  Diagram showing 
possible processes within the cell that could be mediated by kp-10 in different cells types (shown 
in brackets).  These effects may be distinct such as hormone secretion or may influence each 
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This chapter reports on the elucidation of intracellular signalling pathways activated by 
kisspeptin-10 at gpr-54 potentially involved in the inhibition of cell migration and 
GnRH secretion.  The results show that kisspeptin-10 can activate the NF-kappa B, focal 
adhesion kinase (FAK), GSK3β and mitogen-activated protein kinase (MAPK) 
signalling pathways and inhibitors have been used to further elucidate these signalling 




4.2.1. Kisspeptin-10 signals via MAPK, NFκB and focal adhesion pathways 
in CHO cells stably expressing the human gpr-54 
 
As kp-10 is known to be the minimal peptide sequence needed for activation of gpr-54, 
the model cell line, CHO/gpr-54, was tested for receptor binding and activation.  Kp-10 
bound to the human gpr-54 displaced 125I-kisspeptin-10 with an IC50 of 7.7x10
-9M.  This 
confirmed that the cell line expressed the receptor at the cell surface.  Kisspeptin has 
previously been shown to activate Gq/11 and stimulate IP3 production and calcium 
mobilisation through gpr-54  (Hori et al., 2001; Kotani et al., 2001).  Therefore inositol 
phosphate and intracellular calcium activation were examined.  In CHO/gpr-54, kp-10 
robustly stimulated both IP production and calcium mobilization with EC50s of 3.8x10
-
9M and 6x10-8M, respectively (Fig. 60).  Kp-10 could also activate an SRE-luciferase 
reporter gene in another stable cell line, the mouse pituitary cell line LβT2 stably 
expressing the mouse gpr-54.  This confirms that gpr-54 and kp-10 activated the Gq/11 
class of g-proteins.  Untransfected CHO cells gave no IP response when stimulated with 












Figure 60. Kisspeptin binds and activates CHO cells stably expressing human gpr-54. (A) 
Kisspeptin can bind gpr-54 with an affinity of 7.8nM in these cells (n=10). (B, C)  Kisspeptin 
can activate IP (n=12) and intracellular calcium release (n=5) with an EC50 of 3.9nM and 66nM, 
respectively. (D) In LβT2/gpr-54 cells, kp-10 can also increase a SRE-luc reporter gene (n=3). 
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As phosphorylation of ERK1/2 had already been demonstrated (Hori et al., 2001; Kotani 
et al., 2001), studies firstly concentrated on the MAPK signalling pathway.  Kp-10 
stimulated ERK1/2 phosphorylation in a dose and time dependant manner.  ERK1/2 
phosphorylation increased significantly with dose and 10 and 100nM gave a maximal 
stimulation after 10 minutes (Fig 61). Thereafter, 10nM kp-10 was used as the standard 
dose for further studies. 10nM kp-10 also stimulated a significant phosphorylation of c-
Jun NH2-terminal protein kinase 1 (JNK1) and p38MAPK with a maximal response for 
both at 10 minutes (Fig. 62). As ERK1/2 gave a robust phosphorylation inhibitors were 
used to determine the intracellular pathway responsible for this phosphorylation.  A Gq/11 
inhibitor and a MEK inhibitor, completely blocked kp-10 stimulation of ERK1/2 
phosphorylation as did inhibitors of Src, PI(3)K, Akt,  p90rsk and GSK3β (Fig. 61).  
This suggested that Kp-10 activated the classical RAS-Raf-1-MEK-ERK1/2 pathway 
possibly via EGFR receptor transactivation. 
 
Next, it was investigated if kp-10 activates proteins associated with cell migration.  This 
involved the investigation of two pathways, focal adhesion complex associated 
signalling, as modulation of focal adhesion complexes has previously been reported 
(Kotani et al., 2001) and the NFκB pathway, also previously implicated in the context of 
modification of the extracellular matrix (Yan et al., 2001).  However, the details of the 
signalling mechanisms involved have so far not been elucidated.  10nM kp-10 
significantly stimulated phosphorylation of focal adhesion kinase (FAK) at 10-30 
minutes (Fig.63).  This phosphorylation was significantly repressed by inhibitors of 
Gq/11, Src, PI(3)K, MEK, p90rsk, GSK3β and Akt/PKB (Fig. 63).  This suggests FAK is 
phosphorylated via an ERK1/2-p90rsk/Akt-GSK3β pathway.  NFκB was also 
significantly phosphorylated upon stimulation with 10nM kp-10 with a maximal 
stimulation at 30 minutes.  This activation was suppressed by inhibitors of Gq/11 and 
PKC (Fig. 64).  The inhibitor of NFκB (IκBα) was also examined and was 
dephosphorylated at Ser32 throughout the 60 minute stimulation by 10nM kp-10 (Fig. 
64).  This seems unusual as phosphorylation of IκBα at Ser32 is required to enable 
release of NFκB into the nucleus. Dephosphorylation at this residue should restrict 
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NFκB release.  However, as the IκBα signal is weak the results are difficult to interpret; 
therefore immunoprecipitation experiments may need to be performed to confirm these 
results. 
 
4.2.2. Kisspeptin-10 modulates GSK3β and β-catenin pathways in CHO 
cells stably expressing human gpr-54 
 
Next it was decided to investigate if other pathways normally associated with migration 
were activated in these cells.  One such pathway is the adherens junction pathway, 
where β-catenin can associate with cadherins to form adherens junctions, thus inhibiting 
cell movement.  The main signalling pathway associated with β-catenin involves Src and 
PI(3)K activation of Akt which can inhibit glycogen synthase kinase 3β (GSK3β) by 
phosphorylating Ser9, allowing β-catenin to be released from a complex with GSK3β 
(Dominguez and Green, 2001). Akt then phosphorylates β-catenin to cause its 
translocation to the nucleus (Fang et al., 2007). However, a second mechanism for β-
catenin release involves ERK1/2 activation of p90rsk which also inhibits GSK3β, 
allowing β-catenin to associate with cadherins (Torres et al., 1999).  Therefore 
investigations were performed to examine the effect of kp-10 on these proteins. 10nM 
kp-10 stimulation significantly induced phosphorylation of Src, GSK3β (Ser9) and 
increased cytoplasmic levels of β-catenin over 60 minutes (Fig. 65).  Inhibitors were 
again used to delineate the mechanisms involved.  GSK3β phosphorylation was blocked 
by inhibitors of Gq/11, Src, PI(3)K, Akt, PKC, p90rsk and GSK3β whereas β-catenin was 
inhibited by Gq/11, PI(3)K, Akt, PKC, MEK and p90rsk inhibitors (Fig. 65).  The p90rsk 
inhibitor decreased β-catenin levels to below basal, and this is probably due to pools of 
β-catenin with GSK3β that cannot be phosphorylated at Ser9 due to this residue being 
masked within the β-catenin destruction complex. 
 





Figure 61.  Kisspeptin activates ERK1/2 via the classical pathway.  (A) Kisspeptin 
phosphorylates ERK1/2 in a dose dependant manner at 10 minutes (n=4). (B) 10nM Kisspeptin 
phosphorylates ERK1/2 in a time dependant manner peaking at 10 minutes (n=4).  (C, D) 
Quantification of dose and time dependant ERK1/2 activation showing significant 
phosphorylation from 1nM and between 5 and 60 minutes compared to total ERK.  (E) 
Kisspeptin-dependant ERK1/2 phosphorylation is significantly decreased by 100nM YM254890 
(Gq/11), 1uM Src-I1 (Src), 1uM PI-103 (PI(3)K), 1µM Go6983 (PKC α, β, γ, δ, µ, ζ), 1µM Ro-
31-8220 (PKC α, β, γ, ε),20µM PD98059 (MEK), BI-D1870 (p90rsk) and CT99021 (GSK3β) 
inhibitors (n=3) and (F) diagram of classical ERK signaling pathway. 










Figure 62.  Kisspeptin activates other members of the MAPK pathway. (A) Kisspeptin 
phosphorylates p38MAPK and JNK1 (n=3). Total ERK1/2 was used as a loading control.  (B) 
Quantification for phosphorylation of p38MAPK with an increase at 10minutes and JNK1, 
which is significantly increased at 5-60 minutes.  
 
 







Figure 63. Kisspeptin phosphorylates focal adhesion kinase (FAK) in CHO/gpr-54 cells. 
(A) Kisspeptin phosphorylates FAK from 5-60 minutes (n=3).  Total ERK1/2 is used as a 
loading control.  (B) Quantification of FAK phosphorylation compared to loading control shows 
significant increases from 10-30 minutes. (C) This increase at 30 minutes is significantly 
decreased by 100nM YM254890 (Gq/11), 1uM Src-I1 (Src), 1uM PI-103 (PI(3)K), 1µM Akt-
Inhibitor 1/2 (Akt/PKB), 20µM PD98059 (MEK), 1µM BI-D1870 (p90rsk) and 1µM CT99021 










Figure 64.  Kisspeptin activates phosphorylation of NFκB in CHO/gpr-54 cells.  (A) 
Kisspeptin phosphorylates NFκB (n=3) but de-phosphorylates IκBα (n=2).  Total ERK1/2 was 
used as a loading control.  (B) Quantification of NFκB phosphorylation by kisspeptin reaching 
significance from 10-60 minutes. (C) This phosphorylation is blocked by 100nM YM254890 
(Gq/11), 1µM Go6983 (PKC α, β, γ, δ, µ, ζ) and 1µM Ro-31-8220 (PKC α, β, γ, ε) inhibitors 










Figure 65.  Kisspeptin modulates GSK3β and β-catenin pathways.  (A) Kisspeptin 
phosphorylates Src (n=3) and GSK3β (Ser9; n=4), while increasing β-catenin protein within the 
cytoplasm (n=4).  Total ERK1/2 was used as a loading control.  (B) Quantifications of western 
blots showing significant phosphorylation of Src at 30-60 minutes and GSK3β at 10-60 minutes.  
Beta-catenin is significantly increased throughout the stimulation. (C) Phosphorylation of 
GSK3β is blocked by 100nM YM254890 (Gq/11), 1µM Ro-31-8220 (PKC α, β, γ, ε) and 1µM 
BI-D1870 (p90rsk) inhibitors and decreased by 1µM Src Inhibitor 1 (Src), 1µM PI-103 (PI(3)K), 
1µM Akt Inhibitor 1/2 (Akt), 20µM PD98059 (MEK) and 1µM CT99021 (GSK3β) inhibitors 
(n=3). (D) The increase of β-catenin is blocked by 100nM YM254890 (Gq/11), 1µM PI-103 
(PI(3)K), 1µM Akt Inhibitor 1/2 (Akt/PKB), 1µM Go6983 (PKC α, β, γ, δ, µ, ζ) and 1µM BI-
D1870 (p90rsk) inhibitors and decreased by 1µM Ro-31-8220 (PKC α, β, γ, ε) and 20µM 
PD98059 (MEK) inhibitors (n=4). 
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4.2.3. Kisspeptin-10 does not activate Rho GTPases in CHO cells stably 
expressing human gpr-54 
 
Since stimulation with kp-10 induced cell rounding and formation of stress fibres in this 
the CHO cell line, the pathways usually responsible for these activities were investigated 
next.  Stress fibre formation is controlled via Rho GTPase family members, RhoA and 
Rac-1/Cdc42.  RhoA causes the inactivation of MLC phosphatase by ROK 
phosphorylation to promote actin-myosin assembly and stress fibre formation.   Rac-
1/Cdc42 is known to stabilise adherens junctions via inhibition of IQGAP1, which binds 
β-catenin and cadherins to disrupt binding to the actin cytoskeleton (Kaibuchi et al., 
1999; Sah et al., 2000).  As kisspeptin has been shown to regulate β-catenin via a 
pathway that promoted adherens junction formation, this pathway may also be active.  
However, no significant increase of RhoA or Rac-1/Cdc42 could bee seen in these cells 
when stimulated with 10nM kp-10 (Fig. 66).  Therefore a separate pathway must 




Figure 66. Kisspeptin does not activate the Rho GTPase family. (A) Kisspeptin does not 
activate Rac-1, Cdc42 or RhoA (n=3).  Total ERK1/2 is used as a loading control. (B) 
Quantifications of western blots confirming no activation. 
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4.2.4.  Kisspeptin-10 activates a more limited spectrum of pathways in 
GnRH neuronal cells 
 
Pathways delineated in the CHO cells, were next tested in a more physiologically 
relevant cell line.  The GnRH neuronal cell line, GT1-7 was used since gpr-54 has been 
shown to be present on 80% of GnRH neurons (Irwig et al., 2004).  However, as little 
gpr-54 mRNA could be detected in these cells by RT-PCR, the mouse receptor was 
stably expressed to increase the output signal. To test this cell line, receptor binding was 
again examined, and kp-10 could bind with an IC50 of 4.4x10
-8M.  Kp-10 could also 
stimulate IP production and intracellular calcium release in these cells (Fig. 67). 
However, due to a relatively low amount of total binding suggesting low receptor 
number compared to the CHO cells; 100nM kp-10 was used for protein studies in these 
cells.  The first proteins tested were from the MAPK pathway, where a significant 
phosphorylation of ERK1/2 was seen upon stimulation with kp-10, with a maximal 
response at 5 minutes. The use of inhibitors revealed that this involved PKC, Src, EGFR 
transactivation and PI(3)K. A significant phosphorylation of NFκB and GSK3β (Ser9) 
was also induced, with maximal responses at 30 and 10 minutes, respectively (Fig. 68). 
NFκB phosphorylation was shown by inhibitors to be Gq/11 mediated but did not involve 
PKC, MEK, EGFR or Src whereas GSK3β phosphorylation was via a similar pathway to 
ERK1/2 suggesting p90rsk may be involved as above.  However, no significant 
activation of Src, Akt or β-catenin could be found in these cells (Fig. 68). This is in 
accordance with the observation that kp-10 does not influence migration within these 
cells, and therefore the pathway stimulating calcium influx may be preferentially 
activated in neuronal cells. However, as secretion of GnRH could not be detected from 
this cell line, the effect of these signals on secretion could not be assessed.  Work on 
other GnRH neuronal cell lines is needed to clarify the role gpr-54 signalling in the 












Figure 67.  Kisspeptin binds to and activates gpr-54 in GT1-7 neuronal cells stably 
expressing the mouse receptor. (A)  Kisspeptin binds the mouse receptor with an affinity of 
44nM in these cells (n=5). (B, C) Kisspeptin can also activate the mouse receptor to stimulate IP 
and intracellular calcium release with an EC50 of 14nM and 34nM, respectively (n=5). 
 
 






Figure 68. Kisspeptin activates a subset of signalling molecules in GnRH neuronal cells 
stably expressing mouse gpr-54. (A) Kisspeptin phosphorylates ERK1/2 (n=5), GSK3β (Ser9; 
n=3) and NFκB (n=3) in GT1-7/gpr-54 cells.  Total ERK1/2 was used as a loading control. (B) 
Quantification of western blots showing ERK1/2 phosphorylation from 5-60 minutes, GSK3β 
phosphorylation at 10 minutes and NFκB phosphorylation at 30 minutes.  (C) ERK1/2 (n=5) and 
GSK3β (n=3) phosphorylation was decreased by 100nM YM254890 (Gq/11), 1µM Src Inhibitor 1 
(Src), 1µM AG1478 (EGFR), 1µM PI-103 (PI(3)K), 1µM Go6983 (PKC α, β, γ, δ, µ, ζ), 1µM 
Ro-31-8220 (PKC α, β, γ, ε) and 20µM PD98059 (MEK) inhibitors. This was only significant 
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4.2.5. Kisspeptin-10 signals via migratory pathways in breast cancer and 
trophoblast cell lines 
 
Since only a select number of proteins were activated in the GnRH neuronal cells, it was 
decided to see if the other pathways found within the model CHO cell line were active in 
cells from tissues were kisspeptin has peripheral actions on migration.  Therefore 
examination of the intracellular signalling pathways in four cancer cell lines was 
undertaken.   
 
B35 neuroblastoma cells 
Firstly, rat neuroblastoma cells (B35) were tested to look at other cells types within the 
neuronal network of the brain.  B35 cells are neuronal cancer cells and gpr-54 has been 
shown to be present within other areas of the brain.  However, no stimulation of ERK1/2 
could be observed upon kp-10 stimulation; however stable transfection of mouse gpr-54 
DNA into these cells, did allow stimulation of IP production but still no stimulation of  





Figure 69. B35 cells do not express endogenous gpr-54. (A) 10nM Kp-10 could not stimulate 
ERK1/2 phosphorylation in B35 rat neuroblastoma cells (n=2) Total ERK1/2 was used as a 
loading control. (B) Quantification of western blots showing no activation. (C) Kp-10 could 
stimulate IP release in transfected B35 cells in a dose dependant manner (n=3) 
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Neuroendocrine GH3 somatotropes 
Next, rat pituitary adenoma somatotrope cells, GH3, were tested to assess if gpr-54 was 
present within the pituitary.  GH3 cells are secretory somatotropic cancer cells and gpr-
54 has been hypothesised to be present on this cell type; however no phosphorylation of 
ERK1/2, JNK or p38MAPK could be seen at any concentration suggesting there was 
little or no receptor in these cells (Fig. 70). Next other cell types of pituitary origin were 
utilised. LβT2 and αT3 gonadotropes were assessed by PCR to examine if kp-10 is acting 
directly within the pituitary to release LH and FSH but no gpr-54 mRNA could be 







Figure 70.  Gpr-54 is not present in GH3 rat pituitary adenoma cells. (A) Kp-10 does not 
phosphorylated ERK1/2, JNK1 or p38MAPK at any dose in GH3 cells at 10 minutes (n=2). 
Total ERK1/2 was used as a loading control. (B) Quantifications of western blots confirming 
lack of activation. 
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Ishikawa endometrial cancer cells 
As kp-10 is known to act as an inhibitor of metastasis, a human endometrial 
adenocarcinoma cell line (Ishikawas) was examined but again no phosphorylation of 







Figure 71. Gpr-54 is not present in the Ishikawa endometrial epithelial cancer cell line.  (A) 
10nM Kp-10 could not stimulate phosphorylation of ERK1/2 or JNK1 in Ishikawa human 
endometrial adenocarcinoma cells (n=2). Total ERK1/2 was used as a loading control. (B) 
Quantification of western blots confirming no phosphorylation.  
 
 
MCF-7 breast cancer cells 
Finally, to further test if kp-10 was present in cancer cell lines and to examine the 
pathways activated, the human breast adenocarcinoma cell line, MCF-7 was tested and 
kisspeptin stimulation induced phosphorylation of ERK1/2 with a similar fold increase 
to CHO/gpr-54 cells.  This phosphorylation was both dose and time dependant.  
Kisspeptin could also stimulate IP production in these cells with a similar EC50 to CHO 
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cells but a less pronounced stimulation (Fig. 72). Since MCF-7 cells appeared to possess 
an active receptor for kp-10, other pathways activated in the model CHO cell line were 
analysed.  Kp-10 could also significantly induce phosphorylation of FAK, GSK3β and 
stimulated β-catenin release. 10nM and 100nM doses of kp-10 stimulated 
phosphorylation of FAK at 10 minutes and 60 minutes, respectively.  Phosphorylation of 
GSK3β was stimulated by 10nM kp-10 at 10 minutes and by 100nM kp-10 at the later 
time point of 60 minutes.  Finally, β-catenin release was induced with 100nM kp-10 
from 30-60 minutes and only marginally stimulated by 10nM kp-10 at 10 minutes (Fig. 
73).  Therefore, MCF-7 cells express gpr-54 and can regulate some of the migratory 
pathways seen to be activated by kisspeptin in the model cell line previously examined. 
 
Choriocarcinoma cell lines: JEG, JAR and BeWo cells 
As well as looking at these pathways in cancer cell lines; placental trophoblast cell lines 
were also utilised as kisspeptin has been shown to inhibit trophoblast invasion within the 
placenta.  Therefore, four placental cell lines including three choriocarcinoma derived 
cell lines and one immortalised first trimester trophoblast cell line were examined.  
Firstly, the three choriocarcinoma cell lines were analysed as they are both cancerous 
and placental in origin. JEG-3 cells were found to have no stimulation of IP production 
and to induce no phosphorylation of ERK (Fig. 74), suggesting the receptor may not be 
expressed in this cell line.  The other two choriocarcinoma cells lines, BeWo and JAR 
cells were also found to be incapable of phosphorylating ERK1/2 in response to kp-10 
stimulation (Fig. 74).   
 
 





Figure 72. Endogenous gpr-54 is present in MCF-7 breast cancer cells.  (A) 10nM Kp-10 
phosphorylates ERK1/2 from 2-30 minutes peaking at 10 minutes (n=4). (B) 100nM Kp-10 
phosphorylates ERK1/2 from 2-60 minutes peaking after 10 minutes (n=4). Total ERK1/2 was 
used as a loading control. (C, D) Quantifications of western blots for 10 and 100nM confirming 
activation of ERK1/2. (E) Kp-10 also stimulates IP release in a dose dependant manner with an 
EC50 of 6.9nM (n=3).  






Figure 73. Kp-10 activates migratory signalling proteins in MCF-7 cells.  (A) 10nM kp-10 
phosphorylates FAK (n=3), GSK3β (n=4) and increases β-catenin (n=3) in the cytoplasm. Total 
ERK1/2 was used as a loading control.  (B) Quantifications of western blots showing each 
increase peaks at 10 minutes. (C) 100nM kp-10 phosphorylates FAK (n=3), GSK3β (n=4) and 
increases β-catenin (n=3) in the cytoplasm to a greater extent than 10nM. (D) Quantifications of 
100nM kp-10 western blots showing prolonged activation throughout the 60 minute stimulation. 
 
 






Figure 74.  Gpr-54 expression is low in choriocarcinoma cell lines. (A, B) 100nM kp-10 
cannot stimulate ERK1/2 in JEG-3 choriocarcinoma cells (n=2). (C, D) 100nM kp-10 is unable 
to phosphorylate ERK1/2 in BeWo choriocarcinoma cells (n=4). (E, F) 100nM kp-10 could not 





HTR8SVneo immortalised human first trimester extravillious trophoblast cells 
As it appeared that the cancerous phenotype of these cells lines was deleterious to gpr-
54 expression, research was focused on the immortalised human first trimester 
trophoblast cell line termed HTR8SVneo.  In these cells, kp-10 was shown to bind the 
receptor with a 10-fold lower affinity than in the CHO cells of 1.27x10-7M, but curiously 
could not produce an IP response.  Kp-10 could however stimulate intracellular calcium 
release with an EC50 of 4.3x10
-7M, which is consistent with the binding affinity (Fig. 
75).  This may be via ion channel influx of calcium as seen in GnRH neurons. 
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Next the downstream signalling pathways were examined to see if the migratory 
proteins were activated.  For the MAPK pathway, 100nM kp-10 could stimulate 
phosphorylation of ERK1/2 and p38MAPK.  ERK1/2 was phosphorylated at 10 minutes 
and p38MAPK was more robustly phosphorylated at 10 minutes.  Using inhibitors to 
delineate the pathway for these phosphorylations, Gq/11, Src, EGFR, PI(3)K, PKC and 
MEK inhibitors were shown to block ERK1/2 phosphorylation and Gq/11, EGFR, PI(3)K 
and MEK blocked p38MAPK phosphorylation (Fig. 76).  This pathway is similar to that 
observed in the CHO cells as EGF receptor transactivation was also needed for the 
activation of MAPK proteins in those cells.  Next the migratory proteins were examined; 
kp-10 could induce phosphorylation of NFκB, FAK, Src, and GSK3β as well as increase 
β-catenin in the cytoplasm.  NFκB phosphorylation was shown to be stimulated by kp-
10, peaking at 10 minutes.  The pathway for this phosphorylation was similar to the 
CHO cells as Gq/11 and PKCε inhibitors ablated this phosphorylation.  However, in these 
cells this phosphorylation was also inhibited by Src, EGFR, PI(3)K and ERK showing 
again the importance of EGFR transactivation and the MAPK pathway in the trophoblast 
cell (Fig. 77).  FAK phosphorylation was maximally increased at 10 minutes and also 
appeared dependant on Gq/11, EGFR and ERK with input from PKC (α, β or γ; Fig 77).  
Src was next shown to be phosphorylated upon stimulation with kp-10 with a maximal 
increase at 10 minutes, which was sustained until 60 minutes (Fig. 78). However, the 
most important mechanism within these cells appears to be the phosphorylation of Ser9 
within GSK3β, which was increased significantly at 5 minutes. This phosphorylation 
was inhibited by a multitude of factors including Gq/11, Src, EGFR, PI(3)K, PKC and 
MEK (Fig. 78).  This suggests that PKC, Akt and p90rsk are activated by kp-10 within 
these cells to phosphorylate Ser9.  Although, none of these proteins appear to regulate β-
catenin as only the Gq/11 inhibitor blocks the kp-10 induced increase at 30-60 minutes 
within the cytoplasm (Fig. 78).  Therefore, GSK3β inhibition may be activating a 
different mechanism in the HTR8SVneo cells than is activated in the CHO cell line 
where β-catenin is regulated.  However, further investigation is needed to elucidate this 
mechanism fully. 
 








Figure 75.  Endogenous gpr-54 expressed within HTR8SVneo immortalised human 
trophoblast cells. (A) Kp-10 can bind gpr-54 with an affinity of 127nM in first trimester 
trophoblasts (n=6). (B) Kp-10 does not stimulate IP release in these cells (n=3) but (C) does 
induce intracellular calcium release with an EC50 of 433nM (n=3). 
 






Figure 76.  Kp-10 activates MAPK pathways in HTR8SVneo human trophoblast cells.  (A) 
Kp-10 can phosphorylate ERK1/2 (n=4) and p38MAPK (n=3) in HTR8SVneo cells.  Total 
ERK1/2 was used as a loading control.  (B) Quantifications of western blots showing increase 
over the 60 minute stimulation peaking between 5-10 minutes.  (C) Phosphorylation of ERK1/2 
was significantly blocked by 1µM AG1478 (EGFR) and 20µM PD98059 (MEK), and 100nM 
YM254890 (Gq/11), 1µM Src Inhibitor 1(Src), 1µM PI-103 (PI(3)K) and 1µM Go6983 (PKC α, 
β, γ, δ, µ, ζ) caused a significant decrease (n=3). (D) P38MAPK phosphorylation was blocked by 
1µM AG1478 (EGFR), 1µM PI-103 (PI(3)K) and 1µM PD98059 (MEK) inhibitors (n=3). 






Figure 77.  Kp-10 phosphorylates NFκB and FAK migratory proteins in HTR8SVneo 
human trophoblasts. (A) Kp-10 phosphorylates NFκB and FAK at 10 minutes (n=3).  Total 
ERK1/2 was used as a loading control. (B) Quantifications of western blots showing a 
significant increase at 10 minutes. (C) Phosphorylation of NFκB is blocked by 100nM 
YM254890 (Gq/11), 1µM Src Inhibitor 1 (Src), 1µM AG1478 (EGFR), 1µM PI-103 (PI(3)K), 
1µM Ro-31-8220 (PKC α, β, γ, ε) and 20µM PD98059 (MEK) inhibitors (n=3).  (D) FAK 
phosphorylation is ablated by 100nM YM254890 (Gq/11), 1µM AG1478 (EGFR), 1µM Go6983 
(PKC α, β, γ, δ, µ, ζ), 1µM Ro-31-8220 (PKC α, β, γ, ε) and 20µM PD98059 (MEK) and slightly 
decreased by 1µM PI-103 (PI(3)K) inhibitors (n=3). 








Figure 78. Kp-10 mediates GSK3β and β-catenin pathways in HTR8SVneo human 
trophoblast cells. (A) Kp-10 phosphorylates Src and GSK3β at 5-30 minutes and increases β-
catenin in the cytoplasm after 30 minutes (n=4).  Total ERK1/2 is used as a loading control. (B) 
Quantifications of western blots showing significantly increased phosphorylation and protein. 
(C) Phosphorylation of GSK3β is ablated by 100nM YM254890 (Gq/11), 1µM Src Inhibitor 1 
(Src), 1µM AG1478 (EGFR), 1µM PI-103 (PI(3)K), 1µM Go-6983 (PKC α, β, γ, δ, µ, ζ), 1µM 
Ro-31-8220 (PKC α, β, γ, ε) and 20µM PD98059 (MEK) inhibitors (n=3). (D) β-catenin protein 
within the cytoplasm is decrease by the 100nM YM254890 (Gq/11) inhibitor only in trophoblast 
cells (n=3). 
 





Kisspeptin is known to be important for the secretion of GnRH in the hypothalamus 
(Gottsch et al., 2004; Irwig et al., 2004; Messager et al., 2005) and has also been shown 
to affect the migration of a variety of cells including CHO cells, trophoblasts and cancer 
cell lines (Bilban et al., 2004; Hiden et al., 2007; Hori et al., 2001; Kotani et al., 2001; 
Lee et al., 1996).  Until now the intracellular proteins and pathways for these processes 
have not been fully investigated due to large drive to examine the physiological effects 
of kisspeptins and gpr-54 in a variety of animal models.   However, understanding the 
signalling mechanisms activated by gpr-54 in cells from different tissues where kp-10 is 
known to act may help to clarify these physiological effects and differential actions 
associated with gpr-54 activation. 
 
In order to address this issue, the intracellular proteins activated by kp-10 were 
investigated in CHO cells and GT1-7 neuronal cells stably expressing gpr-54, and a 
variety of cancer and trophoblast cell lines. The majority of the above pathway analysis 
has been undertaken using western blot and inhibitor studies as these are commonly used 
methods; however alternative techniques could have been used to obtain the findings 
within this chapter.  Other methods to inhibit the proteins within the pathways studied 
may have been utilised, such as introduction of dominant negative mutants or short-
interfering RNA (siRNA).  Dominant negative proteins are proteins with inactivating 
mutations (negatives), which when over-expressed in cells can cause inhibition of the 
wild-type protein function (dominant).  Dominant negatives are useful as they can be 
more specific than inhibitors, even enabling separate analysis of different isoforms of 
proteins.  An alternative method would be to use siRNAs, which when transfected into 
cells can bind to the RNA-induced silencing complex (RISC), which then cleaves the 
target mRNA complementary to the bound siRNA, effectively silencing the gene of 
interest.  However, the knockdown of the gene expression is not always complete, which 
may lead to less effective results than with inhibitors; on the other hand they can give a 
more specific inhibition.   
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Another area where alternative techniques may also have been employed is within the 
detection of the protein levels within samples.  Quantitative proteomic analysis may 
have been used to obtain information on all the proteins within a sample.  Mass 
spectrometry-based proteomics is used for this purpose, with the most common form 
being stable isotope labeling with amino acids in cell culture (SILAC). This involves the 
culture of two cell populations were one is given normal amino acids in growth medium 
and the other given heavy isotope amino acids (to increase the mass).  Once combined, 
chemically identical proteins with different masses can be identified by mass 
spectrometry and the ratio used to calculate the abundance of a protein in a sample. This 
technique can also be used to examine the overall phosphorylation status of a sample.  
Alternatively, 2-D gel electrophoresis could have been used to separate proteins by 
charge via isoelectric focusing and then by mass via SDS-PAGE.  This allows all the 
proteins within a sample to be quantified at once. Also, if protein samples are labeled 
with different flourophores they can be run on the same gel, decreasing the amount of 
inter-gel differences and allowing variations between samples to be calculated. 
  
However, as mentioned above western blots and inhibitor were utilised and it was found 
that the main signalling pathways activated in all cell types are MAPK, GSK3β and 
NFκB signalling with some influence of FAK signalling in certain cell types.  The 
mechanism of this activation appears consistent between tissues with most cell lines 
exhibiting EGF receptor transactivation.  This suggests that gpr-54 signalling, although 
cell type dependant, recruits similar pathways to facilitate a range of physiological 
outcomes. 
 
The main pathway activated in all cell types that responded to kp-10 was the MAPK 
signalling cascade. In the CHO/gpr-54 cell line, representative members of the MAPK 
family were activated, with a very robust stimulation of ERK1/2. ERK1/2 activation 
involved a mechanism where EGFR transctivation is centrally important (Fig. 79).  
However, in MCF-7 breast cancer cells and HTR8SVneo trophoblast cells only 
activation of ERK1/2 and p38MAPK was induced by kp-10 with no stimulation of the 
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JNK pathway (Fig. 80). In GT1-7 neuronal cells, of the MAPKs, only ERK1/2 activation 
was detectable and this also involved EGF receptor transactivation (Fig. 81).  
Transactivation has previously been shown in these cells in response to GnRH where 
p90rsk was also up regulated and may explain why GSK3β is inhibited in this cell line 
(Shah et al., 2003).  Also, in GT1-7 cells there appears to be a constitutive 
phosphorylation of ERK1/2, due to the fact that inhibitors used in these cells reduced 
this phosphorylation below basal levels.  In these cells it is known that diverse stimuli 
such as lead can induce ERK phosphorylation as can prion protein clustering (Monnet et 
al., 2004; Zhang et al., 2003), also Ark, a receptor tyrosine kinase has been shown to 
activate ERK1/2 to regulate anti-apoptotic effects in these cells (Allen et al., 2002; Allen 




Figure 79. Schematic diagram of signalling pathways activated by kp-10 in CHO cells 
stably expressing the human gpr-54. Kp-10 mediates MAPK, GSK3β, NFκB and FAK. 
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Activation of MAPK signalling by kp-10 within all cell types studied was further shown 
to be pivotal to the inhibition of GSK3β via Ser9 phosphorylation to release β-catenin in 
to the cytoplasm in CHO and trophoblast cells (Fig. 79 and 80).  This occurs via ERK1/2 
phosphorylating p90rsk at Thr573 to activate an auto-phosphorylation event to fully 
activate p90rsk and at the same time ERK1/2 also primes GSK3β for Ser9 
phosphorylation by p90rsk (Anjum and Blenis, 2008).  This then becomes a pseudo-
substrate for GSK3β that can occupy the anoxyion binding pocket, but cannot be further 
phosphorylated as a proline is situated at the first GSK3β phosphorylation site four 
residues N-terminally to Ser9 in place of a Thr/Ser residue.  This can then compete with 
β-catenin to inhibit GSK3β (Frame and Cohen, 2001; Pearl and Barford, 2002).  MAPK 
may also influence GSK3β inhibition via p38MAPK which can phosphorylate a specific 
Ser389 residue to cause the release of β-catenin into the cytoplasm (Thornton et al., 




Figure 80. Schematic diagram of multiple pathways activated by kp-10 in trophoblast cells. 
Kp-10 mediates MAPK, GSK3β, NFκB and FAK signalling in HTR8SVneo cells. Note the 
absence of inositol phosphate production and JNK activation and a preference for PKCε isoform. 
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Inhibition of GSK3β and release of β-catenin into the cytoplasm appears critical to kp-
10 signalling in the CHO and trophoblast cell lines, with some effect of GSK3β in the 
GnRH neuronal cell line; however, this does not appear to be the regulation of β-catenin.   
In contrast, the role of GSK3β in the GnRH neuron is unclear but may involve gene 
transcription or regulation of the insulin pathway (Fig. 81).  Whereas in the CHO and 
trophoblast cell lines; inhibition of GSK3β by Ser9 phosphorylation may play an 
influential role on release of β-catenin into the cytoplasm.  Again, similarities between 
cells are evident with CHO, GT1-7 and trophoblast cells using transactivation of the EGF 
receptor.  In the CHO cells as well as the MAPK/p90rsk pathway, inhibition of the 
PI(3)K/Akt pathway members and PKC also reduces the phosphorylation of Ser9 and 
blocks the release of β-catenin into the cytoplasm (Fig. 79).  This suggests that multiple 
pathways are utilised to ensure the release of β-catenin, with p90rsk being the main 
contributor as blocking this pathways completely ablates this release and GSK3β 
phosphorylation.  Whereas, blocking Akt or PKC only decreases GSK3β inhibition 
suggesting p90rsk can compensate for Akt/PKC but Akt/PKC cannot compensate for the 
loss of p90rsk in CHO cells.  Due to the involvement of p90rsk this suggest that β-
catenin should be assembling at adherens junctions to inhibit the movement of CHO 
cells (Torres et al., 1999), and this is backed up as no translocation to the nucleus could 
be seen in CHO cells (data not shown).  Therefore, investigation of the cadherins in 
response to kp-10 and examining the phosphorylation status of β-catenin would resolve 
the mechanism utilise by β-catenin after release into the cytoplasm.  Investigating the 
phosphorylation status would be beneficial as Akt is known to phosphorylate β-catenin 
to cause nuclear translocation (Fang et al., 2007).   
 
In the trophoblast cell line, Akt and PKC also appear to be important for GSK3β 
phosphorylation of Ser9 along with p90rsk, as inhibitors of Src, PI(3)K ablate this 
phosphorylation as does inhibitors of PKC and MEK (Fig. 81).  However, none of these 
inhibitors affect β-catenin release suggesting that GSK3β inhibition is not important for 
β-catenin activation.  In order to examine if this is indeed the case, inhibitors of Akt, 
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p90rsk and GSK3β need to be utilised in this cell line to see if they directly affect this 





Figure 81. Schematic diagram of select pathways activated by kp-10 in GnRH neuronal 




Another characteristic of the trophoblast cell line used is apparent constitutive 
phosphorylation of GSK3β at Ser9, shown as when inhibitors were used to map the 
pathway involved they decreased the phosphorylation status of Ser9 to below basal 
levels.  This may be due to activation of Akt or p90rsk via a different substrate to affect 
the cells migration, as the regulation of trophoblast invasion in the first trimester is 
probably due to a cocktail of substrates including kp-10.  For example, EGF has been 
shown to regulate Akt and ERK1/2 in these cells and interleukins are also known to 
regulate extravillious trophoblasts (Paiva et al., 2009; Pollheimer and Knofler, 2005; Qiu 
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et al., 2004).  Another reason for this constitutive phosphorylation may be GSK3β 
regulation of glycogen synthase within the insulin pathway, where GSK3β is known to 
be inhibited by Ser9 phosphorylation in response to the Akt/PKB pathway (Pearl and 
Barford, 2002). 
 
The regulation of GSK3β via ERK1/2 and p90rsk and any other actions of the MAPK 
pathway appears to be important in the CHO and HTR8SVneo immortalised trophoblast 
cells lines. In these cell lines, FAK is also regulated by kp-10 via phosphorylation at 
Tyr925.  This phosphorylation is known to create a SH2 binding site for the Grb2-SOS 
complex within FAK. As SOS is a nucleotide exchange factor this can increase the 
activation of RAS to increase ERK1/2 phosphorylation (Fig. 82) (Schlaepfer et al., 1994; 
Schlaepfer and Hunter, 1996).  Since this phosphorylation of FAK is dependant on 
ERK1/2, p90rsk, Akt and GSK3β this creates a feedback loop via FAK and Grb2 to 
increase ERK1/2 phosphorylation to further inhibit GSK3β and increase β-catenin 
within the cytoplasm (Fig. 79 and 80). It has been previously shown that GSK3β can 
regulate FAK phosphorylation and activation, and can even form a complex in regards 
to cell migration (Bianchi et al., 2005).  Another role of FAK may also be to associate 
with integrins to form focal adhesion complexes to inhibit cell movement.  FAK can be 
activated in response to integrin clustering via autophosphorylation of Tyr397, creating a 
SH2 domain for binding with Src. Full activation of FAK can then occur via 
phosphorylation of Tyr567/577 by Src and FAK can enhance Src activity via 
phosphorylation at Tyr418.  The FAK-Src complexes can then bind to paxillin and 
p130Cas at focal adhesion or regulate downstream signalling cascades such as MAPK.  
At focal adhesions, paxillin also binds to integrins which are bound to the ECM and 
vinculin which binds to the actin cytoskeleton.  This complex then creates a tight 
connection between the ECM and cytoskeleton to modulate stresses inside and outside 
the cell (Parsons, 2003).   
 






Figure 82.  Diagram showing binding of Grb2 to FAK after phosphorylation of Tyr925.  
Diagram showing phosphorylation of FAK at Tyr925 by Src to create a binding site for the Grb2-
SOS complex.  SOS then acts to exchange GTP-GDP within RAS to activate the MAPK 
pathways to increase phosphorylation of ERK1/2. Diagram taken from Schlaepfer, D.D and 
Hunter, T, Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal 




Another pathway activated via kp-10 in all cell types tested except the MCF-7 cells, is 
the NFκB signalling pathway specifically dimers involving p65 as the antibody used 
detects Ser536 phosphorylation of the p65 subunit.  NFκB has previously been shown in 
primary trophoblast cells to bind to the promoter of MMP-9 causing its activation.  This 
then causes the breakdown of the ECM to facilitate trophoblast invasion.  Kp-10 has 
been shown to disrupt binding of NFκB to the promoter in these cells to decrease MMP-
9 expression (Yan et al., 2001).  However, in the three positive cell lines tested in this 
thesis, there is an increase in NFκB activation suggesting that this is not the action 
occurring in these cell lines and that NFκB may be regulating a different set of genes.  
Differences can be seen in the activation of NFκB with CHO cells using only PKC 
mediated mechanisms and the trophoblast cells using both PKC and EGF receptor 
mechanisms possibly via MEK (Fig. 79 and 80).  MEK has previously been shown to 
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activate NFκB in osteoclasts (Gingery et al., 2008).  However, the mechanism in the 
GnRH neuron is still to be established as none of the inhibitors except for Gq/11 had an 
effect (Fig. 81).  Also from the results obtained in this study, it appears that the most 
important PKC isoform is PKCε, since Ro-31-8220 is more effective than Go6983 at 
inhibiting the important proteins in each cell type such as NFκB, ERK1/2 and GSK3β.  
PKCε is a novel calcium-independent, phospholipid-dependant enzyme, known to 
phosphorylate Ser/Thr residues to activate downstream signalling cascades when 
activated by DAG.  Although, most commonly known as a cardioprotectant against 
infarction, PKCε has also been shown to regulate calcium release and MAPK signalling 
(Burgos et al., 2007; Comalada et al., 2003).  
 
In summary, kp-10 can activate a range of signalling pathways in CHO and trophoblast 
cells with select pathways also activated in the GnRH neuron.  The main pathway 
activated in the CHO and trophoblast cell lines is an ERK1/2 mediated inhibition of 
GSK3β via p90rsk to release β-catenin into the cytoplasm.  This is then further enhanced 
via a FAK-mediated feedback loop to increase ERK1/2 phosphorylation further.  The 
pathways activated in these cells suggest a role for kisspeptin in the regulation of 








Kisspeptin-10 inhibits migration of  
CHO/gpr-54, human umbilical vein 
endothelial cells and human placental 
trophoblast cells 





GnRH neurons are regulated by afferent networks of kisspeptin-producing 
neurons. To date, research has concentrated on signals affecting kisspeptin neurons 
such as sex steroids and environmental cues; however, kisspeptin was first 
discovered as an inhibitor of metastasis and trophoblast migration.  Therefore, 
using an in vitro assay to assess cell migration; a model CHO cell line, GnRH 
neuronal cells along with cancer and placental cells were examined for kp-10 
mediated inhibition of cell migration.  The model CHO cell line and both placental 
cells, showed a dose-dependant inhibition of cell migration upon stimulation with 
kisspeptin-10.  However, no effect was observed on the migration of the GnRH 
neuronal cells or MCF-7 breast cancer cells, suggesting differential effects of gpr-
54 activation on the cytoskeleton. 
 
In the previous chapter, kisspeptin-10 was shown to activate signalling pathways 
associated with migration. Inhibitors were utilised to gauge the involvement of 
particular proteins in this process.  In both the CHO and placental cell lines, 
inhibition of GSK3β to release β-catenin into the cytoplasm appears critical to this 
mechanism.  In these cells, this occurs via EGF receptor transactivation to activate 
the MAPK signalling cascade.  Specifically, this transactivation phosphorylates 
ERK1/2 causing the activation of p90rsk, which can in turn inhibit GSK3β via Ser9 
phosphorylation.  Inactivation of GSK3β results in release of β-catenin into the 
cytoplasm. Previous research has shown that p90rsk causes β-catenin to associate 
with cadherins at adherens junctions, suggesting a possible mechanism for 
kisspeptin-10 mediated inhibition of cell migration. 
 
These results suggest that kisspeptin may activate different pathways to mediate 
inhibition of trophoblast cell migration which are distinct from effects on breast 
cancer cell migration since no migrational affects were seen in MCF-7 cells.  
Further confirming kisspeptins actions are cell and tissue specific. 





Kisspeptin and gpr-54 have recently emerged as potent regulators of the HPG axis via 
regulating the secretion of GnRH in the hypothalamus and have been shown to relay 
hormonal and metabolic cues to GnRH neurons.  However, the KiSS-1 gene was 
originally discovered as a suppressor of metastasis in a variety of cancers suggesting that 
the kisspeptin/gpr-54 system may regulate cellular migration and tissue invasion.  Since 
then kisspeptin has been shown to inhibit cell migration in a model CHO cell line stably 
expressing the human receptor and has been shown to inhibit the migration of 
trophoblast cells during placentation. 
 
The process of placentation relies on the migration of extravillious trophoblast cells into 
the maternal arteries of the decidua, these cells then cause remodelling of the spiral 
arteries to promote blood flow to the placenta and foetus during pregnancy (Lunghi et 
al., 2007). In order for this process to occur normally, a host of excitatory and inhibitory 
signals, including kisspeptin, are needed to control the degree of migration by the 
trophoblasts, to allow sufficient supply of blood to the foetus without damaging uterine 
function (Cohen and Bischof, 2007; Hiden et al., 2007). If these signals fall out of 
balance with each other, this can lead to either shallow migration of the trophoblast cells 
leading to pre-eclampsia or over-migration into the decidua, known as  placental accreta 
(Khong, 2008; Sankaralingam et al., 2006).  
 
It has recently been shown that kisspeptins can inhibit the migration of trophoblasts cells 
in vitro and that KiSS-1 and gpr-54 mRNA are present in the placental trophoblast cells 
(Bilban et al., 2004). KiSS-1 and gpr-54 mRNA have been shown to be up regulated in 
the first trimester of pregnancy in the placenta then down-regulated throughout the 
second and third trimesters (Janneau et al., 2002).  This suggests a role for kisspeptin in 
placentation and trophoblast migration. Also in pre-eclampsia, KiSS-1 mRNA is 
increased, suggesting that kp-10 mediated inhibition of migration is overtly increased in 
this disease or that the target cells are inadequately responsive, contributing to the 
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altered migration of trophoblast cells into the maternal arteries of the decidua (Qiao et 
al., 2005; Zhang et al., 2006). Studies have emerged examining the cell migrational 
effects of kisspeptin; however these have mainly concentrated on its anti-metastatic 
properties. 
 
Different mechanisms have been hypothesised for this inhibition of metastasis in several 
cancer cells (Table 10). Several publications have shown an increase in ERK1/2 
phosphorylation and a decrease in MMP-2 expression (Masui et al., 2004; Ringel et al., 
2002; Yoshioka et al., 2008). Other suggested mechanisms include antagonism of 
stromal cell-derived factor-1 (SDF-1) action, inhibiting the pro-migration properties of 
its chemokine receptor CXCR4 via inhibition of Akt phosphorylation and calcium ion 
mobilization. Also, the up-regulation of modulatory calcineurin-interacting protein-1 
(MCIP-1), a chemokine capable of inhibiting the calcinuerin signalling pathway 
(Navenot et al., 2005; Stathatos et al., 2005).  Another hypothesis is that kisspeptin gene 
expression is regulated by Specificity Protein 1 (SP1) and its co-activator DRIP130 
which is located on chromosome region 6q16.3q23. When Loss of hetrozygosity (LOH) 
occurs at this region KiSS-1 is frequently lost from tumours and this allows metastasis to 
occur. This can be rescued by SP1 and DRIP130 (Mitchell et al., 2007; Shirasaki et al., 
2001). Within the placenta, the regulation of MMPs is thought to be important; one 
study has shown that kp-10/gpr-54 activation can dephosphorylate NFκB, causing it to 
dissociate from the MMP-9 promoter, thereby decreasing the expression of MMP-9, and 
inhibiting the re-modelling of the ECM (Yan et al., 2001).  However, further research is 
needed to delineate the signalling pathways within the placenta fully.   
 
The results in this chapter encompass the signalling pathways identified as important for 
the inhibitory effects of kp-10 on cell migration using an in vitro assay.  The results 
show that ERK1/2, p90rsk and GSK3β are critical to this inhibition in both a model 
CHO cell line and within human placental cell lines. However, this migratory pathway is 
not affected by kisspeptin in GnRH neuronal cells or within human MCF-7 breast cancer 
cells. 




Table 10. Types of cancer affected by KiSS-1/gpr-54 expression. Table listing the types of 




5.2.1. Kisspeptin-10 inhibits migration of CHO cells stably expressing 
human gpr-54 via an ERK1/2-dependant mechanism 
 
In the previous chapter, it was shown that migratory signalling proteins were activated in 
the CHO/gpr-54 cell line and it has also previously shown that kp-10 can inhibit the 
migration of this cell line when the receptor is stably expressed (Hori et al., 2001; Ohtaki 
et al., 2001).  However, the molecular pathways associated with this inhibition are yet to 
be elucidated, the following research aims to analyse the response of the pathways to 
gpr-54 activation.  It was firstly established that migration could be inhibited within the 
CHO/gpr-54 cell line using a cell migration assay.  In these cells, kp-10 caused a potent 
dose-dependant inhibition of migration at 22 hours, with 100nM kp-10 maximally 
inhibiting migration by 80% at 22 hours.  To prove that this was specifically due to 
activation of gpr-54, the gpr-54 antagonist characterised in chapter three, peptide 234 
was used.  100nM peptide 234 was able to ablate the inhibition of cell migration caused 
by 100nM kp-10 at 22 hours, with no intrinsic effects when used alone (Fig. 83 and 
Table 11).  Now that it was established that kp-10 and gpr-54 were able to inhibit the 
migration of this cell line, inhibitors were used to delineate the signalling molecules 
responsible for this action.  100nM kp-10 mediated inhibition of migration was blocked 
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when inhibitors of Gq/11, calcium, EGFR, PKC, MEK, p90rsk and GSK3β were used 
(Fig. 84 and Table 11).  This suggests that GSK3β inhibition via ERK1/2 and p90rsk, as 
determined in chapter four is responsible for this effect probably through regulation of 












Figure 83. Kp-10 inhibits migration via gpr-54 in CHO/gpr-54 cells. (A)  Kp-10 inhibits cell 
migration in a dose-dependant manner at 22 hours with 100nM inhibiting by 80% (n=5). (B) 
Quantification of cell migration assay showing dose-dependant inhibition.  (C) Kp-10 inhibited 
migration is ablated by the gpr-54 antagonist, peptide 234 with no intrinsic effects (n=3).  (D) 
Quantification of cell migration assay showing kp-10 mediated inhibition of migration and 













Figure 84. Kp-10 inhibits migration via an ERK1/2 dependant mechanism in CHO/gpr-54 
cells.  (A) Cell migration assay showing inhibition of migration by kp-10.  This was ablated by 
1µM BAPTA-AM (Calcium), 1µM Ro-31-8220 (PKC α, β, γ, ε), 1µM AG1478 (EGFR), 20µM 
PD98059 (MEK), 1µM BI-D1870 (p90rsk) and 1µM CT99021 (GSK3β) inhibitors (n=4). (B) 





In this pathway FAK was activated to effect MAPK activation.  However, FAK can also 
associate with integrins at focal adhesions and kp-10 has previously been shown to 
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promote formation of focal adhesion complexes (Ohtaki et al., 2001).  To investigate 
whether focal adhesions were involved in the kp-10 mediate inhibition, an Arg-Gly-Asp-
Ser (RGDS) tetrapeptide was used as this is the minimum consensus peptide sequence 
required to disrupt integrin receptor interactions with the extracellular matrix.  When an 
excess of RGDS is incubated within cells this displaces the extracellular region of the 
integrin from the ECM disrupting the integrin receptor dimer causing the destruction of 
the focal adhesion complex (Davidson et al., 2004).  Therefore, RGDS was used to 
examine the influence of focal adhesions on kp-10 mediated inhibition of migration and 
another tetrapeptide, RGES was used as a negative control.  However, the use of both 
RGDS and RGES did not affect the ability of kp-10 to inhibit the migration of these 





Figure 85.  Integrins are not responsible for kp-10 mediated inhibition of migration. (A) 
Cell Migration assay assessing kp-10 mediate inhibition of migration in CHO/hgpr-54 cells.  
This is not ablated by the integrin disrupting tetrapeptide RGDS or the negative control tetra 
peptide RGES (n=3). (B) Quantification of cell migration assay showing RGDS does not disrupt 




5.2.2. Kisspeptin-10 does not affect migration of mouse embryonic GnRH 
neuronal cells or human MCF-7 breast cancer cells 
 
As GSK3β and ERK1/2 were activated in GnRH neuronal cells, it was decided to 
analyse whether kp-10 had any migratory effects in this cell type or if kisspeptins 
primary role in the GnRH neuron is the regulation of GnRH production.  This was 
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examined using an in vitro cell migration assay with 1-100nM kp-10 but no inhibition of 
migration was seen in these cells, with relatively little migration even in the control cells 
throughout the 22 hour time period.  It therefore appears the migratory effects of kp-10 





Figure 86.  Kp-10 does not affect the migration of GnRH neuronal cells. (A) Cell migration 
assay showing no effect of kp-10 on the GT1-7 neuronal cell line stably expressing mouse gpr-54 




Since kp-10 has been shown to have anti-metastatic effects in cancer cells, MCF-7 
breast cancer cells were examined to explore if this was due to an inhibition of migration 
in response to kisspeptin.  However, 100nM kp-10 could not inhibit the migration of 
these cells by 22 hours of migration (Fig. 87 and Table 11). Also, no effect of peptide 
234 was seen as expected.  Therefore it appears that inhibition of migration does not 
play a role in kisspeptins anti-metastatic properties in these cells. 
 
5.2.3. Kisspeptin-10 inhibits the migration of HUVEC cells via an ERK1/2-
dependant mechanism 
 
The main migrational affects of kisspeptin reside in the placental cells where kisspeptin 
inhibits trophoblast invasion into the maternal vasculature.  To examine the mechanism 
of this inhibition, human cell lines from two different areas of the placenta were 
examined; human umbilical vein endothelial cells (HUVECs) and immortalised first 
trimester extravillious trophoblast cells (HTR8SVneo). 






Figure 87. Kp-10 does not inhibit the migration of MCF-7 breast cancer cells. (A) 100nM 
kp-10 does not inhibit migration within a MCF-7 cell migration assay and peptide 234 also has 
no affect (n=2). (B) Quantification of cell migration assay showing no differences in percentage 




In the HUVEC cell line, kp-10 was able to inhibit migration in an inverse dose-
dependant manner with 1nM giving a maximal inhibition of 50% at 16 hours (16 hours 
was used for the placental cell lines as 22 hours was to long to see an effect).  Increasing 
the dose of kp-10 reduced the percentage of inhibition (Fig. 88 and Table 11).  Again to 
verify that the inhibition noted was due to gpr-54 in these cells, two of the antagonists 
delineated in chapter three, peptides 234 and 273 were utilised.  Both of these 
antagonists ablated the kp-10 mediated inhibition of migration in these cells, confirming 
the affect is mediated via gpr-54.  Since, kp-10 could inhibit the migration of the 
HUVEC cells, inhibitors were again employed to delineate the mechanism of this 
inhibition.  These studies revealed that inhibitors of Gq/11, Src, PKC, EGFR and ERK1/2 
could ablate the inhibitory affects of kp-10 (Fig. 88 and Table 11).  These results again 
suggest that the ERK1/2, p90rsk, GSK3β pathway to release β-catenin is also 
responsible for this inhibition in the placental HUVEC cells as well as in the model 
CHO cell line and both are via an EGF receptor transactivation mediated pathway. 
 
 





Figure 88.  Kp-10 inhibits migration within HUVEC placental cells.  (A) Kp-10 inhibits 
migration in a dose-dependant manner with 1nM kp-10 giving a maximal inhibition of 50% 
using a cell migration assay (n=3).  (B) Kp-10 mediated inhibition is ablated with 100nM 
YM254890 (Gq/11), 1µM Src Inhibitor 1 (Src), 1µM AG1478 (EGFR), 1µM Ro-31-8220 (PKC 
α, β, γ, ε) and 20µM PD98059 (MEK) inhibitors (n=2). (C, D) Quantification of cell migration 




5.2.4. Kisspeptin-10 inhibits migration of HTR8SVneo trophoblast cells via 
an ERK1/2-dependant mechanism 
 
Next, the first trimester extravillious trophoblast cell line, the HTR8SVneo cells were 
tested in the cell migration assay; these cells were derived from an area of the placenta 
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where gpr-54 is supposed to elicit inhibitory affects.  As expected, kp-10 could inhibit 
the migration of these cells in a dose-dependant manner with 100nM giving a maximal 
inhibition of 50% (Fig. 89 and Table 11).  The signalling pathways responsible for this 
inhibition were investigated using inhibitors.  Kp-10 mediated inhibition of migration 
was blocked in these cells with inhibitors of Gq/11, PKC, EGFR, ERK1/2, Akt, p90rsk 
and GSK3β (Fig. 89 and Table 11).  This is the same pathway utilised in both the CHO 





Figure 89. Kp-10 inhibits migration in trophoblast cells via an ERK1/2-dependant 
pathway. (A) Kp-10 inhibits the migration of HTR8SVneo trophoblast cells in a dose dependant 
manner with 100nM giving a maximal inhibition of 50% in a cell migration assay (n=3).  This 
inhibition is ablated by 100nM YM254890 (Gq/11), 1µM AG1478 (EGFR), 1µM Ro-31-8220 
(PKC α, β, γ, ε), 20µM PD98059 (MEK), 1µM BI-D1870 (p90rsk), 1µM Akt-I1/2 (Akt) and 
1µM CT99021 (GSK3β) inhibitors (n=3). (B, C) Quantification of cell migration assays showing 
inhibition of kp-10 and ablation of this inhibition by select inhibitors. 





Table 11. Summary of kp-10 mediated migrational effects in a variety of cell types. Table 
summarising the migrational effects mediated by kp-10. The mechanisms responsible for this 






In the previous chapter it was shown that complex intracellular signalling pathways are 
mediated by kisspeptin-10 upon activation of gpr-54 in a stably transfected CHO 
epithelial-like cells, immortalized embryonic GnRH neuron-like cells as well as human 
breast cancer cells and immortalized human placental trophoblast cells. In this chapter, 
these pathways are revealed to be involved in kisspeptin mediated inhibition of 
migration in two of these cell types; CHO/gpr-54 and placental cell lines. In GnRH 
neurons and MCF-7 breast cancer cells no effect on migration via kp-10 and gpr-54 
could be observed.  
 
The involvement of MAPK pathways is well documented in the signalling mechanisms 
of GPCR receptor activation, with many other receptors also signalling via these 
molecules, such as GnRH-R (White et al., 2008).  For the GnRH receptor the MAPK 
pathway has been implicated in the induction of cell death (White et al., 2008), 
regulation of gene transcription of gonadotropin subunits and gonadotropin release 
(Naor, 2009).  It is therefore possibly that this more classical pathway could stimulate 
release of GnRH from neurons upon gpr-54 activation, which has so far been associated 
Chapter Five  Kisspeptin inhibits cell migration 
 
 194
with calcium fluxes (Constantin et al., 2008; Liu et al., 2008).  However, here we have 
shown that MAPK mechanisms are also involved in the migrational effects.  We can 
show that ERK1/2 activates p90rsk, a molecule known to be involved in the inhibition of 
GSK3β via phosphorylation of Ser9, a glycogen synthase signaling mechanism (Torres 
et al., 1999).  GSK3β, is usually associated with β-catenin activation in 
tumorigenesis/embryonic development and cell fate specification (Kim and Kimmel, 
2000), but has recently been shown to be activated by GPCR signaling cascades, for 
example by the GnRH receptor (Gardner et al., 2007).  For the GnRH receptor, GSK3β 
has been implicated in the accumulation of β-catenin in the nucleus to modulate gene 
transcription.  However, this does not appear to be the mechanism for gpr-54, as Akt 
needs to phosphorylate β-catenin for nuclear translocation to occur, however kisspeptin 
has recently been shown to disrupt EGFR mediated Akt activation (Daugherty and 
Gottardi, 2007; Fang et al., 2007; Navenot et al., 2009). This decrease may be due to an 
increase of PTEN, as p38MAPK is phosphorylated by kisspeptin-10, which is needed to 
up regulate PTEN via transcription of AFT2, (Shen et al., 2006), though further 
investigation is needed. This inactivation of Akt is also supported as we have shown that 
GSK3β inhibition at Ser9, a mechanism needed to release β-catenin is only slightly 
decreased by members of the Akt pathway. It seems that for gpr-54, GSK3β and β-
catenin are associated with migration via p90rsk.  P90rsk is known to also phosphorylate 
Ser9 of GSK3β, but causes β-catenin to be retained in the cytoplasm and associate with 
cadherins (Torres et al., 1999). Once β-catenin has bound cadherins it can then bind to α-
catenin which is linked to the actin cytoskeleton causing formation of adherens junctions 
to inhibit cell movement and migration (Aberle et al., 1996; Daugherty and Gottardi, 
2007). This mechanism may be critical in the inhibition of trophoblast invasion mediated 
by kisspeptin and gpr-54.   
 
The inhibition of GSK3β via ERK1/2 and p90rsk appears to be important in the 
CHO/gpr-54 and immortalised placental trophoblast cells. In these two cell types, FAK 
is also regulated by kp-10 via phosphorylation at Tyr925.  This phosphorylation creates a 
SH2 binding site for the Grb2-SOS complex within FAK. As SOS is a nucleotide 
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exchange factor this can increase the activation of RAS to increase ERK1/2 and p90rsk 
phosphorylation (Schlaepfer et al., 1994; Schlaepfer and Hunter, 1996).  In the previous 
chapter this phosphorylation of FAK was shown to be dependant on ERK1/2, p90rsk, 
Akt and GSK3β creating a feedback loop via FAK and Grb2 to increase ERK1/2 and 
p90rsk phosphorylation to further inhibit GSK3β and increase β-catenin within the 
cytoplasm.  This would further increase the formation of adherens junctions to inhibit 
cell movement. Another role of FAK may be to associate with integrins to form focal 
adhesion complexes.  FAK usually forms a complex with Src and two other proteins, 
paxillin and talin upon activation by phosphorylation (Li and Hua, 2008; Petit and 
Thiery, 2000).  This complex can then interact with integrins to link the ECM to the 
cytoskeleton, holding adjacent cells together and allowing the assessment of stresses 
upon the cell. Although these results suggest that FAK via integrins play a role in this 
migrational affect, the use of an integrin disrupting tetrapeptide, RGDS, shows no effect.  
When RGDS is added to cell cultures it can displace integrins but cannot bind the ECM 
disrupting focal adhesions (Davidson et al., 2004), as the use of this peptide had no 
affect on kp-10 mediated inhibition of migration it appears that focal adhesions are not 
responsible for this affect or that their loss can be compensated for.  Therefore, the main 
role of FAK in this pathway may be to enhance the MAPK signalling pathway through 
ERK1/2. 
 
Kisspeptin-mediated activation of NF-kappa B has also been implicated in the inhibition 
of trophoblast invasion via down regulation of NF-kappa B binding to the promoter of 
MMP-9.  This reduces expression of MMP-9 leading to inhibition of ECM degradation 
and trophoblast invasion (Yan et al., 2001).  Activation of NFκB by phosphorylation via 
kp-10 was shown in the previous chapter within all cell types and this was shown to be 
dependant on PKC activation only. However, its importance in kp-10 mediated 
inhibition of migration is yet to be assessed due to a lack of specific and potent 
inhibitors for this pathway. 
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The above results show that kp-10 is a potent inhibitor of migration in selected cell types 
such as placental cells, where this action may prove advantageous for restricting the 
amount of trophoblast invasion during placentation.  However, the lack of effect on the 
migration of GnRH neuronal cells, GT1-7, suggests that the actions and signalling 
mechanisms mediated by kp-10 and gpr-54 are cell-type specific rather than universal.  
This is interesting as similar proteins, although only a select few are increased by kp-10 
in these cells, giving the potential for similar actions at both sites.  Therefore, kp-10 
must be able to differentially regulate the same molecules for diverse purposes; however 
the function of these pathways in the GnRH neuron is still to be examined. This cell type 
specific signalling seen for kp-10 and gpr-54 may arise via a multitude of mechanism 
within the different cells.  The differences may be the result of receptor expression 
levels, signalling dynamics, differences in components of the signalling apparatus or due 
to differential post-translational modifications of the receptor. This cell-type specific 
signalling is further confirmed by the lack of inhibition on the migration of MCF-7 
breast cancer cells, as kp-10 has been shown to inhibit metastasis in this type of cancer 
and again similar pathways are activated.  This suggests that different mechanisms are 
utilized by kp-10 to inhibit cancer metastasis and trophoblast invasion, further 
confirming the cell type specificity of kisspeptins actions. 
 
In summary, in placental cells kp-10 activates a GSK3β dependant mechanism to release 
β-catenin into the cytoplasm to associate with cadherins causing an inhibition of the 
migration of these cell lines. This pathway is then further amplified via a FAK mediated 
feedback loop to increase MAPK signalling enhancing p90rsk mediated GSK3β 
inhibition. To further confirm this pathway, the affect of kp-10 on cadherins and 
examination of β-catenin’s association with these upon kp-10 stimulation needs to be 
investigated. Also the effects of the inhibitors alone on the migration of each cell type 
also have to be assessed. However, it is clear that this mechanism is essential for these 
actions both in extravillious trophoblast and umbilical cord cells within the placenta, but 













The research presented within this thesis has identified important residues within 
kisspeptin-10 that facilitate binding to (Asn2, Trp3, Phe6, Arg9, Phe10) and activation of 
(Tyr1, Leu8) gpr-54. Four novel potent synthetic peptide kisspeptin antagonists were 
produced.  One antagonist was used in vivo to confirm the role of kisspeptin in the 
control of gonadotropin secretion, mediation of steroid-hormone feedback, the pre-
ovulatory LH surge and the onset of puberty.  
 
This thesis also includes analyses of the intracellular signalling pathways activated 
following gpr-54 activation.  The role of these pathways in kisspeptin-mediated 
inhibition of cell migration was studied in a variety of cell types.  The results showed 
that gpr-54 activation affected MAPK, GSK3β, NFκB and FAK signalling and that these 
signals create a feedback loop to enhance GSK3β inhibition by Ser9 phosphorylation 
resulting in release of β-catenin into the cytoplasm in epithelial-like CHO and human 
placental trophoblast cells.  This pathway was shown to be critically important for 
kisspeptin-mediated inhibition of the in vitro migration of these cells and HUVEC cells.  
In contrast, this pathway was not activated in GnRH neuronal cells or a human breast 
cancer cell line. 
 
6.1. Summary of Chapter Three 
 
Since kisspeptin was shown to be a potent regulator of the HPG axis with functions in 
steroid hormone feedback and the initiation of puberty, different studies have emerged to 
try to delineate the mechanism of this regulation.  However, evidence for the functions 
of kisspeptin in the HPG axis has been indirect due to a lack of potent antagonists.  
Therefore, in this chapter a structure-function study was undertaken using intuitive 
changes to the kisspeptin-10 sequence, to determine which residues in synthetic peptides 
are involved in binding and activating gpr-54. Cell culture studies using these peptides 
enabled screening for potent agonists and antagonists. 
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These studies identified five residues in kisspeptin-10 involved in binding to gpr-54. 
Two residues were shown to be involved in receptor activation and four potent 
kisspeptin antagonists were identified (Fig. 90).  Firstly, Phe6, Trp9 and Phe10 were 
shown to be critical to receptor binding as substitution of each of these residues 
abolished binding to gpr-54.  This occurred even when the side chains were moved out 
of position via substitution with D-amino acid isomers.  Alterations to two further 
residues, Asn2 and Trp3, also significantly decreased binding to the receptor when 
substituted with alanine, suggesting that the side chains were important either for ligand-
receptor interactions or structural conformation of the peptide.  Two residues were also 
shown to be involved in activation of the receptor, substitution of Leu8 ablated 
stimulation of IP release and increased receptor antagonism and similar results were 
obtained upon substitution of Tyr1 (Fig. 90).  Finally, these studies produced four potent 
antagonists, all of which possessed Tyr8 to create steric hindrance within the C-terminal 
region combined with small, flexible side chains (glycine or D-serine) in place of Ser5.  
This suggests that antagonists require rigidity in the C-terminal region and flexibility in 
the N-terminal region.  Antagonism was further enhanced by substitutions at Tyr1, with 




Figure 90. Schematic diagram of important kisspeptin-10 residues. Residues that are 
important for receptor binding (red) and receptor activation (blue) within kp-10 are highlighted. 
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Peptide 234 was selected to be tested for effects in vivo to assess the role of kisspeptin in 
the regulation of gonadotropin secretion.  Firstly, peptide 234 was shown to inhibit firing 
of the GnRH neuron in mice and pulsatile GnRH secretion in primates, confirming that 
kisspeptin regulates the secretion of GnRH.  Peptide 234 could also ablate the post 
castration rise of LH in rodents and LH pulse amplitude in OVX ewes, but had no effect 
on basal LH levels.  This suggests that basal and pulsatile GnRH/LH may be regulated 
by separate pathways within the brain and also confirms the role of kisspeptin in 
negative steroid feedback.  Application of peptide 234 also confirmed a role for 
kisspeptin in the pre-ovulatory LH surge in rats as this was completely inhibited and in 
the onset of puberty, as peptide 234 delayed vaginal opening in rats.  Thus, peptide 234 
is a potent in vivo kisspeptin antagonist and is a useful tool to investigate the actions of 
kisspeptin in a variety of species.  Kisspeptin antagonists may also be useful as 
medicines for conditions involving elevated levels of gonadotropins such as PCOS and 
precocious puberty or even as a novel contraceptive. 
 
6.2. Summary of Chapter Four 
 
To date the intracellular signalling pathways mediated by kisspeptin and gpr-54 have 
remained relatively uncharacterized.  A select number of studies have focused on the 
intracellular mechanisms of gpr-54 signalling mainly in cancer tissue.  Therefore, in this 
chapter studies were undertaken to elucidate the intracellular pathways mediated by 
kisspeptin-10 in a variety of cell types.  The aim was to look for cell-specific activation 
of signalling. 
 
The studies within the chapter used four main cell types; epithelial-like CHO cells stably 
expressing human gpr-54, mouse GT1-7, GnRH neuron-like cells, human MCF-7 breast 
cancer cells and human HTR8SVneo placental trophoblast cells.  Similar signalling 
pathways were shown to be active in each cell type with some mechanistic differences. 
In the CHO, MCF-7 and HTR8SVneo cell lines, kisspeptin-10 mediated effects on 
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MAPK, GSK3β, FAK and NFκB signalling pathways.  A major pathway activated in 
these cells was activation of ERK1/2 enhanced p90rsk-mediated inhibition of GSK3β 
via Ser9 phosphorylation.  This caused release of β-catenin from GSK3β and resulted in 
phosphorylated of FAK at Tyr925, which in turn increased phosphorylation of ERK1/2 
(Fig. 91).  The main differences between these cell types are the initial mode of ERK1/2 
phosphorylation.  In CHO cells, only EGF transactivation is needed for the MAPK 
pathway to be activated, whereas in the HTR8SVneo cells PKCε and transactivation of 
the EGF receptor are required.  This suggests that kisspeptin may regulate the migration 





Figure 91. Schematic diagram of the ERK1/2-mediated signalling pathway activated by 
gpr-54.  Potential feedback loop involving ERK1/2, p90rsk, GSK3β and FAK-Grb2 to release β-
catenin into the cytoplasm. 
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As for the GT1-7 cells, signalling appeared less diverse when activated by kisspeptin/gpr-
54. Only ERK1/2, GSK3β and NFκB were modulated by gpr-54; all of which appear to 
rely on EGF receptor transactivation.  Although these are similar to the pathways 
activated in the other cell types, the consequences of signalling may be different as 
adherens junctions are not found in neuronal cells. No regulation of β-catenin was 
observed. 
   
6.3. Summary of Chapter Five 
 
Since some of the intracellular signalling pathways mediated by kisspeptin and gpr-54 
had been delineated in the previous chapter, the next step was to investigate the function 
of this signalling. As many of these pathways have previously been shown to affect cell 
migration and kisspeptin can inhibit this process, cell migration was the functional 
output chosen. Therefore, in this chapter kisspeptin was tested for its ability to inhibit 
the migration of the cell types studied in chapter four and then inhibitors were used to 
test the involvement of the delineated pathways. 
 
From these studies, it was determined that kisspeptin could inhibit the migration of 
epithelial-like CHO cells, HUVEC cells and placental trophoblast cells but had no effect 
on the migration of MCF-7 breast cancer cells or GT1-7 neuronal cells.  In the CHO and 
trophoblast cells, this inhibition was dose-dependant with 100nM kisspeptin-10 
inhibiting migration by 80% and 50%, respectively at 22 or 16 hours.  In HUVEC cells, 
the inhibition seemed to follow an inverse dose-response with 1nM inhibiting migration 
by 50% and this gradually decreased as the dose increased.  However, it was clear that 
kisspeptin-10 could inhibit the migration of these cells and therefore inhibitors were 
used to elucidate the pathways responsible for this inhibition.  In all three cell types, the 
ERK1/2-mediated pathway delineated in chapter three was shown to be responsible for 
effects on migration.  This effect probably involves the formation of junctions between 
cells such as adherens junctions involving β-catenin released via GSK3β inhibition.  One 
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consequence may be the alteration of MMP-9 production via NFκB; however, due to a 
lack of specific inhibitors for this pathway, further studies would be required to 
determine these possibilities.  Focal adhesions had also been hypothesized to be 
involved in this inhibition; however the use of RGDS tetrapeptides to disrupt the focal 
adhesion complex did not affect kisspeptin-10 mediated inhibition of cell migration 
suggesting this is not the case.   
 
6.4. Future Work 
 
6.4.1. Kisspeptin antagonists in vitro 
 
Kisspeptin is a pivotal component of the HPG axis, regulating the onset of puberty, 
gonadotropin secretion and the pre-ovulatory LH surge. However, due to the indirect 
methods used for examining these functions to date, this thesis elucidated four potent 
kisspeptin antagonists, each possessing the potential for direct assessment of the 
functions of kisspeptin and gpr-54.  These antagonists still need further characterization 
in vitro, for example to evaluate the on-rate and off-rate of each analogue, or to calculate 
the half life of each analogue in in vivo studies.   
 
However, there is a problem with the binding assay. The 125I-radiolabelled kisspeptin 
exhibits non-specific binding to plastic, making interpretation of whole cell binding data 
difficult. To try to resolve this problem, coating of the plate with matrigel or PLL may 
reduce the interactions made with the plastic.  Also, pre-incubation of the plates with 
tryptophan residues, which should hydrophobically interact with the plastic, may reduce 
the capacity for kisspeptin interactions allowing more binding to just gpr-54.  Another 
problem encountered within these studies recently, is a reduction in antagonism of 
kisspeptin-10 stimulated IP production within the current assay used and this may be due 
to changes within the analogues or the assay utilised.  Therefore, varying the incubation 
periods for each may improve the antagonism, for example, the antagonists may be 
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incubated for longer or kisspeptin for shorter time periods. Another way to change these 
effects may be to vary the temperature as temperature is known to be a vital factor for 
on/off rates. There is also a possibility that the analogues are forming non-covalent 
complexes when dissolved in propylene glycol and preliminary studies may have had no 
effect since the kisspeptin was still dissolved in propylene glycol when mixed with the 
analogues.  Therefore, studies examining the use of different solvents to dissolve both 
the analogues and kisspeptin may be beneficial. 
 
Once the assay conditions are improved, further studies may be undertaken to carefully 
assess the on-rate and off-rate of kisspeptin and each analogue, to give an indication of 
the peptides half-life.  This would be done via extensive binding studies using a single 
concentration of labelled kisspeptin alone over a long time course.  Once these rates 
were known for the four antagonist, modifications could then be made to each to try and 
improve their half life and IC50. The new analogues would then need to be extensively 
tested in vitro to assess their ability to bind to and activate gpr-54, to test for any cross 
reactions with other RFamide receptors and to assess their ability to antagonize at gpr-
54. These studies would be beneficial to the in vivo studies as it should decrease the 
dosing for each species and the length of stimulation used.   
 
However, if the inositol phosphate assay cannot be improved then other assays would 
need to be utilized.  Two other assays maybe used, the FLIPR calcium 4 assay which 
could be modified to increase the resulting antagonism observed or an SRE-luciferase 
reporter assay using the LβT2/gpr-54 cells, where stimulation of SRE-luciferase with 
kisspeptin has been demonstrated.  Therefore, this assay could be used to examine the 
antagonism of the analogues within these cells.  Once the antagonists are refined, they 
could then be further utilized in vitro to assess signalling pathways or to examine the 
role of kisspeptin within GnRH neuronal cell lines on GnRH secretion from the cells. 
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6.4.2. Kisspeptin antagonists in vivo 
 
Since antagonists could potentially show direct effects of kisspeptin in the HPG axis, in 
vivo testing is essential.  Within this thesis one of the antagonists, peptide 234 was 
extensively tested in vivo and confirmed effects for kisspeptin in gonadotropin 
regulation, the timing of puberty onset and regulation of the pre-ovulatory LH surge.  
However, as all of these tests used central delivery, peptide 234 has to be tested for 
antagonism when delivered peripherally.  Also, the three other antagonists from this 
thesis also have to be tested for their effects in vivo both via central and peripheral 
delivery.  To do this, all of the antagonists could be compared using one assay looking at 
the effect of each on LH secretion in the rodent, to compare the potency and half-life of 
the analogues.  This should also help with decisions about modifications to the 
analogues as discussed above as when analogues are exposed to in vivo settings other 
factors come into play.  These include clearance rate, peptidases and the blood-brain 
barrier.  These may affect the analogues in ways that are unforeseeable in vitro.  Next, 
any improved analogues developed via these modifications, would again need to 
undergo in vivo tests to assess the effects on the HPG axis.  Also as some observations 
such as pubertal effects have been studied in rodents, similar experiments could be 
undertaken in primates, which could give results that are more comparable to the human. 
 
Once the most potent antagonist has been evaluated both in vitro and in vivo, this 
peptide could then be purified for use in clinical trials.  Firstly, the antagonist could be 
tested alone in these trials, to test if it has any effects on basal secretion of LH in the 
human or it could be given in conjunction with kisspeptin to assess its antagonistic 
effects.  If the antagonist is successful in the human setting, it could then be tested to see 
if it can inhibit the female pre-ovulatory surge of LH.  This would assess if the 
antagonist would be useful as an alternative contraceptive, which can inhibit ovulation 
without affecting basal levels of gonadotropins and steroids.  Another use for the 
antagonist that could be tested in these trials is as a therapeutic for PCOS.  In PCOS, 
gonadotropin levels are high causing cysts to form in the ovary (Blank et al., 2006).  The 
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antagonists may be able to suppress the gonadotropin secretion to basal levels which 
should cause the cysts to decreases and may return fertility to the patient.   However, this 
would need to be tested in an animal model of PCOS before human trials could proceed.  
Finally, the antagonist may also be useful for inhibiting the onset of puberty in children 
undergoing precocious puberty. 
 
As well as being useful for delineating kisspeptins function in the HPG axis, another 
setting for in vivo trials with the antagonists may be the placenta.  As has been shown in 
this thesis, kisspeptin can inhibit the migration of cells including a placental trophoblast 
cell lines.  KiSS-1 and gpr-54 mRNA have also been shown to be present within the 
human and rat placenta and KiSS-1 mRNA is known to be up regulated in the 
pathological condition pre-eclampsia (Bilban et al., 2004; Hiden et al., 2007; Terao et 
al., 2004; Zhang et al., 2006).  In pre-eclampsia, the trophoblast cells do not completely 
migrate into the maternal decidua and spiral artery remodelling is insufficient. The lack 
of migration into the decidua has been hypothesized to be due to an overproduction of 
kisspeptin (Sankaralingam et al., 2006).  Therefore, using animal models with normal or 
pre-eclampsia-like placentas, the antagonist could be used to assess kisspeptins role in 
trophoblast invasion if given directly into the placental region and effects, if any, on the 
remodelling of the spiral arteries may also be assessed.  This would directly evaluate 
kisspeptins role in this event and may provide a mechanism for increasing the amount of 
invasion within a pre-eclamptic placenta. 
 
6.4.3. Kisspeptin signalling mechanisms in GnRH neuronal cells 
 
Within this thesis, studies were also undertaken to delineate the intracellular signalling 
mechanisms mediated by kisspeptin in a variety of cell types.  One of the cell types used 
was an immortalized GnRH neuronal cell line called GT1-7.  In these cells, only three of 
the proteins tested were mediated by kisspeptin; these were ERK1/2, GSK3β and NFκB.  
Although these proteins were also activated in other cell types, the function of these 
proteins in the GT1-7 cells seems to be different as no inhibition of migration occurs in 
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these cells when stimulated with kisspeptin and no release of β-catenin can be observed. 
However, further studies with new inhibitors may help establish a functional pathway 
for GSK3β in these cells. Still, other studies are needed to establish the role of these 
molecules within the GnRH neuron. 
 
The obvious role for these proteins when activated by kisspeptin is to regulate the 
secretion of GnRH from the hypothalamus, as this is kisspeptins main role within the 
HPG axis (Gottsch et al., 2004; Messager et al., 2005; Popa et al., 2008).  However, as 
secretion of GnRH cannot be detected from the GT1-7 cells used in this thesis, other cells 
would need to be sourced in order to evaluate the roles of these proteins in kisspeptin-
mediated secretion of GnRH in vitro.  Other cell types that could be utilized for these 
studies would be Gnv3, Gn11, GTI-t or NLT neuronal cell lines reported to secrete 
GnRH.  The first step for each cell line would be to screen for endogenous receptor and 
then create stable cell lines if needed.  These cell lines could then be tested for 
kisspeptins ability to cause secretion of GnRH into the medium.  If this could be 
established for one of the above cell lines, and the same proteins could be shown to be 
mediated by kisspeptin then inhibitors for these proteins could be used to examine their 
effects on GnRH secretion.  
 
Another plausible function of these proteins is to regulate gene transcription within the 
nucleus, therefore quantitative RT-PCR could be performed for known gene targets of 
each protein to establish if they are mediated by kisspeptin in the GnRH neuron.  Each 
protein can regulate a variety of genes within the nucleus; ERK1/2 has roles in the 
regulation of c-jun, c-myc, NFAT and fra-1, which in turn can induce cell 
differentiation, apoptosis or proliferation (Anjum and Blenis, 2008; Boutros et al., 
2008).  NFκB can also regulate gene transcription within the nucleus, to up regulate 
MMP-2, MMP-9, IκBα and cyclinD1 among others again promote cell differentiation 
and proliferation (Ghosh and Hayden, 2008; Yan et al., 2001).  
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6.4.4. Kisspeptin signalling mechanisms in CHO and placental cells 
 
As well as examining kisspeptins signalling events within the GnRH neuron, two other 
cell types were used; epithelial-like CHO cells stably expressing human gpr-54 were 
used as a model cell line and immortalized human HTR8SVneo placental trophoblast 
cells were used to examine the signalling pathways involved in kisspeptin-mediated 
inhibition of trophoblast invasion.  The pathways found in each cell type were very 
similar, with only slight differences.  Both mediated an ERK1/2-p90rsk-GSK3β-
βcatenin-FAK feedback loop with separate regulation of NFκB. However further 
experiments are still needed to clarify this pathway and to investigate if it can regulate 
gene transcription as well as mediate migrational effects. 
 
To fully clarify that this is the active pathway in the HTR8SVneo cells further inhibitors 
for Akt, p90rsk and GSK3β could be used, as has been shown within thesis for the CHO 
cells.  Also the inhibitors within this thesis have only been used in conjunction with 
kisspeptin and therefore need to be individually tested alone on each cell type to test if 
any of the effects seen are independent of kisspeptin stimulation. Once the pathway is 
clarified in both cell types, further investigation into the role of β-catenin would be 
merited. The studies within this thesis have only shown accumulation of β-catenin in the 
non-nuclear fraction; therefore further elaboration could be undertaken to establish the 
role of β-catenin after this accumulation.  One way this could be examined is to look at 
the phosphorylation status of β-catenin upon release, as Akt is known to phosphorylate 
β-catenin at Ser552 to facilitate nuclear translocation and dissociation from adherens 
junctions (Fang et al., 2007).  Therefore, investigation of the phosphorylation status of 
this residue may clarify whether β-catenin associates with adherens junctions or 
regulates gene transcription upon kisspeptin stimulation (Gooding et al., 2004; Moon et 
al., 2004).  Another study that could be done to examine this would be to investigate the 
regulation of cadherins by kisspeptin.  This could be done using microscopy to visualize 
whether kisspeptin stimulation causes cadherins to form junctions and if β-catenin 
associates with these or via western blots to examine if E-cadherins are either up 
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regulated by kisspeptin or activated via phosphorylation at Ser684/686/692 (Gooding et al., 
2004).   
 
Another role of the pathways mediated by kisspeptin in these cells may be the regulation 
of gene transcription.  Beta-catenin is known to bind to and activate the transcription 
factors, TCF/Lef by recruiting co-factors to the complex.  For, example PP2A can 
regulate β-catenin binding to the co-factors CBP and p300 to regulate cell growth vs. 
cell differentiation (Daugherty and Gottardi, 2007). This could be examined using a TCF 
reporter construct or quantitative RT-PCR to examine regulation by kisspeptin and 
would further examine β-catenin’s role in this pathway.  ERK1/2 is also known to 
regulate gene transcription via activation of transcription factors in the nucleus to up 
regulate NFAT, c-jun and fra-1 among others, causing effects on cell differentiation, 
proliferation and apoptosis.  Kisspeptin also phosphorylates NFκB, which is a known 
mediator for transcription of adhesion molecules such as MMPs.  However transcription 
of MMPs from these two cell types would not be in line with kisspeptins inhibitory 
mechanism as MMPs degrade the ECM to allow cell migration (Yan et al., 2001).  
Therefore, studies could be undertaken to see the effect of kisspeptin on MMPs within 
these two cell types and inhibitors could be used to examine if NFκB is responsible or 
whether NFκB is playing a different role in these cells. 
 
6.4.5. Kisspeptin migrational effects in CHO and placental cells 
 
Studies within this thesis also mapped the involvement of the delineated signalling 
mechanism in cell migration within these two cells lines.  This was achieved by utilizing 
inhibitors within a cell migration assay in conjunction with kp-10.  However, the 
inhibitors used still need to be tested alone within this assay to assess if any of the 
effects observed are independent of kisspeptin.  The assay used within this thesis was a 
scratch assay, where a scratch is made within a monolayer of cells and the migration into 
that scratch over time is measured.  Therefore, to confirm the effects seen in this assay 
and the signalling mechanism delineated, these experiments could be tested using well 
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inserts.  In this assay, the insert would be placed inside a 12-well plate and the cells 
grown on the insert and then kisspeptin with or without inhibitors would be added to the 
media and the migration through the insert would be assessed.  It may also be useful to 
assess the affect that kisspeptin has on proliferation and differentiation within these two 
cell types, to confirm the results obtained are mainly due to migration rather than 
proliferation or differentiation.   
 
Primary cell cultures or placental tissue could also be used to look at the migrational 
effects of these pathways in a more physiologically relevant setting.  The use of primary 
cell cultures of trophoblasts would allow the evaluation of this process in unaltered cells 
and these could be assessed in the same manner as the immortalised trophoblast cell line.  
Tissue samples could also be used to assess the overall effect of kisspeptin within the 
placenta as the cell-cell contacts would be kept in place and the overall cellular structure 
of the placenta would be preserved.  This may be useful as patients with mutations to 
gpr-54, have normal placentation during pregnancy suggesting that kisspeptin is either 
not involved or that it can be compensated for (Pallais et al., 2006), therefore the use of 
placental tissue may be able to assess the degree of involvement that kisspeptin has in 





The research presented within this thesis highlights the potential for direct examination 
of kisspeptins functions within the HPG axis and other tissues through the development 
of the first potent kisspeptin antagonists.  It also facilitates the creation of further 
antagonists and agonists through the delineation of residues important for receptor 
binding and activation.  Furthermore, these studies are the first to show regulation of 
GSK3β and β-catenin via an ERK1/2-p90rsk feedback loop in response to kisspeptin 
stimulation. This signalling pathway may be critical for kisspeptin to inhibit the 
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8.0. Appendix A: Abbreviations, Charge and Structures of Amino Acids 
 
Amino Acid Three letter code One letter code Charge 
Alanine Ala A Non-Polar 
Arginine Arg R Basic 
Asparagine Asn N Polar 
Aspartic Acid Asp D Acidic 
Cysteine Cys C Polar 
Glutamine Gln Q Polar 
Glutamic Acid Glu E Acidic 
Glycine Gly G Non-Polar 
Histidine His H Basic 
Isoleucine Iso I Non-Polar 
Leucine Leu L Non-Polar 
Lysine Lys K Basic 
Methionine Met M Non-Polar 
Phenylalanine Phe F Non-Polar 
Proline Pro P Non-Polar 
Serine Ser S Polar 
Threonine Thr T Polar 
Tryptophan Trp W Polar 
Tyrosine Tyr Y Polar 
Valine Val V Non-Polar 
 
For amino acid structures please see overleaf. 
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8.1. Appendix B: Abbreviations 
aCSF   artificial Cerebrospinal fluid 
AMPA   α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate 
APC   Adenomatous polyposis coli 
AR   Androgen receptor 
ARC   Arcuate nucleus 
ATCC   American Type Culture Collection 
ATP   Adenosine triphosphate 
AUC   Area under curve 
AVPV   Anteroventral periventricular nucleus 
BCL   B-cell CLL/lymphoma 
BDNF   Brain derived neurotrophic factor 
BMI   Body Mass Index 
Bp   Base pairs 
BSA   Bovine Serum Albinum 
BW   Body weight 
Ca2+   Calcium 
CaMK   Camodulin-dependant kinase 
CBP   CREB-binding protein 
CHO   Chinese Hamster Ovary 
CK   Casein kinase 
CKTD   C-terminal kinase domain 
COX   Cyclooxygenase 
DAG   Diacyl glycerol 
DEPC   Diethylpyrocarbonate 
DMEM  Dulbecco’s modified Eagle’s Medium 
DMSO   Dimethylsulphoxide 
DNA   Deoxyriboneucleic Acid 
DPC   Dodecylphosphocholine 
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E   Embryonic Day 
EC50   Excitatory constant at 50% maximum 
ECACC  European Collection of Cell Cultures 
ECM   Extracellular Matrix 
EDTA   Ethylenediaminetetraacetic acid 
EGF   Epidermal growth factor 
EGFR   Epidermal growth factor receptor 
EL   Extracellular loop 
EPSC   Excitatory post-synaptic current 
ER   Estrogen Receptor 
ERK   Extracellular-Regulated Kinase 
evCT   Extravillious Trophoblasts 
FAK   Focal Adhesion Kinase 
FasL   Fas Ligand 
FAT   Focal adhesion targeting 
FERM   Band 4.1, ezrin, radixin, moesin homology 
FGF   Fibroblast growth factor 
FISH   Fluorescent In-situ Hybridisation 
FSH   Follicle Stimulating Hormone 
GABA   Gamma Aminobutyric acid 
GalR   Galanin Receptor 
GBP   GSK3-binding protein 
GDP   Guanosine diphosphate 
GEF   Guanine nucleotide exchange factor 
GFP   Green florescent protein 
GH   Growth Hormone 
GnRH   Gonadotropin Releasing Hormone 
GPCR   G-protein coupled receptor 
Gpr-54   G-protein coupled receptor 54 
GSK3   Glycogen Synthase Kinase 3 
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GTP   Guanosine triphosphate 
hCG   Human Chorionic Gonadotropin 
HCL   Hydrochloric acid 
HPG   Hypothalamic Pituitary Gonadal 
HUVEC  Human Umbilical Vein Endothelial Cells 
IC50   Inhibitory constant at 50% maximum 
icv   Intracerebroventricular 
iHH   Idiopathic Hypogonadotropic Hypogonadism 
IκBα   Inhibitor of NFκB 
IKK   IκB kinase 
IL   Intracellular loop 
ip   Intraperitoneal 
IP   Inositol Phosphate 
IP3   Inositol trisphosphate 
iv   Intravenous 
JNK   Jun N-terminally regulated Kinase 
Kir   Inwardly rectifying potassium channels 
Kp-10   Kisspeptin-10 
Kp-13   Kisspeptin-13 
Kp-54   Kisspeptin 54 
LD   Long Day 
LEF   Lymphoid enhancer factor 
LH   Luteinising Hormone 
LiCl   Lithium Chloride 
LOH   Loss of hetrozygosity 
LRP   Lipoprotein receptor-related protein 
LSB   2x Laemmli sample buffer 
Luc   Luciferase 
M   Molar 
MAPK   Mitogen-activated protein kinase 
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MAPKAP  Mitogen-activated protein kinase-activated protein kinase 
MAPKK  Mitogen-activated kinase kinase 
MAPKKK  Mitogen-activated kinase kinase kinase 
MCIP1    Modulatory Calcineurin-interacting Protein-1 
ME   Median Eminence 
MEK   Mitogen-activated protein kinase kinase 
MEKK  Mitogen-activated protein kinase kinase kinase 
MK   MAPK specific substrate 
MKP   MAPK specific phosphatase 
MLC   Myosin light chain 
MLK   Mixed-lineage Kinase 
MMP   Matrix Metalloproteinases 
MNK   MAP kinase-interacting kinase 
MSK   Mitogen- and stress-activated protein kinase 
NaOH   Sodium Hydroxide 
NFκB   Nuclear Factor kappa B 
NMR   Nuclear Magnetic Resonance 
NaCl   Sodium Chloride 
NFAT   Nuclear factor of activated T-cells 
NPAF   Neuropeptide AF 
NPFF   Neuropeptide FF 
NPSF   Neuropeptide SF 
NPVF   Neuropeptide VF 
NTKD   N-terminal kinase domain 
ORF   Open Reading Frame 
OSE   Ovarian Surface Epithelium 
OVX   Ovariectomised 
P   Postnatal day 
PARP   Poly (ADP-ribose) polymerase 
PBS   Phosphate buffered saline 
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PCOS   Polycystic Ovarian Syndrome 
PeN   Periventricular Nucleus 
PG   Prostaglandin 
PI(3)K   Phosphoinositide 3-kinase  
PIP2   Phosphatidyl Inositol bisphosphate 
PKA   Protein Kinase A 
PKB   Protein Kinase B 
PKC   Protein Kinase C 
PLC   Phospholipase C 
POA   Preoptic Area 
PR   Progesterone receptor 
PrPR   Prolactin-releasing peptide 
PTEN   Phosphatase and tensin homology 
PVDF   Polyvinylidene difluoride 
RFRP   RFamide related peptide 
RHD   Rel homology domain 
RNA   Ribonucleic Acid 
ROS   Reactive oxygen species 
RT-PCR  Real time polymerase chain reaction 
SAPK   Stress-activated protein kinases 
SD   Short Day 
SDF-1   Stromal Derived Factor 1 
SDS   Sodium dodecyl sulphate 
SDS-PAGE  Sodium dodecyl sulphate -polyacrylamide gel electrophoresis 
SEM   Standard Error of the Mean 
SH2/3   Src homology 2/3 domains 
SP1   Specificity Protein 1 
ST   Syncytiotrophoblast  
TAD   Transactivation domain 
TBS-T   Tris-Buffered Saline Tween-20 
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TCF   T-cell factor 
TGF   Transforming growth factor 
TM   Transmembrane domain 
TLR   Toll-like receptors 
TNF   Tumour necrosis factor 
TRPC   Transient receptor potential canonical 
TTX   Tetrodotoxin 
vCT   Villous Cytotrophoblast  
VO   Vaginal opening 
WT   Wild type 
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